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COMPOSITIONS AND METHODS FOR LIPID biodiesel . In particular , biodiesel production grants a high 
PRODUCTION net energy gain compared to other alternative fuels with 
minimal environmental impact , and harvesting lipid reserves 
CROSS - REFERENCES TO RELATED from a microbial source such as Y . lipolytica enables easily 
APPLICATIONS scaled - up production without compromising food supply 
( Christophe et al . 2012 ; Hill et al . 2006 ; Kirstine and 
This application claims the benefit of U . S . Provisional Galbally 2012 ; Subramaniam et al . 2010 ) . Y . lipolytica ' s 
Patent Application No . 61 / 819 , 476 , filed May 3 , 2013 , natural lipid content consists of predominantly C16 : 0 , C16 : 
which is incorporated herein by reference in its entirety and 1 , C18 : 0 , C18 : 1 , and C18 : 2 fatty acids ( Beopoulos et al . 
for all purposes . 10 2008 ; Blazeck et al . 2013a ; Tai and Stephanopoulos 2013 ) , 
very similar to the fatty acid content of biodiesel derived 
STATEMENT AS TO RIGHTS TO INVENTIONS from soybeans and rapeseed ( Gruzdiene and Anelauskaite 
MADE UNDER FEDERALLY SPONSORED 2011 ; Hammond et al . 2005 ) . Economic viability can be 
RESEARCH AND DEVELOPMENT greatly improved by fully utilizing all sugars from lignocel 
15 lulosic biomass or by using carbon from industrial waste 
This invention was made with government support under streams . In this regard , Y . lipolytica can efficient utilize 
N000141110669 awarded by Office of Naval Research . The hydrophobic and waste carbon sources , such as crude glyc 
government has certain rights in the invention . erol ( Andre et al . 2009 ; Fickers et al . 2005 ; Makri et al . 
2010 ; Rywinska et al . 2013 ) , and has shown excellent 
REFERENCE TO A " SEQUENCE LISTING , " A 20 heterologous gene expression when utilizing glucose , 
TABLE , OR A COMPUTER PROGRAM LISTING sucrose , glycerol , or oleic acid as a carbon source ( Blazeck 
APPENDIX SUBMITTED ON A COMPACT et al . 2013b ) . Finally , Y . lipolytica is regarded as a " safe 
DISK to - use ” organism ( Groenewald et al . 2013 ) . 
Lipid accumulation in Y . lipolytica can be induced by 
The Sequence Listing written in file 93331 - 003510US - 25 nitrogen starvation and has been associated with the activity 
907029 _ ST25 . TXT , created on Apr . 29 , 2014 , 210 , 560 of four enzymes : AMP Deaminase ( AMPDp ) , ATP - Citrate 
bytes , machine format IBM - PC , MS - Windows operating Lyase ( ACLP ) , Malic Enzyme ( MAEP ) and Acetyl - COA 
system , is hereby incorporated herein by reference in its Carboxylase ( ACCp ) ( Beopoulos et al . 2009a ; Dulermo and 
entirety and for all purposes . Nicaud 2011 ) . AMPDp cleaves AMP into NH + and inosine 
30 5 ' - monophosphate to replenish intracellular nitrogen levels ; 
BACKGROUND AMP deficiency inhibits the citric acid cycle resulting in 
citric acid accumulation . ACLp cleaves citric acid into 
Increasing oil consumption makes continued dependence oxaloacetate and acetyl - CoA , and ACCp carboxylates 
on petroleum reserves untenable . Microbial production of acetyl - CoA into malonyl - CoA fatty acid building blocks . 
renewable alternatives can reduce petroleum footprints 35 Fatty acid synthesis is further encouraged by a MEAP 
through the in vivo synthesis of ethanol , biodiesel , and mediated increase in NADPH levels ( Beopoulos et al . 
industrial precursors ( Curran et al . 2013 ; Elshahed 2010 ; Li 2009a ) . Fatty acids can be directly stored in intracellular 
et al . 2008 ; Xu et al . 2013 ; Yim et al . 2011 ) . Economic lipid bodies or further incorporated in triacylglycerides 
viability is highly dependent upon microbial choice , and an before storage ( Beopoulos et al . 2008 ) . Triacylglyceride 
ideal host efficiently generates high titers independent of 40 synthesis follows the Kennedy Pathway to fuse three fatty 
fermentation condition , through native or imported biosyn - acids to a glycerol - 3 - phosphate ( G3P ) backbone ( Kennedy 
thetic metabolism ( Alper and Stephanopoulos 2009 ) . In this 1961 ) . The ultimate step is catalyzed by the DGA1 or DGA2 
regard , Yarrowia lipolytica ' s genetic tractability , efficient acyl - CoA : diacylglycerol acyltransferases ( Beopoulos et al . 
utilization of many energy sources , and native capacity to 2009a ; Beopoulos et al . 2012 ) . G3P backbone is synthesized 
accumulate lipids make it an ideal platform for oleo - chemi - 45 from dihydroxyacetone phosphate ( DHAP ) by the cytosolic , 
cal synthesis ( Barth and Gaillardin 1996 ; Beopoulos et al . NAD + - dependent glycerol - 3 - phosphate dehydrogenase 
2009a ; Papanikolaou and Aggelis 2002 ) . ( GPD1 ) and recycled into glycolysis by the mitochondrial , 
Here we have employed a large - scale combinatorial FAD + - dependent glycerol - 3 - phosphate dehydrogenase iso 
approach to maximize lipid production in Y . lipolytica form ( GUT2 ) ( Dulermo and Nicaud 2011 ) . TAG hydrolysis 
through both genomic engineering and combinatorial and 50 mobilizes free fatty acids for peroxisomal degradation 
inverse metabolic engineering multiplexed with phenotypic through the four step B - oxidation cycle ( Beopoulos et al . 
induction . 2011 ) - oxidation by one of six acyl - CoA oxidases ( POX1 
Y . lipolytica has a fully defined metabolic engineering 6 ) , hydration and dehydrogenation by the multifunctional 
toolbox that enables intracellular flux control through enzyme ( MFE1 ) , and thiolysis by a 3 - ketoacyl - CoA - thiolase 
genomic manipulation ( Blazeck et al . 2013b ; Dujon et al . 55 ( POT1 or PAT1 ) ( Beopoulos et al . 2009a ) . The PEX10p 
2004 ; Fickers et al . 2003 ; Juretzek et al . 2001 ; Matsuoka et transcription factor has been implicated in peroxisomal 
al . 1993 ) . Y . lipolytica is commonly utilized for heterologous biogenesis and Apex10 mutants display increased triacyl 
protein excretion and to examine and manipulate lipid and glyceride content ( Blazeck et al . 2013a ; Hong et al . 2012 ; 
fatty acid metabolism ( Beopoulos et al . 2009b ; Beopoulos et Zhu et al . 2012 ) . 
al . 2008 ; Dulermo and Nicaud 2011 ; Madzak et al . 2004 ; 60 Genomic modifications to Y . lipolytica ' s fatty acid , lipid , 
Thevenieau et al . 2009 ) , and has proven amenable to down - and central carbon metabolism have shown promise towards 
stream manipulation of its fatty acid content to alter desatu - increasing lipid accumulation capacity . Deletion of the six 
ration levels ( Chuang et al . 2010 ) or to synthesize novel POX genes increased ex novo incorporation of oleic acid in 
oleo - chemicals ( Blazeck et al . 2013a ) . Thus , Y . lipolytica Y . lipolytica , while deletion of the single MFE1 gene had a 
lipid reserves are ideal for in vivo catalysis to alkanes 65 similar effect ( Beopoulos et al . 2008 ; Dulermo and Nicaud 
( Schirmer et al . 2010 ) , fatty acid esters ( Shi et al . 2012 ) or 2011 ) . Increasing G3P backbone levels by combining 
for standard transesterification - based conversion and use as GUT2p deletion and GPD1p overexpression in these B - oxi 
US 9 , 896 , 691 B2 
dation deficient backgrounds further increased ex novo lipid FIG . 5 . Heat map of lipid content based on Nile Red 
accumulation to 65 - 75 % triacylglyceride content ( Dulermo signal of Polf WT cultured in media formulations with 
and Nicaud 2011 ) . Overexpression of DGAlp increased de different carbon to nitrogen ratios after 4 days . 
novo triacylglyceride accumulation fourfold over control FIG . 6 . Heat map of lipid content based on Nile Red 
levels to 33 . 8 % triacylglyceride content , and co - overexpres - 5 signal of Polf - S1 - S2 - 0 cultured in media formulations with 
sion of ACC1p further increased triacylglyceride accumu - different carbon to nitrogen ratios after 4 days . 
lation to a final yield of 41 % triacylglyceride content ( Tai FIG . 7 . Heat map of lipid content based on Nile Red 
and Stephanopoulos 2013 ) . To date , no study has attempted signal of APEX10AMFEl cultured in media formulations 
to combine the beneficial effects of engineering Y . lipolyti 
ca ' s fatty acid , lipid and central metabolism in a single 10 FIG . 8 . Heat map of lipid content based on Nile Red 
strain . Additionally , Y . lipolytica ' s dependence on media signal of APEX10AMFE1 - pMCS - DGA1 cultured in media 
formulation for lipid accumulation has not been adequately formulations with different carbon to nitrogen ratios after 4 
explored , nor has its ability to randomly accumulate muta days . 
tions that enhance lipid accumulation . Furthermore , no FIG . 9 . Nile Red assay quantify lipid content on Day 4 
attempt has been made to utilize mutation - based evolution - 15 with different strains growing on different saccharides as 
ary selection to identify novel lipogenic genotypes . Thus , genic genotynes . Thus carbon sources . Saccharide initial concentration was set at 
the ultimate capacity of Y . lipolytica to accumulate lipids and 80 g / L with 5 g / L ammonium sulfate . 
other oleochemicals has not been unlocked . To this end , we FIG . 10 . Nile Red assay quantify lipid content of isolated 
have employed a large scale combinatorial approach to L36 strain cultured in C160NO . 2 media supplemented with 
maximize lipid production while accounting for unexpected 20 multiple micronutrients after 2 , 4 , and 8 days of cultivation . 
interactions between genotype and environmentally - induced FIG . 11 . Nile Red assay quantify lipid content with EMS 
phenotype . The present invention provides solutions to these mutagenesis in evolved L36 strains and L36 . 
and other problems in the art . FIG . 12 . Fluorescence light microscopy pictures of lipid 
accumulation in selected strains . Lipids were stained with 
BRIEF SUMMARY 25 Nile Red as usual . Strain APEX10AMFE1 - PMCS - DGA1 
shows almost total lipid content while PO1f WT has very 
In a first aspect is provided a genetically modified ole little . 
aginous organism ( e . g . yeast cell , oleaginous yeast cell , FIG . 13 . General lipid metabolism in yeast and a portion 
Yarrowia lipolytica , algae , or plant cell ) wherein the dry of selected targets to engineering lipid metabolism . 
weight of said yeast cell includes greater than 60 % wt / wt 30 FIG . 14 . The isolation and characterization of superior 
lipids , lipid precursors , and / or oleochemicals . lipid production strain L36 . 
In a second aspect is provided a method of producing a FIG . 15 . Fatty acid profiles for different strains . 
lipid , lipid precursor , or oleochemical ( e . g . , lipid , lipid FIG . 16 . Lipid accumulation in strain POlf and 
precursor , oleochemical ) including : 1 ) culturing a yeast cell PO1fAaco1 DGA1 leu + ura + characterized with flow cytom 
as described herein ( including embodiments or as described 35 etry using cells stained with Nile Red on 48 hour and 96 hour 
in the examples , tables , figures , and / or claims ) in a growth time point . The starting OD of the culture is 2 . 5 and the cells 
medium ; and 2 ) isolating the lipid , lipid precursor , or were cultivated in yeast synthetic medium with 80 g / L 
oleochemical ( e . g . , lipid , lipid precursor , oleochemical ) ( e . g . glucose . 
from the medium or yeast cell ) . FIG . 17 . Lipid accumulation characterized with flow 
In a third aspect is provided a method of isolating a 40 cytometry using cells stained with Nile Red on 192 h time 
genetically modified yeast cell from a plurality of yeast cells , point . The starting OD of the culture is 5 and the cells were 
including greater than 60 % wt / wt lipids , lipid precursors , cultivated in yeast synthetic medium with 160 g / L glucose 
and / or oleochemicals in dry weight , including allowing a and 0 . 2 g / L ammonium sulfate . Illustrated in the bar graph , 
genetically modified yeast cell to separate from a population L36Amga2 presented a significantly reduced lipid level 
of yeast cells within the plurality of yeast cells by floating 45 comparing to L36 and L36Amga2 MGA2 - 36 presented an 
above the population of yeast cells within an aqueous elevated level of lipid accumulation comparing to 
medium thereby isolating the genetically modified yeast L36Amga2 , indicating that mga2 - 36 is the reason of the high 
cell , wherein the population of yeast cells includes a lower lipid accumulation phenotype in L36 strain . Combining the 
percentage wt / wt of lipids , lipid precursors , and / or oleo data with Amga2 and Amga2 MGA2 - 36 in POlf , this set of 
chemicals than said genetically modified yeast cell . 50 data proves that Amga2 can lead to improved lipid accumu 
lation and further introduce the mutant transcriptional factor 
BRIEF DESCRIPTION OF THE DRAWINGS MGA2 - 36 can further elevate the level of lipid accumula 
tion . ( All strains in the set contain an episomal plasmid with 
FIG . 1 . Nile Red assay quantifying lipid content of Polf LEU2 ) . Lipid accumulation characterized with flow cytom 
WT strain in C160NO . 2 media supplemented with individual 55 etry using cells stained with Nile Red on 192 h time point 
micronutrients after 2 , 4 , and 8 days of cultivation . with yeast synthetic medium containing 160 g / L glucose and 
FIG . 2 . Nile Red assay quantifying lipid content of Polf 0 . 2 g / L ammonium sulfate and 96 h time point with yeast 
WT strain in C160NO . 2 media supplemented with multiple synthetic medium containing 80 g / L glucose and 5 g / L 
micronutrients after 2 , 4 , and 8 days of cultivation . ammonium sulfate . Introducing MGA2 - 36 to the engineered 
FIG . 3 . Nile Red assay quantify lipid content of 46 60 strain leads to elevated level of lipid accumulation , suggest 
rationally constructed genetically modified Polf deriva - ing MGA2 - 36 can be used a lipid enhancer in the rationally 
tives . engineered lipid production strain . Lipid accumulation char 
FIG . 4 . Fold improvement of lipid accumulation ( from acterized with flow cytometry using cells stained with Nile 
Nile Red assay signal ( RFU ) ) by enabling the capacity to Red on 192 h time point with yeast synthetic medium 
synthesis leucine through incorporation of the LEU2 marker 65 containing 160 g / L glucose and 0 . 2 g / L ammonium sulfate . 
to different genotypic background . LEU2 expression can be PO1fAmga2 leu + showed improved level of lipid accumu 
from an episomal or an integrated sequence . lation comparing to Polf leur indicating mga2 knockout 
US 9 , 896 , 691 B2 
could improve lipid accumulation . Introducing a transmem - analyzed the effect of nitrogen starvation and carbon level on 
brane domain truncated MGA2 - 36 in POlf could elevate the a wildtype Y . lipolytica strain and a strain with two genomic 
lipid level inside the cell . modifications to increase lipid ( e . g . triacylglyceride ) accu 
FIG . 18 . Gas chromatography characterization of major m ulation . By testing twenty media formulations containing 
fatty acid species profile in POlf , Engineered strain and 5 between 10 g / L and 320 g / L glucose and 0 . 04 g / L and 10 g / L 
L36 . L36 overproduced C16 : 1n9 fatty acid which could be ammonium sulfate , we demonstrated that increasing carbon 
linked with the mutant of MGA2 gene , which plays an to nitrogen ratio ( C : N ratio ) generally induces lipid ( e . g . important function on activating / regulating delta9 desatu triacylglyceride ) accumulation , that carbon level is more rase expression . important than nitrogen level towards this induction , and FIG . 19 . Lipid accumulation characterized with flow 10 that this optimum carbon level is dependent upon genomic cytometry using cells stained with Nile Red on 96 h time background . We further determined that lipid ( e . g . triacyl point with yeast synthetic medium containing 80 g / L glucose 
glyceride ) accumulation could be increased through the and 5 g / L ammonium sulfate . 1 ” round EMS mutagenesis 
and floating cell transfer method selected strain E26 and E13 addition of certain metallic cofactors in the wildtype back 
using final engineered strain POlf Apex10 , mfe DGA1 leu + ground as well as for some Y . lipolytica strains already 
ura + presented a higher lipid accumulation level comparing 15 engineered for increased lipid ( e . g . triacylglyceride ) content . 
to the engineered strain . In an effort to rationally engineer Y . lipolytica for increased 
FIG . 20 . Lipid production ( g / L ) in bioreaction with 160 lipid ( e . g . triacylglyceride ) accumulation while accounting 
g / L glucose and 13 . 4 g / L YNB with ammonium sulfate for unpredictable cumulative effects arising from simulta 
without amino acid ( set control DO at 50 % and pH = 3 . 5 ) neously altering fatty acid , lipid , and central carbon metabo 
with engineered strain and evolved strain E26 . 20 lism , we overexpressed multiple ( e . g . five ) enzymes impli 
FIG . 21 . List of consensus mutations in strain E26 and cated in lipid ( e . g . triacylglyceride ) accumulation in multiple 
E13 identified in open reading frame through next genera ( e . g . four ) background strains differentially deficient in fatty 
tion sequencing analysis . Among them , YLOSH6 ; acid degradation . These native enzymatic overexpressions 
YLIRC20 ; YLRME1 ; YLYOX1 ; YLUGA2 contains mis were driven by high - strength constitutive promoters , 
sense mutations in annotated protein . occurred singly or in tandem with a second enzyme over 
FIG . 22 . Summary illustration of 1st and 2nd round of expression , and alleviated one of two auxotrophies ( leucine EMS mutagenesis and floating cells transfer selection with and uracil ) . This combinatorial approach generated over 50 final engineered strain Polf Apex10 , mfe DGA1 leu + ura + distinct genotypes that produced a large range in lipid ( e . g . as starting strain for evolving and selecting high lipid triacylglyceride ) accumulation ability , culminating in production strain . Green indicating the final engineering 
strain , blue indicating the non - EMS treated control stains 30 upwards of 40 - fold above control when using Nile - red based 
and red indicating the selected high lipid production strains . fluorescence and nearly 5 - fold when using concentration 
Strains were rank ordered based on the value cultured ( g / L ) or percent lipid by cell mass ( % dcw ) . In the process , 
OD600 * Nile Red mean fluorescence intensity * 10 - 4 . we discovered a correlation between the auxotrophic marker 
FIG . 23 . Fermentation profiles of pex10 mfel leucine + used to select for protein overexpression and a strain ' s 
uracil + DGA1 and Polf leucine + uracil " . Time courses of 35 capacity to accumulate oleo - content . Specifically , the ability 
the 1 . 5 L scale batch fermentation of the pex 10 mfel to endogenously produce the amino acid leucine , conferred 
leucine uracil + DGA1 ( a , b ) and Polf leucine uracil + ( c , d ) by a selectable leucine auxotrophic marker , is beneficial 
strains in 80 g / L glucose , 6 . 7 g / L YNB ( no amino acids , ( e . g . essential ) to enable high lipid titer . We further exam 
1 . 365 g / L ammonium ) are shown , including production of ined a few ( e . g . thirteen ) of these strains to determine how 
biomass , lipids , and citric acid ( left axis a , c ) , consumption of 40 C : N ratio and genotype interacted towards producing lipid 
glucose ( right axis a , c ) , and ammonium level ( b , d ) . ( a ) ( e . g . triacylglyceride ) content on a larger scale . We observed 
During the pex10 mfel leucine uracil + DGA1 fermentation , a strong tendency towards high lipid ( e . g . triacylglyceride ) 
negligible citric acid was produced , and lipid product accu - levels in most high producers at a single media formula 
mulated during and after biomass production phases . This tion — cultivated in 80 g / L glucose and 5 g / L ammonium 
fermentation was run three times in identical conditions , 45 sulfate . We selected a MFE1 , PEX10 double knockout strain fermentation was run three times in identical conditions , 15 sulfate We selected a MFEL PEX10 double knockout strain reaching final yields of 15 . 25 g / L lipids and 20 . 3 g / L with no auxotrophies overexpressing the DGAlp lipid syn 
biomass ( 75 % lipid content ) , 14 . 96 g / L lipids and 20 . 6 g / L thesis as our final rationally engineered strain , and demon biomass ( 73 % lipid content ) , and 16 . 9 g / L lipids and 19 . 21 strated its triacylglyceride accumulation ability on a variety g / L biomass ( 88 % lipid content ) . Most time points show of carbon sources , demonstrating its robust capacity to average values from the former two fermentations ( 75 % and 
73 % final lipid content ) , while endpoints represent averages 50 accumulate triacylglycerides regardless of media composi 
from all three final values . Glucose and ammonium substrate tion . 
were fully consumed after 72 hours , but surprisingly , ( b ) Through our time working with Y . lipolytica , we became 
ammonium level was replenished to a steady state level of aware of its surprising capacity to randomly ( or forcibly 
- 0 . 5 g / L , almost 40 % of the original starting level . ( c ) through the use of an exogenous mutagen such as EMS ) 
During the PO1f leucine + uracil + fermentation , citric acid 55 generate isolatable sub - strains that reproducibly displayed 
accumulated to more than 14 g / L after 72 hours before higher than wildtype triacylglyceride levels . In fact , one 
quickly reducing to 4 g / L . Lipid production did not trend such strain , dubbed L36 , displayed remarkable accumula 
with biomass production , reaching a final yield of only 3 g / L tion ability . Whole - genome sequencing of this strain pin 
lipids , compared to 30 g / L biomass , and glucose was again pointed a mutation in the MGA2 transcriptional regulator as 
consumed within 72 hours . ( d ) Ammonium was fully con - 60 the most likely genomic explanation . Complementation 
sumed after 72 hours with no replenishment as observed in assays of an MGA2p truncation mutant into wildtype back 
the mutant strain . ground reached 50 % of L36 lipid levels . We sought to 
harness this general capacity for beneficial mutation by 
DETAILED DESCRIPTION subjecting wildtype , L36 , and two of our highest producing 
65 rationally engineered strains to ethylmethanesulfonate 
Our work described herein represents the largest scale ( EMS ) mutagenesis and positive selection . By combining 
engineering effort in an oleaginous organism to date . We large - scale investigations of phenotypic induction , genomic 
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engineering , and positive random mutations , this work minuta , Rhodotorula mucilaginosa , Rhodotorula mucilagi 
establishes a framework for engineering oleaginous organ nosa Rhodotorula mucilaginosa , Rhodotorula terpenoidalis , 
isms for increased lipid production . In this regard , we have Rhodotorula toruloides , Sporobolomyces alborubescens , 
pinpointed specific media formulations , genomic modifica Starmerella bombicola , Torulaspora delbruekii , Toru 
tions , and genomic mutations that positively effect lipid ( e . g . 5 laspora pretoriensis , Trichosporon behrend , Trichosporon 
triacylglyceride ) biosynthesis . The resultant strains are ideal brassicae , Trichosporon cutaneum , Trichosporon domesti 
for direct biodiesel precursor synthesis , lipid synthesis , cum , Trichosporon fermentans , Trichosporon laibachii , 
oleochemical synthesis , lipid precursor synthesis , or for in Trichosporon loubieri , Trichosporon loubieri var . loubieri , 
vivo catalysis of fatty acid reserves to value added chemi - Trichosporon montevideense , Trichosporon pullulans , Wick 
cals . Lipid accumulation characterized with flow cytometry 10 erhamomyces canadensis , Yarrowia lipolytica , and Zygoas 
using cells stained with Nile Red on 192 h time point with cus meyerae . 
yeast synthetic medium containing 160 g / L glucose and 0 . 2 The term “ buoyancy ” is used according to its plain 
g / L ammonium sulfate and 96 h time point with yeast ordinary meaning and refers to the upward force exerted by 
synthetic medium containing 80 g / L glucose and 5 g / L a fluid , which opposes the weight of an immersed object 
ammonium sulfate . Introducing MGA2 - 36 to the engineered 15 ( e . g . oleaginous organism or oleaginous yeast cell ) . Pressure 
strain leads to elevated level of lipid accumulation , suggest increases with depth , resulting in a net force tending to 
ing MGA2 - 36 can be used a lipid enhancer in the rationally accelerate object upward , wherein the magnitude of the 
engineered lipid production strain . Lipid accumulation char - force is proportional to the difference between the top and 
acterized with flow cytometry using cells stained with Nile bottom of the fluid and is equivalent to the weight of the fluid 
Red on 192 h time point with yeast synthetic medium 20 that would otherwise occupy the space occupied by the 
containing 160 g / L glucose and 0 . 2 g / L ammonium sulfate . Object ( i . e . the displace fluid ) . In embodiments , an oleagi 
PO1fAmga2 leu + showed improved level of lipid accumu - nous organism or yeast cell is considered “ buoyant ” when it 
lation comparing to Polf leu + indicating mga2 knockout does not settle ( e . g . due to gravitation force alone , due to 
could improve lipid accumulation . Introducing a transmem centrifugal force , due to an applied force , or due to a 
brane domain truncated MGA2 - 36 in PO1fcould elevate the 25 combination of forces such as centrifugation ) to the bottom 
lipid level inside the cell . of a vessel holding a liquid ( e . g . media ) in which the 
oleaginous organism or yeast cell resides . For example , a 
I . DEFINITIONS cell may be buoyant if it floats above the bottom of the 
vessel , at an intermediate position between the bottom level 
The term " oleaginous organism ” means an organism ( e . g . 30 and top level of the liquid , or on top of the upper surface of 
a cell such as a yeast cell ) that is capable of producing a the liquid . An example of a measurement of the buoyancy of 
lipid , lipid precursor , oleochemical , or oil ( or combinations an object ( e . g . cell ) is the weight of the fluid the object would 
thereof ) at a level exceeding the amount required for normal displace if the object were placed in the fluid . Another 
cellular survival and propagation of the organism ( e . g . cell , example of a measurement of the buoyancy of an object ( e . g . 
yeast cell ) , such as for example necessary for structural 35 cell ) is a comparison of the average density of the object and 
integrity ( e . g . membrane formation and maintenance ) and the average density of the liquid to be displaced , taking into 
cellular maintenance . Examples of amounts exceeding the account the depth of the liquid in a column of the liquid . The 
amount required for normal cellular survival and propaga - term “ buoyant density ” is used according to its plain ordi 
tion include an amount of lipids , oils , lipid precursors , and nary meaning and refers to a measure of the tendency of a 
oleochemicals greater than 20 % wt / wt total dry weight ( e . g . 40 substance to float in some other substance . 
greater than 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , The term " carbon substrate ” means a carbon source that 
33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , a microorganism ( e . g . oleaginous organism or oleaginous 
49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , yeast ) will metabolize to derive energy ( e . g . monosaccha 
65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , rides , oligosaccharides , polysaccharides , alkanes , fatty 
81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 45 acids , esters of fatty acids , monoglycerides , carbon dioxide , 
97 , 98 , or 99 % ) . In embodiments , the oleaginous organism methanol , formaldehyde , formate or carbon - containing 
is an oleaginous yeast . In some embodiments , the oleaginous amines ) . The term " carbon source ” refers to a carbon 
yeast is from a genus selected from the group consisting of containing composition ( e . g . compound , mixture of com 
Apiotrichum , Candida Cryptococcus , Debaromyces , pounds ) that an organism ( e . g . oleaginous organism , yeast 
Endomycopsis , Geotrichum , Hyphopichia , Lipomyces , 50 cell ) may metabolize for use by the organism or that may be 
Lypomyces , Pichia , Rodosporidium , Rhodotorula , Sporobo - used for organism viability . A “ majority carbon source ” 
lomyces , Starmerella , Torulaspora , Trichosporon , Wicker - refers to a carbon containing composition that accounts for 
hamomyces , Yarrowia , and Zygoascus . In embodiments , the greater than 50 % of the available carbon sources for an 
oleaginous yeast is selected from the group consisting of organism ( e . g . in a media , in a growth media , in a defined 
Apiotrichum curvatum , Candida apicola , Candida curvata , 55 media for growing yeast cells , or in a defined media for 
Candida revkaufi , Candida pulcherrima , Candida tropica producing lipids by yeast cells ) at a specified time ( e . g . 
lis , Candida utilis , Cryptococcus curvatus , Cryptococcus media when starting a yeast culture , media in a bioreactor 
terricolus , Debaromyces hansenii , Endomycopsis vernalis , when growing yeast , or media when producing lipids from 
Geotrichum carabidarum , Geotrichum cucujoidarum , yeast ) . In embodiments , an oleaginous yeast may be cultured 
Geotrichum histeridarum , Geotrichum silvicola , Geotri - 60 using a medium comprising one or more carbon sources 
chum vulgare , Hyphopichia burtonii , Lipomyces lipoferus , selected from the group consisting of glucose , fructose , 
Lipomyces lipofer , Lypomyces orentalis , Lipomyces starkevi , sucrose , lactose , galactose , xylose , mannose , rhamnose , 
Lipomyces tetrasporous , Pichia mexicana , Rodosporidium arabinose , glycerol , acetate , depolymerized sugar beet pulp , 
sphaerocarpum , Rhodosporidium toruloides , Rhodotorula black liquor , corn starch , depolymerized cellulosic material , 
aurantiaca , Rhodotorula dairenensis , Rhodotorula diffluens , 65 corn stover , sugar beet pulp , switchgrass , milk whey , molas 
Rhodotorula glutinus , Rhodotorula glutinis var . glutinis , ses , potato , rice , sorghum , sugar cane , wheat , and mixtures 
Rhodotorula gracilis , Rhodotorula graminis , Rhodotorula thereof ( e . g . mixtures of glycerol and glucose , mixtures of 
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glucose and xylose , mixtures of fructose and glucose , mix - centage is calculated based on the weight of the biomass 
tures of sucrose and depolymerized sugar beet pulp , black after substantially all water has been removed . 
liquor , corn starch , depolymerized cellulosic material , corn The term " growth ” means an increase in cell size , total 
stover , sugar beet pulp , switchgrass , milk whey , molasses , cellular contents , and / or cell mass or weight of a cell ( e . g . 
potato , rice , sorghum , sugar cane , and / or wheat ) . In embodi - 5 oleaginous organism or oleaginous yeast ) . 
ments , an oleaginous yeast is cultured using a medium The term " lipid ” refers to a class of molecules that are 
comprising one or more carbon sources selected from the soluble in nonpolar solvents ( e . g . ether or chloroform ) , are 
group consisting of depolymerized sugar beet pulp , black relatively or completely insoluble in water , and include one 
liquor , corn starch , depolymerized cellulosic material , corn or more hydrocarbon chains which are hydrophobic . In 
stover , sugar beet pulp , switchgrass , milk whey , molasses , 10 embodiments , a lipid may be a triacylglyeride ( i . e . fat ) , fatty 
potato , rice , sorghum , sugar cane , thick cane juice , sugar acid ( e . g . saturated or unsaturated ) ; glyceride or glycerolipid 
beet juice , and wheat . In embodiments , an oleaginous yeast ( e . g . monoglyceride , diglyceride , triglyceride , neutral fat , 
is cultured using a medium comprising lignocellulosic bio - phosphoglyceride , or glycerophospholipid ) ; sphingolipid ; 
mass . In embodiments carbon sources may be monosaccha - sterol lipid ( e . g . cholesterol or a steroid hormone ) ; prenol 
rides ( e . g . , glucose , fructose ) , disaccharides ( e . g . , lactose , 15 lipid ( e . g . terpenoid ) ; fatty alcohol ; wax ; polyketide ; sugar 
sucrose ) , oligosaccharides , polysaccharides ( e . g . , starch , linked lipid , glycolipid , or protein - linked lipid . 
cellulose or mixtures thereof ) , sugar alcohols ( e . g . , glycerol ) The term “ oil ” means a triacylglyceride ( or triglyceride 
or mixtures from renewable feedstocks ( e . g . , cheese whey oil ) , produced by an organism ( e . g . oleaginous organism , 
permeate , cornsteep liquor , sugar beet molasses , or barley oleaginous yeast , plant , and / or animal ) . An oil is generally 
malt ) . Additionally , carbon sources may include alkanes , 20 liquid at normal ambient temperatures and pressures . In 
fatty acids , esters of fatty acids , monoglycerides , diglycer - embodiments , oil may be vegetable or seed oils derived from 
ides , triglycerides , phospholipids , various commercial plants ( e . g . soy , rapeseed , canola , palm , palm kernel , coco 
sources of fatty acids including vegetable oils ( e . g . , soybean nut , corn , olive , sunflower , cotton seed , cuphea , peanut , 
oil ) or animal fats . camelina sativa , mustard seed , cashew nut , oats , lupine , 
Nitrogen may be supplied from an inorganic ( e . g . , ( NH4 ) 2 25 kenaf , calendula , hemp , coffee , linseed , hazelnut , euphor 
SO4 ) or organic source ( e . g . , urea , glutamate ) . The term bia , pumpkin seed , coriander , camellia , sesame , safflower , 
" nitrogen source ” refers to a nitrogen containing composi - rice , tung oil tree , cocoa , copra , pium poppy , castor beans , 
tion ( e . g . compound , mixture of compounds , salt ) that an pecan , jojoba , jatropha , macadamia , Brazil nuts , avocado , or 
organism ( e . g . oleaginous organism , yeast cell ) may metabo - combinations thereof ) . An oil may include a plurality of 
lize for use by the organism or that may be used for organism 30 different triacylglycerides . For example , a vegetable or seed 
viability . A “ majority nitrogen source ” refers to a nitrogen oil may include more than one triacylglyceride and use of 
containing composition that accounts for greater than 50 % the name of that vegetable or seed oil ( e . g . soy , rapeseed , 
of the available nitrogen sources for an organism ( e . g . in a canola , palm , etc . ) when referring to an oil generated by an 
media , in a growth media , in a defined media for growing oleaginous organism will be understood to mean an oil 
yeast cells , or in a defined media for producing lipids by 35 including most ( e . g . all ) of the triacylglycerides normally in 
yeast cells ) at a specified time ( e . g . media when starting a the vegetable or seed oil ( e . g . at different ratios relative to 
yeast culture , media in a bioreactor when growing yeast , or each other or the same or similar ratios relative to each 
media when producing lipids from yeast ) . other ) . In other embodiments , an oil may be a plurality of 
The term “ Biomass ” refers to material produced by triacylglyceride and other lipid molecules produced by an 
growth and / or propagation of cells . “ Lignocellulosic bio - 40 oleaginous organism . 
mass ” is used according to it plain ordinary meaning and The term " propagation ” refers to an increase in cell 
refers to plant dry matter comprising carbohydrate ( e . g . number via cell division . 
cellulose or hemicellulose ) and polymer ( e . g . lignin ) . Ligno The terms “ V / V ” , “ vol / vol ” , or “ v / v ” , referring to pro 
cellulosic biomass may include agricultural residues ( e . g . portions by volume , means the ratio of the volume of one 
corn stover or sugarcane bagasse ) , energy crops ( e . g . poplar 45 substance in a composition to the volume of the total 
trees , willow , Miscanthus purpureum , Pennisetum pur - composition including the substance . 
pureum , elephant grass , maize , Sudan grass , millet , white The term “ W / W ” , " wt / wt " , or " w / w ” , referring to pro 
sweet clover , rapeseed , giant miscanthus , switchgrass , jatro - portions by weight , means the ratio of the weight of one 
pha , Miscanthus giganteus , or sugarcane ) , wood residues substance in a composition to the weight of the total com 
( e . g . sawmill or papermill discard ) , or municipal paper 50 position including the substance . For example , 5 % w / w 
substance X means that 5 % of the composition ' s weight is 
The term “ Culture ” , " cultivate ” , and “ ferment ” are used composed of substance X and the remainder of the weight of 
interchangeably and refer to the intentional growth , propa the composition ( i . e . 95 % ) is composed of other substances . 
gation , proliferation , and / or enablement of metabolism , The term “ promoter ” or “ regulatory element ” refers to a 
catabolism , and / or anabolism of one or more cells ( e . g . 55 region or sequence determinants located upstream or down 
oleaginous organism or oleaginous yeast ) . The combination stream from the start of transcription and which are involved 
of both growth and propagation may be termed proliferation in recognition and binding of RNA polymerase and other 
Examples include production by an organism of lipids , lipid proteins to initiate transcription . Promoters need not be of 
precursors , and / or oleochemicals or production of a lipid , yeast origin , for example , promoters derived from viruses or 
lipid precursor , and / or oleochemical of interest . Culture does 60 from other organisms can be used in the compositions or 
not refer to the growth or propagation of microorganisms in methods described herein . 
nature or otherwise without human intervention . A polynucleotide sequence is " heterologous to ” a second 
The terms “ dry weight ” and “ dry cell weight ” are used polynucleotide sequence if it originates from a foreign 
interchangeably and refer to a weight determined in the species , or , if from the same species , is modified by human 
relative absence of water . In embodiments , oleaginous yeast 65 action from its original form . For example , a promoter 
biomass comprising a fraction or percentage of a particular operably linked to a heterologous coding sequence refers to 
component by dry weight means that the fraction or per a coding sequence from a species different from that from 
waste . 
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which the promoter was derived , or , if from the same sium channel splice variants is discussed in Leicher , et al . , 
species , a coding sequence which is different from naturally J . Biol . Chem . 273 ( 52 ) : 35095 - 35101 ( 1998 ) . 
occurring allelic variants . The term “ expression cassette ” refers to a nucleic acid 
The term “ recombinant ” refers to a human manipulated construct , which when introduced into a host cell , results in 
nucleic acid ( e . g . polynucleotide ) or a copy or complement 5 transcription and / or translation of a RNA or polypeptide , 
of a human manipulated nucleic acid ( e . g . polynucleotide ) , respectively . 
or if in reference to a protein ( i . e , a “ recombinant protein " ) , The terms “ identical ” or percent “ identity , ” in the context 
a protein encoded by a recombinant nucleic acid ( e . g . of two or more nucleic acids or polypeptide sequences , refer 
polynucleotide ) . In embodiments , a recombinant expression to two or more sequences or subsequences that are the same 
cassette comprising a promoter operably linked to a second and 10 or have a specified percentage of amino acid residues or nucleotides that are the same ( i . e . , about 60 % identity , nucleic acid ( e . g . polynucleotide ) may include a promoter preferably 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , that is heterologous to the second nucleic acid ( e . g . poly 69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , nucleotide ) as the result of human manipulation ( e . g . , by 79 % , 80 % , 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 
methods described in Sambrook et al . , Molecular Clon - 15 89 % , 90 % . 91 % 92 % . 93 % . 94 % , 95 % , 96 % , 97 % , 98 % , 
ing — A Laboratory Manual , Cold Spring Harbor Laboratory , 99 % or higher identity over a specified region when com 
Cold Spring Harbor , N . Y . , ( 1989 ) or Current Protocols in pared and aligned for maximum correspondence over a 
Molecular Biology Volumes 1 - 3 , John Wiley & Sons , Inc . comparison window or designated region ) as measured 
( 1994 - 1998 ) ) . In another example , a recombinant expression using a BLAST or BLAST 2 . 0 sequence comparison algo 
cassette may comprise nucleic acids ( e . g . polynucleotides ) 20 rithms with default parameters described below , or by 
combined in such a way that the nucleic acids ( e . g . poly manual alignment and visual inspection ( see , e . g . , NCBI 
nucleotides ) are extremely unlikely to be found in nature . web site or the like ) . Such sequences are then said to be 
For instance , human manipulated restriction sites or plasmid “ substantially identical . ” This definition also refers to , or 
vector sequences may flank or separate the promoter from may be applied to , the compliment of a test sequence . The 
the second nucleic acid ( e . g . polynucleotide ) . In embodi - 25 definition also includes sequences that have deletions and / or 
ments , a recombinant nucleic acid is a nucleic acid in an additions , as well as those that have substitutions . As 
oleaginous organism ( e . g . oleaginous yeast ) that has been described below , the preferred algorithms can account for 
manipulated by a human , for example a recombinant nucleic gaps and the like . Preferably , identity exists over a region 
acid comprising a coding region for a protein that is over that is at least about 10 amino acids or 20 nucleotides in 
expressed in an oleaginous organism relative to the absence 30 length , or more preferably over a region that is 10 - 50 amino 
of the recombinant nucleic acid or a recombinant nucleic acids or 20 - 50 nucleotides in length . As used herein , percent 
acid that results in disruption of a coding region or promoter ( % ) amino acid sequence identity is defined as the percent 
region of an oleaginous organism and reduces or eliminates age of amino acids in a candidate sequence that are identical 
expression of a protein relative the absence of the recom to the amino acids in a reference sequence , after aligning the 
binant nucleic acid . One of skill will recognize that nucleic 35 sequences and introducing gaps , if necessary , to achieve the 
acids ( e . g . polynucleotides ) can be manipulated in many maximum percent sequence identity . Alignment for pur 
ways and are not limited to the examples above . poses of determining percent sequence identity can be 
“ Nucleic acid ” or “ oligonucleotide ” or “ polynucleotide ” achieved in various ways that are within the skill in the art , 
or grammatical equivalents used herein means at least two for instance , using publicly available computer software 
nucleotides covalently linked together . The term “ nucleic 40 such as BLAST , BLAST - 2 , ALIGN , ALIGN - 2 or Megalign 
acid ” includes single - , double - , or multiple - stranded DNA , ( DNASTAR ) software . Appropriate parameters for measur 
RNA and analogs ( derivatives ) thereof . Oligonucleotides are ing alignment , including any algorithms needed to achieve 
typically from about 5 , 6 , 7 , 8 , 9 , 10 , 12 , 15 , 25 , 30 , 40 , 50 maximal alignment over the full - length of the sequences 
or more nucleotides in length , up to about 100 nucleotides being compared can be determined by known methods . 
in length . Nucleic acids and polynucleotides are a polymers 45 For sequence comparisons , typically one sequence acts as 
of any length , including longer lengths , e . g . , 200 , 300 , 500 , a reference sequence , to which test sequences are compared . 
1000 , 2000 , 3000 , 5000 , 7000 , 10 , 000 , etc . In certain When using a sequence comparison algorithm , test and 
embodiments , the nucleic acids herein contain phosphodi - reference sequences are entered into a computer , subse 
ester bonds . In other embodiments , nucleic acid analogs are quence coordinates are designated , if necessary , and 
included that may have alternate backbones . The term 50 sequence algorithm program parameters are designated . 
encompasses nucleic acids containing known analogues of Preferably , default program parameters can be used , or 
natural nucleotides which have similar or improved binding alternative parameters can be designated . The sequence 
properties , for the purposes desired , as the reference nucleic comparison algorithm then calculates the percent sequence 
acid . A particular nucleic acid sequence also encompasses identities for the test sequences relative to the reference 
" splice variants . ” Similarly , a particular protein encoded by 55 sequence , based on the program parameters . 
a nucleic acid encompasses any protein encoded by a splice A " comparison window ” , as used herein , includes refer 
variant of that nucleic acid . “ Splice variants , " as the name ence to a segment of any one of the number of contiguous 
suggests , are products of alternative splicing of a gene . After positions selected from the group consisting of from 10 to 
transcription , an initial nucleic acid transcript may be 600 , usually about 50 to about 200 , more usually about 100 
spliced such that different alternate ) nucleic acid splice 60 to about 150 in which a sequence may be compared to a 
products encode different polypeptides . Mechanisms for the reference sequence of the same number of contiguous posi 
production of splice variants vary , but include alternate tions after the two sequences are optimally aligned . Methods 
splicing of exons . Alternate polypeptides derived from the of alignment of sequences for comparison are well - known in 
same nucleic acid by read - through transcription are also the art . Optimal alignment of sequences for comparison can 
encompassed by this definition . Any products of a splicing 65 be conducted , e . g . , by the local homology algorithm of 
reaction , including recombinant forms of the splice prod Smith & Waterman , Adv . Appl . Math . 2 : 482 ( 1981 ) , by the 
ucts , are included in this definition . An example of potas homology alignment algorithm of Needleman & Wunsch , J . 
13 
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Mol . Biol . 48 : 443 ( 1970 ) , by the search for similarity The phrase " stringent hybridization conditions ” refers to 
method of Pearson & Lipman , Proc . Nat ' l . Acad . Sci . USA conditions under which a probe will hybridize to its target 
85 : 2444 ( 1988 ) , by computerized implementations of these subsequence , typically in a complex mixture of nucleic 
algorithms ( GAP , BESTFIT , FASTA , and TFASTA in the acids , but to no other sequences . Stringent conditions are 
Wisconsin Genetics Software Package , Genetics Computer 5 sequence - dependent and will be different in different cir 
Group , 575 Science Dr . , Madison , Wis . ) , or by manual cumstances . Longer sequences hybridize specifically at 
alignment and visual inspection ( see , e . g . , Current Protocols higher temperatures . An extensive guide to the hybridization 
in Molecular Biology ( Ausubel et al . , eds . 1995 supple of nucleic acids is found in Tijssen , Techniques in Biochem 
ment ) ) . istry and Molecular Biology - Hybridization with Nucleic 
One example of algorithm that is suitable for determining Probes , " Overview of principles of hybridization and the 
percent sequence identity and sequence similarity are the strategy of nucleic acid assays ” ( 1993 ) . Generally , stringent 
BLAST and BLAST 2 . 0 algorithms , which are described in conditions are selected to be about 5 - 10° C . lower than the 
Altschul et al . ( 1977 ) Nuc . Acids Res . 25 : 3389 - 3402 , and thermal melting point ( Tm ) for the specific sequence at a 
Altschul et al . ( 1990 ) J . Mol . Biol . 215 : 403 - 410 , respec - 15 defined ionic strength pH . The T , is the temperature ( under 
tively . Software for performing BLAST analyses is publicly defined ionic strength , pH , and nucleic concentration ) at 
available through the National Center for Biotechnology which 50 % of the probes complementary to the target 
Information ( http : / / www . ncbi . nlm . nih . gov / ) . This algorithm hybridize to the target sequence at equilibrium ( as the target 
involves first identifying high scoring sequence pairs ( HSPs ) sequences are present in excess , at Tm , 50 % of the probes are 
by identifying short words of length W in the query 20 occupied at equilibrium ) . Stringent conditions may also be 
sequence , which either match or satisfy some positive achieved with the addition of destabilizing agents such as 
valued threshold score T when aligned with a word of the formamide . For selective or specific hybridization , a positive 
same length in a database sequence . T is referred to as the signal is at least two times background , preferably 10 times 
neighborhood word score threshold ( Altschul et al . , supra ) . background hybridization . Exemplary stringent hybridiza 
These initial neighborhood word hits act as seeds for initi - 25 tion conditions can be as following : 50 % formamide , 
ating searches to find longer HSPs containing them . The 5xSSC , and 1 % SDS , incubating at 42° C . , or , 5xSSC , 1 % 
word hits are extended in both directions along each SDS , incubating at 65° C . , with wash in 0 . 2xSSC , and 0 . 1 % 
sequence for as far as the cumulative alignment score can be SDS at 65° C . 
increased . Cumulative scores are calculated using , for Nucleic acids that do not hybridize to each other under 
nucleotide sequences , the parameters M ( reward score for a 30 stringent conditions are still substantially identical if the 
pair of matching residues ; always > 0 ) and N ( penalty score polypeptides which they encode are substantially identical . 
for mismatching residues ; always < 0 ) . For amino acid This occurs , for example , when a copy of a nucleic acid is 
sequences , a scoring matrix is used to calculate the cumu - created using the maximum codon degeneracy permitted by 
lative score . Extension of the word hits in each direction are the genetic code . In such cases , the nucleic acids typically 
halted when : the cumulative alignment score falls off by the 35 hybridize under moderately stringent hybridization condi 
quantity X from its maximum achieved value ; the cumula - tions . Exemplary “ moderately stringent hybridization con 
tive score goes to zero or below , due to the accumulation of ditions ” include a hybridization in a buffer of 40 % forma 
one or more negative - scoring residue alignments ; or the end mide , 1 M NaCl , 1 % SDS at 37° C . , and a wash in 1xSSC 
of either sequence is reached . The BLAST algorithm param - at 45° C . A positive hybridization is at least twice back 
eters W , T , and X determine the sensitivity and speed of the 40 ground . Those of ordinary skill will readily recognize that 
alignment . The BLASTN program ( for nucleotide alternative hybridization and wash conditions can be utilized 
sequences ) uses as defaults a wordlength ( W ) of 11 , an to provide conditions of similar stringency . Additional 
expectation ( E ) or 10 , M = 5 , N = - 4 and a comparison of both guidelines for determining hybridization parameters are 
strands . For amino acid sequences , the BLASTP program provided in numerous reference , e . g . , and Current Protocols 
uses as defaults a wordlength of 3 , and expectation ( E ) of 10 , 45 in Molecular Biology , ed . Ausubel , et al . One of skill will 
and the BLOSUM62 scoring matrix ( see Henikoff and recognize that these values can be appropriately adjusted to 
Henikoff ( 1989 ) Proc . Natl . Acad . Sci . USA 89 : 10915 ) determine corresponding identity of proteins encoded by 
alignments ( B ) of 50 , expectation ( E ) of 10 , M = 5 , N = - 4 , and two nucleotide sequences by taking into account codon 
a comparison of both strands . degeneracy , amino acid similarity , reading frame positioning 
The BLAST algorithm also performs a statistical analysis 50 and the like . Polypeptides which are “ substantially similar ” 
of the similarity between two sequences ( see , e . g . , Karlin share sequences as noted above except that residue positions 
and Altschul ( 1993 ) Proc . Natl . Acad . Sci . USA 90 : 5873 - which are not identical may differ by conservative amino 
5787 ) . One measure of similarity provided by the BLAST acid changes . Conservative amino acid substitutions refer to 
algorithm is the smallest sum probability ( P ( N ) ) , which the interchangeability of residues having similar side chains . 
provides an indication of the probability by which a match 55 For example , a group of amino acids having aliphatic side 
between two nucleotide or amino acid sequences would chains is glycine , alanine , valine , leucine , and isoleucine ; a 
occur by chance . For example , a nucleic acid is considered group of amino acids having aliphatic - hydroxyl side chains 
similar to a reference sequence if the smallest sum prob - is serine and threonine ; a group of amino acids having 
ability in a comparison of the test nucleic acid to the amide - containing side chains is asparagine and glutamine ; a 
reference nucleic acid is less than about 0 . 2 , more preferably 60 group of amino acids having aromatic side chains is phe 
less than about 0 . 01 . nylalanine , tyrosine , and tryptophan ; a group of amino acids 
The phrase " selectively ( or specifically ) hybridizes to " having basic side chains is lysine , arginine , and histidine ; 
refers to the binding , duplexing , or hybridizing of a mol and a group of amino acids having sulfur - containing side 
ecule only to a particular nucleotide sequence with a higher chains is cysteine and methionine . Exemplary conservative 
affinity , e . g . , under more stringent conditions , than to other 65 amino acids substitution groups are : valine - leucine - isoleu 
nucleotide sequences ( e . g . , total cellular or library DNA or c ine , phenylalanine - tyrosine , lysine - arginine , alanine - va 
RNA ) . line , aspartic acid - glutamic acid , and asparagine - glutamine . 
15 
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The term “ modulator ” refers to a composition that 30000 , 40000 , 50000 , 60000 , 70000 , 80000 , 90000 , 
increases or decreases the level of a target molecule or the 100000 % , compared to the control . Similarly , the term 
level of activity or function of a target molecule or the “ decreased ” refers to a measurable decrease compared to a 
physical state of the target of the molecule . In embodiments control . In some embodiments , the decrease is by about 1 , 2 , 
a modulator is a recombinant nucleic acid that is capable of 5 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 
increasing or decreasing the amount of a protein in a cell or 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 
the level of activity of a protein in a cell or transcription of 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 
a second nucleic acid in a cell . In embodiments , a modulator 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 
increases or decreases the level of activity of a protein or the 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 
amount of the protein in a cell . The term “ modulate ” is used 10 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 
in accordance with its plain ordinary meaning and refers to 100 % , or more compared to the control . In embodiments , the 
the act of changing or varying one or more properties . decrease is by 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 
“ Modulation ” refers to the process of changing or varying 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 
one or more properties . For example , as applied to the effects 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 
of a modulator on a target protein , to modulate means to 15 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 
change by increasing or decreasing a property or function of 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 
the target molecule or the amount of the target molecule . In 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 
embodiments , a recombinant nucleic acid that modulates the 96 , 97 , 98 , 99 , 100 % , or more compared to the control . In 
level of activity of a protein may increase the activity or embodiments , the decrease is by at least 1 , 2 , 3 , 4 , 5 , 6 , 7 , 
amount of the protein relative the absence of the recombi - 20 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 
nant nucleic acid . In embodiments , an increase in the 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 
activity or amount of a protein may include overexpression 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 
of the protein . " Overexpression ” is used in accordance with 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 
its plain meaning and refers to an increased level of expres - 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 
sion of a protein relative to a control ( e . g . cell or expression 25 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 % , compared 
system not including a recombinant nucleic acid that con - to the control . One of ordinary skill will be able to identify 
tributes to the overexpression of a protein ) . In embodiments , a relevant control . 
a decrease in the activity or amount of a protein may include Nucleic acid is " operably linked ” when it is placed into a 
a mutation ( e . g . point mutant , loss of function mutation , functional relationship with another nucleic acid sequence . 
missense mutation , deletion , or insertion of heterologous 30 For example , DNA for a presequence or secretory leader is 
nucleic acid , all / any of which may be in the coding region operably linked to DNA for a polypeptide if it is expressed 
for a protein or in an operably linked region ( e . g . promoter ) ) as a preprotein that participates in the secretion of the 
of the protein . The term “ increased ” refers to a detectable polypeptide ; a promoter or enhancer is operably linked to a 
increase compared to a control . In some embodiments , the coding sequence if it affects the transcription of the 
increase is by about 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 35 sequence ; or a ribosome binding site is operably linked to a 
14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , coding sequence if it is positioned so as to facilitate trans 
30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , lation . Generally , " operably linked ” means that the DNA 
46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , sequences being linked are near each other , and , in the case 
62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , of a secretory leader , contiguous and in reading phase . 
78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 40 However , operably linked nucleic acids ( e . g . enhancers and 
94 , 95 , 96 , 97 , 98 , 99 , 100 , 110 , 120 , 130 , 140 , 150 , 160 , coding sequences ) do not have to be contiguous . Linking is 
170 , 180 , 190 , 200 , 250 , 300 , 350 , 400 , 500 , 550 , 600 , 650 , accomplished by ligation at convenient restriction sites . If 
700 , 750 , 800 , 850 , 900 , 950 , 1000 , 2000 , 3000 , 4000 , 5000 , such sites do not exist , the synthetic oligonucleotide adap 
6000 , 7000 , 8000 , 9000 , 10000 , 20000 , 30000 , 40000 , tors or linkers are used in accordance with conventional 
50000 , 60000 , 70000 , 80000 , 90000 , 100000 % , or more 45 practice . In embodiments , a promoter is operably linked 
compared to the control . In embodiments , the increase is by with a coding sequence when it is capable of affecting ( e . g . 
1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , modulating relative to the absence of the promoter ) the 
20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , expression of a protein from that coding sequence ( i . e . , the 
36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , coding sequence is under the transcriptional control of the 
52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 50 promoter ) . 
68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , “ Transformation ” refers to the transfer of a nucleic acid 
84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , molecule into a host organism ( e . g . oleaginous organism or 
100 , 110 , 120 , 130 , 140 , 150 , 160 , 170 , 180 , 190 , 200 , 250 , oleaginous yeast ) . In embodiments , the nucleic acid mol 
300 , 350 , 400 , 500 , 550 , 600 , 650 , 700 , 750 , 800 , 850 , 900 , ecule may be a plasmid that replicates autonomously or it 
950 , 1000 , 2000 , 3000 , 4000 , 5000 , 6000 , 7000 , 8000 , 9000 , 55 may integrate into the genome of the host organism ( e . g . 
10000 , 20000 , 30000 , 40000 , 50000 , 60000 , 70000 , 80000 , oleaginous organism or oleaginous yeast ) . Host organisms 
90000 , 100000 % , or more compared to the control . In containing the transformed nucleic acid molecule may be 
embodiments , the increase is by at least 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , referred to as “ transgenic ” or “ recombinant ” or “ trans 
9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , formed ” organisms ( e . g . oleaginous organism or oleaginous 
25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 60 yeast ) . A " genetically modified ” organism ( e . g . genetically 
41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , modified yeast cell ) is an organism ( e . g . yeast cell ) that 
57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , includes a nucleic acid that has been modified by human 
73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , intervention . Examples of a nucleic acid that has been 
89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 110 , 120 , 130 , modified by human intervention include , but are not limited 
140 , 150 , 160 , 170 , 180 , 190 , 200 , 250 , 300 , 350 , 400 , 500 , 65 to , insertions , deletions , mutations , expression nucleic acid 
550 , 600 , 650 , 700 , 750 , 800 , 850 , 900 , 950 , 1000 , 2000 , constructs ( e . g . over - expression or expression from a non 
3000 , 4000 , 5000 , 6000 , 7000 , 8000 , 9000 , 10000 , 20000 , natural promoter or control sequence or an operably linked 
=
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promoter and gene nucleic acid distinct from a naturally the protein and / or nucleic acid is a wildtype version of the 
occurring promoter and gene nucleic acid in an organism ) , protein or nucleic acid . In embodiments , the protein and / or 
extra - chromosomal nucleic acids , and genomically con nucleic acid is a mutant form of the protein and / or nucleic 
tained modified nucleic acids . Genetically modified organ acid ( e . g . point mutant , loss of function mutation , missense 
isms may be made by rational modification of a nucleic acid 5 mutation , deletion , or insertion of heterologous nucleic 
or may be made by use of a mutagen or mutagenesis acid ) . 
protocol that results in a mutation that was not identified In embodiments , the protein Leucine Biosynthesis Gene 
( e . g . intended or targeted ) prior to the use of the mutagen or ( LEU2 ) , also known as 3 - isopropylmalate dehydrogenase , is 
mutagenesis protocol ( e . g . UV exposure , EMS exposure , a protein able to be translated from the nucleic acid corre 
mutagen exposure , random genomic mutagenesis , transfor - 10 sponding to GenBank AF260230 or YALIOC00407 g of the 
mation of a library of different nucleic acid constructs ) . Genolevures database ( i . e . found at http : / / www . genolevure 
Genetically modified organisms that include a modification s . org / ) , wherein YALIO stands for Yarrowia lipolytica and 
( e . g . modification , insertion , deletion , mutation ) not previ - A , B , C , D , E , F specifies chromosome . In embodiments , the 
ously known or intended prior to making of the genetically nucleic acid or gene Leucine Biosynthesis Gene ( LEU2 ) is 
modified organism may be identified through screening a 15 the nucleic acid or gene corresponding to GenBank 
plurality of organism including one or more genetically AF260230 or YALIOC00407 g of the Genolevures database 
modified organisms by using a selection criteria that iden ( i . e . found at http : / / www . genolevures . org ) . In embodi 
tifies the genetically modified organism of interest ( e . g . an ments , Leucine Biosynthesis Gene ( LEU2 ) is a protein or 
increased level of lipids , lipid precursors , and / or oleochemi - nucleic acid / gene of a yeast strain corresponding to 
cals ; floats above an organism not including the same 20 AF260230 of Yarrowia lipolytica as described above . In 
genetic modification ) . In embodiments , a genetically modi - embodiments , Leucine Biosynthesis Gene ( LEU2 ) is a pro 
fied organism includes a recombinant nucleic acid . tein or nucleic acid / gene of an oleaginous organism corre 
Methods for synthesizing sequences and bringing sponding to AF260230 of Yarrowia lipolytica as described 
sequences together are well established and known to those above . In embodiments , the protein and / or nucleic acid is a 
of skill in the art . For example , in vitro mutagenesis and 25 wildtype version of the protein or nucleic acid . In embodi 
selection , site - directed mutagenesis , error prone PCR ( Mel - ments , the protein and / or nucleic acid is a mutant form of the 
nikov et al . , Nucleic Acids Research , 27 ( 4 ) : 1056 - 1062 ( Feb . protein and / or nucleic acid ( e . g . point mutant , loss of func 
15 , 1999 ) ) , " gene shuffling " or other means can be employed tion mutation , missense mutation , deletion , or insertion of 
to obtain mutations of naturally occurring genes . heterologous nucleic acid ) . 
Mutagenesis ( e . g . chemical mutagenesis or site directed 30 In embodiments , the protein Uracil Biosynthesis gene 
mutagenesis ) may be used to modulate lipid production or ( URA3 ) , also known as Orotidine 5 ' - phosphate decarboxy 
storage in an oleaginous organism ( e . g . oleaginous yeast ) . lase , is a protein able to be translated from the nucleic acid 
For example , a mutant construct or mutagen is transformed corresponding to GenBank YLU40564 or YALIOE26741 g 
into an oleaginous yeast cell and the ability of the resulting of the Genolevures database ( i . e . found at http : / / www . ge 
transformed oleaginous yeast cell to produce or store one or 35 nolevures . org / ) , wherein YALIO stands for Yarrowia 
more lipids is assayed and compared to the control cell . In lipolytica and A , B , C , D , E , F specifies chromosome . In 
some embodiments , it may be useful to disrupt or inactivate embodiments , the nucleic acid or gene Uracil Biosynthesis 
a host organism ' s native gene to modulate lipid production gene ( URA3 ) is the nucleic acid or gene corresponding to 
or storage . For example , a recombinant DNA fragment ( e . g . GenBank YLU40564 or YALIOE26741 g of the Genolevures 
a selectable marker gene ) may be inserted into the gene to 40 database ( i . e . found at http : / / www . genolevures . org ) . In 
be disrupted in order to interrupt its coding sequence and the embodiments , Uracil Biosynthesis gene ( URA3 ) is a protein 
resulting recombinant nucleic acid then transformed into a or nucleic acid / gene of a yeast strain corresponding to 
host cell . Another example of a method of gene disruption YLU40564 of Yarrowia lipolytica as described above . In 
is the use of transposable elements or transposons , which is embodiments , Uracil Biosynthesis gene ( URA3 ) is a protein 
well known to those of skill in the art . 45 or nucleic acid / gene of an oleaginous organism correspond 
In general , means for the purification of lipids , may ing to YLU40564 of Yarrowia lipolytica as described above . 
include extraction with organic solvents , sonication , super - In embodiments , the protein and / or nucleic acid is a wild 
critical fluid extraction , saponification physical means such type version of the protein or nucleic acid . In embodiments , 
as presses , extraction , treatment with urea , fractional crys - the protein and / or nucleic acid is a mutant form of the 
tallization , HPLC , fractional distillation , silica gel chroma - 50 protein and / or nucleic acid ( e . g . point mutant , loss of func 
tography , high - speed centrifugation or distillation , or com - tion mutation , missense mutation , deletion , or insertion of 
binations of these techniques . heterologous nucleic acid ) . 
In embodiments , the protein AMP Deaminase ( AMPD ) is In embodiments , the protein ATP - Citrate Lyase ( ACL ) is 
a protein able to be translated from the nucleic acid corre - a protein including the protein ACL1 , also called ATP 
sponding to YALIOE11495 of the Genolevures database ( i . e . 55 Citrate Lyase 1 , able to be translated from the nucleic acid 
found at http : / / www . genolevures . org / ) , wherein YALIO corresponding to YALIOE34793 of the Genolevures data 
stands for Yarrowia lipolytica and A , B , C , D , E , F specifies base ( i . e . found at http : / / www . genolevures . org / ) , wherein 
chromosome . In embodiments , the nucleic acid or gene YALIO stands for Yarrowia lipolytica and A , B , C , D , E , F 
AMP Deaminase ( AMPD ) is the nucleic acid or gene specifies chromosome . In embodiments , the nucleic acid or 
corresponding to YALIOE11495 of the Genolevures data - 60 gene ATP - Citrate Lyase ( ACL ) includes the nucleic acid or 
base ( i . e . found at http : / / www . genolevures . org / ) . In embodi - gene ACL1 corresponding to YALIOE34793 of the Genole 
ments , AMP Deaminase ( AMPD ) is a protein or nucleic vures database ( i . e . found at http : / / www . genolevures . org ) . 
acid / gene of a yeast strain corresponding to YALIOE11495 In embodiments , the protein ATP - Citrate Lyase ( ACL ) is a 
of Yarrowia lipolytica as described above . In embodiments , protein including the protein ACL2 , also called ATP - Citrate 
AMP Deaminase ( AMPD ) is a protein or nucleic acid / gene 65 Lyase 2 , able to be translated from the nucleic acid corre 
of an oleaginous organism corresponding to YALIOE11495 sponding to YALIOD24431 of the Genolevures database ( i . e . 
of Yarrowia lipolytica as described above . In embodiments , found at http : / / www . genolevures . org / ) . In embodiments , the 
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nucleic acid or gene ATP - Citrate Lyase ( ACL ) includes the nucleic acid / gene of a yeast strain corresponding to 
nucleic acid or gene ACL2 corresponding to YALIOD24431 YALIOE32769 of Yarrowia lipolytica as described above . In 
of the Genolevures database ( i . e . found at http : / / www . ge - embodiments , acyl - CoA : diacylglycerol acyltransferase 
nolevures . org / ) . In embodiments , ATP - Citrate Lyase ( ACL ) ( DGA1 ) is a protein or nucleic acid / gene of an oleaginous 
includes a protein or nucleic acid / gene of a yeast strain 5 organism corresponding to YALIOE32769 of Yarrowia 
corresponding to YALIOD24431 of Yarrowia lipolytica as lipolytica as described above . In embodiments , the protein 
described above . In embodiments , ATP - Citrate Lyase ( ACL ) and / or nucleic acid is a wildtype version of the protein or 
includes a protein or nucleic acid / gene of an oleaginous nucleic acid . In embodiments , the protein and / or nucleic 
organism corresponding to YALIOD24431 of Yarrowia acid is a mutant form of the protein and / or nucleic acid ( e . g . 
lipolytica as described above . In embodiments , the protein 10 point mutant , loss of function mutation , missense mutation , 
ATP - Citrate Lyase ( ACL ) is a protein including the protein deletion , or insertion of heterologous nucleic acid ) . 
ACL1 able to be translated from the nucleic acid corre In embodiments , the protein acyl - CoA : diacylglycerol 
sponding to YALIOE34793 of the Genolevures database and acyltransferase ( DGA2 ) , also called acyl - CoA : diacylglyc 
the protein ACL2 able to be translated from the nucleic acid erol acyltransfer 2 , is a protein able to be translated from the 
corresponding to YALIOD24431 of the Genolevures data - 15 nucleic acid corresponding to YALIOD07986 of the Genole 
base ( i . e . found at http : / / www . genolevures . org / ) . In embodi - vures database ( i . e . found at http : / / www . genolevures . org / ) , 
ments , the nucleic acid or gene ATP - Citrate Lyase ( ACL ) wherein YALIO stands for Yarrowia lipolytica and A , B , C , 
includes the nucleic acid or gene ACL1 corresponding to D , E , F specifies chromosome . In embodiments , the nucleic 
YALIOE34793 and the nucleic acid or gene ACL2 corre - acid or gene acyl - CoA : diacylglycerol acyltransferases 
sponding to YALIOD24431 of the Genolevures database ( i . e . 20 ( DGA2 ) is the nucleic acid or gene corresponding to 
found at http : / / www . genolevures . org / ) . In embodiments , YALIOD07986 of the Genolevures database ( i . e . found at 
ATP - Citrate Lyase ( ACL ) includes proteins or nucleic acids / http : / / www . genolevures . org / ) . In embodiments , acyl - COA : 
genes of a yeast strain corresponding to YALIOE34793 and diacylglycerol acyltransferases ( DGA2 ) is a protein or 
YALIOD24431 of Yarrowia lipolytica as described above . In nucleic acid / gene of a yeast strain corresponding to 
embodiments , ATP - Citrate Lyase ( ACL ) includes proteins or 25 YALIOD07986 of Yarrowia lipolytica as described above . In 
nucleic acids / genes of an oleaginous organism correspond - embodiments , acyl - CoA : diacylglycerol acyltransferases 
ing to YALIOE34793 and YALIOD24431 of Yarrowia ( DGA2 ) is a protein or nucleic acid / gene of an oleaginous 
lipolytica as described above . In embodiments , the protein organism corresponding to YALIOD07986 of Yarrowia 
and / or nucleic acid is a wildtype version of the protein or lipolytica as described above . In embodiments , the protein 
nucleic acid . In embodiments , the protein and / or nucleic 30 and / or nucleic acid is a wildtype version of the protein or 
acid is a mutant form of the protein and / or nucleic acid ( e . g . nucleic acid . In embodiments , the protein and / or nucleic 
point mutant , loss of function mutation , missense mutation , acid is a mutant form of the protein and / or nucleic acid ( e . g . 
deletion , or insertion of heterologous nucleic acid ) . point mutant , loss of function mutation , missense mutation , 
In embodiments , the protein Malic Enzyme ( MAE , MEA , deletion , or insertion of heterologous nucleic acid ) . 
MEA1 ) is a protein able to be translated from the nucleic 35 In embodiments , the protein Lipid synthesis regulator 
acid corresponding to YALIOE18634 of the Genolevures ( MGA2 ) is a protein able to be translated from the nucleic 
database ( i . e . found at http : / / www . genolevures . org / ) , acid corresponding to YALIOB12342 of the Genolevures 
wherein YALIO stands for Yarrowia lipolytica and A , B , C , database ( i . e . found at http : / / www . genolevures . org / ) , 
D , E , F specifies chromosome . In embodiments , the nucleic wherein YALIO stands for Yarrowia lipolytica and A , B , C , 
acid or gene Malic Enzyme ( MAE , MEA , MEA1 ) is the 40 D , E , F specifies chromosome . In embodiments , the nucleic 
nucleic acid or gene corresponding to YALIOE18634 of the acid or gene Lipid synthesis regulator ( MGA2 ) is the nucleic 
Genolevures database ( i . e . found at http : / / www . genolevure - acid or gene corresponding to YALIOB12342 of the Genole 
s . org / ) . In embodiments , Malic Enzyme ( MAE , MEA , vures database ( i . e . found at http : / / www . genolevures . org / ) . 
MEA1 ) is a protein or nucleic acid / gene of a yeast strain In embodiments , Lipid synthesis regulator ( MGA2 ) is a 
corresponding to YALIOE18634 of Yarrowia lipolytica as 45 protein or nucleic acid / gene of a yeast strain corresponding 
described above . In embodiments , Malic Enzyme ( MAE , to YALIOB12342 of Yarrowia lipolytica as described above . 
MEA , MEA1 ) is a protein or nucleic acid / gene of an In embodiments , Lipid synthesis regulator ( MGA2 ) is a 
oleaginous organism corresponding to YALIOE18634 of protein or nucleic acid / gene of an oleaginous organism 
Yarrowia lipolytica as described above . In embodiments , the corresponding to YALIOB12342 of Yarrowia lipolytica as 
protein and / or nucleic acid is a wildtype version of the 50 described above . In embodiments , the protein and / or nucleic 
protein or nucleic acid . In embodiments , the protein and / or acid is a wildtype version of the protein or nucleic acid . In 
nucleic acid is a mutant form of the protein and / or nucleic embodiments , the protein and / or nucleic acid is a mutant 
acid ( e . g . point mutant , loss of function mutation , missense form of the protein and / or nucleic acid ( e . g . point mutant , 
mutation , deletion , or insertion of heterologous nucleic loss of function mutation , missense mutation , deletion , or 
acid ) . 55 insertion of heterologous nucleic acid ) . 
In embodiments , the protein acyl - CoA : diacylglycerol In embodiments , the protein Chromatin assembly gene 
acyltransferase ( DGA1 ) , also called acyl - CoA : diacylglyc ( RLF2 subunit p90 ) is a protein able to be translated from 
erol acyltransfer 1 is a protein able to be translated from the the nucleic acid corresponding to YALIOF21637 g of the 
nucleic acid corresponding to YALIOE32769 of the Genole - Genolevures database ( i . e . found at http : / / www . genolevure 
vures database ( i . e . found at http : / / www . genolevures . org / ) , 60 s . org / ) , wherein YALIO stands for Yarrowia lipolytica and 
wherein YALIO stands for Yarrowia lipolytica and A , B , C , A , B , C , D , E , F specifies chromosome . In embodiments , the 
D , E , F specifies chromosome . In embodiments , the nucleic nucleic acid or gene Chromatin assembly gene ( RLF2 
acid or gene acyl - CoA : diacylglycerol acyltransferase subunit p90 ) is the nucleic acid or gene corresponding to 
( DGA1 ) is the nucleic acid or gene corresponding to YALIOF21637 g of the Genolevures database ( i . e . found at 
YALIOE32769 of the Genolevures database ( i . e . found at 65 http : / / www . genolevures . org / ) . In embodiments , Chromatin 
http : / / www . genolevures . org / ) . In embodiments , acyl - CoA : assembly gene ( RLF2 subunit p90 ) is a protein or nucleic 
diacylglycerol acyltransferase ( DGA1 ) is a protein or acid / gene of a yeast strain corresponding to YALIOF21637 
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g of Yarrowia lipolytica as described above . In embodi - ing to YALIOE15378 of Yarrowia lipolytica as described 
ments , Chromatin assembly gene ( RLF2 subunit p90 ) is a above . In embodiments , the protein and / or nucleic acid is a 
protein or nucleic acid / gene of an oleaginous organism wildtype version of the protein or nucleic acid . In embodi 
corresponding to YALIOF21637 g of Yarrowia lipolytica as ments , the protein and / or nucleic acid is a mutant form of the 
described above . In embodiments , the protein and / or nucleic 5 protein and / or nucleic acid ( e . g . point mutant , loss of func 
acid is a wildtype version of the protein or nucleic acid . In tion mutation , missense mutation , deletion , or insertion of 
embodiments , the protein and / or nucleic acid is a mutant heterologous nucleic acid ) . 
form of the protein and / or nucleic acid ( e . g . point mutant , In embodiments , the protein 0 - 6 - methylguanine - DNA 
loss of function mutation , missense mutation , deletion , or methyltransferase ( MGMT , O6M ) is a protein able to be 
insertion of heterologous nucleic acid ) . 10 translated from the nucleic acid corresponding to 
In embodiments , the protein Mitochondrial 2 ' O - ribose YALIOC10010p of the Genolevures database ( i . e . found at 
methyltransferase ( MRM2 ) is a protein able to be translated http : / / www . genolevures . org ) , wherein YALIO stands for 
from the nucleic acid corresponding to YALIOE31933 of the Yarrowia lipolytica and A , B , C , D , E , F specifies chromosome . 
Genolevures database ( i . e . found at http : / / www . genolevure - In embodiments , the nucleic acid or gene 0 - 6 - methylgua 
s . org / ) , wherein YALIO stands for Yarrowia lipolytica and 15 nine - DNA methyltransferase ( MGMT , O6M ) is the nucleic 
A , B , C , D , E , F specifies chromosome . In embodiments , the acid or gene corresponding to YALIOC10010p of the 
nucleic acid or gene Mitochondrial 2 ' O - ribose methyltrans - Genolevures database ( i . e . found at http : / / www . genolevure 
ferase ( MRM2 ) is the nucleic acid or gene corresponding to s . org / ) . In embodiments , 0 - 6 - methylguanine - DNA methyl 
YALIOE31933 of the Genolevures database ( i . e . found at transferase ( MGMT , O6M ) is a protein or nucleic acid / gene 
http : / / www . genolevures . org ) . In embodiments , Mitochon - 20 of a yeast strain corresponding to YALIOC10010p of Yar 
drial 2 ' O - ribose methyltransferase ( MRM2 ) is a protein or r owia lipolytica as described above . In embodiments , O - 6 
nucleic acid / gene of a yeast strain corresponding to methylguanine - DNA methyltransferase ( MGMT , O6M ) is a 
YALIOE31933 of Yarrowia lipolytica as described above . In protein or nucleic acid / gene of an oleaginous organism 
embodiments , Mitochondrial 2 ' O - ribose methyltransferase corresponding to YALIOC10010p of Yarrowia lipolytica as 
( MRM2 ) is a protein or nucleic acid / gene of an oleaginous 25 described above . In embodiments , the protein and / or nucleic 
organism corresponding to YALIOE31933 of Yarrowia acid is a wildtype version of the protein or nucleic acid . In 
lipolytica as described above . In embodiments , the protein embodiments , the protein and / or nucleic acid is a mutant 
and / or nucleic acid is a wildtype version of the protein or form of the protein and / or nucleic acid ( e . g . point mutant , 
nucleic acid . In embodiments , the protein and / or nucleic loss of function mutation , missense mutation , deletion , or 
acid is a mutant form of the protein and / or nucleic acid ( e . g . 30 insertion of heterologous nucleic acid ) . 
point mutant , loss of function mutation , missense mutation , In embodiments , the protein Aconitase ( ACO1 ) is a 
deletion , or insertion of heterologous nucleic acid ) . protein able to be translated from the nucleic acid corre 
In embodiments , the protein Transcription Factor sponding to YALIOD09361 of the Genolevures database ( i . e . 
( PEX10 ) is a protein able to be translated from the nucleic found at http : / / www . genolevures . org / ) , wherein YALIO 
acid corresponding to YALIOC01023 g of the Genolevures 35 stands for Yarrowia lipolytica and A , B , C , D , E , F specifies 
database ( i . e . found at http : / / www . genolevures . org / ) , chromosome . In embodiments , the nucleic acid or gene 
wherein YALIO stands for Yarrowia lipolytica and A , B , C , Aconitase ( ACO1 ) is the nucleic acid or gene corresponding 
D , E , F specifies chromosome . In embodiments , the nucleic to YALIODO9361 of the Genolevures database ( i . e . found at 
acid or gene Transcription Factor ( PEX10 ) is the nucleic http : / / www . genolevures . org / ) . In embodiments , Aconitase 
acid or gene corresponding to YALIOC01023 g of the 40 ( ACO1 ) is a protein or nucleic acid / gene of a yeast strain 
Genolevures database ( i . e . found at http : / / www . genolevure corresponding to YALIOD09361 of Yarrowia lipolytica as 
s . org / ) . In embodiments , Transcription Factor ( PEX10 ) is a described above . In embodiments , O Aconitase ( ACO1 ) is a 
protein or nucleic acid / gene of a yeast strain corresponding protein or nucleic acid / gene of an oleaginous organism 
to YALIOC01023 g of Yarrowia lipolytica as described corresponding to YALIODO9361 of Yarrowia lipolytica as 
above . In embodiments , Transcription Factor ( PEX10 ) is a 45 described above . In embodiments , the protein and / or nucleic 
protein or nucleic acid / gene of an oleaginous organism acid is a wildtype version of the protein or nucleic acid . In 
corresponding to YALIOC01023 g of Yarrowia lipolytica as embodiments , the protein and / or nucleic acid is a mutant 
described above . In embodiments , the protein and / or nucleic form of the protein and / or nucleic acid ( e . g . point mutant , 
acid is a wildtype version of the protein or nucleic acid . In loss of function mutation , missense mutation , deletion , or 
embodiments , the protein and / or nucleic acid is a mutant 50 insertion of heterologous nucleic acid ) . 
form of the protein and / or nucleic acid ( e . g . point mutant , In embodiments , the protein Citrate Synthase ( CIT1 ) is a 
loss of function mutation , missense mutation , deletion , or protein able to be translated from the nucleic acid corre 
insertion of heterologous nucleic acid ) . sponding to YALIOE02684 of the Genolevures database ( i . e . 
In embodiments , the protein multifunctional enzyme found at http : / / www . genolevures . org / ) , wherein YALIO 
( MFE1 ) is a protein able to be translated from the nucleic 55 stands for Yarrowia lipolytica and A , B , C , D , E , F specifies 
acid corresponding to YALIOE15378 of the Genolevures chromosome . In embodiments , the nucleic acid or gene 
database ( i . e . found at http : / / www . genolevures . org / ) , Citrate Synthase ( CIT1 ) is the nucleic acid or gene corre 
wherein YALIO stands for Yarrowia lipolytica and A , B , C , sponding to YALIOE02684 of the Genolevures database ( i . e . 
D , E , F specifies chromosome . In embodiments , the nucleic found at http : / / www . genolevures . org / ) . In embodiments , 
acid or gene multifunctional enzyme ( MFE1 is the nucleic 60 Citrate Synthase ( CIT1 ) is a protein or nucleic acid / gene of 
acid or gene corresponding to YALIOE15378 of the Genole a yeast strain corresponding to YALIOE02684 of Yarrowia 
vures database ( i . e . found at http : / / www . genolevures . org ) . lipolytica as described above . In embodiments , Citrate Syn 
In embodiments , multifunctional enzyme ( MFE1 ) is a pro - thase ( CIT1 ) is a protein or nucleic acid / gene of an oleagi 
tein or nucleic acid / gene of a yeast strain corresponding to nous organism corresponding to YALIOE02684 of Yarrowia 
YALIOE15378 of Yarrowia lipolytica as described above . In 65 lipolytica as described above . In embodiments , the protein 
embodiments , multifunctional enzyme ( MFE1 ) is a protein and / or nucleic acid is a wildtype version of the protein or 
or nucleic acid / gene of an oleaginous organism correspond nucleic acid . In embodiments , the protein and / or nucleic 
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acid is a mutant form of the protein and / or nucleic acid ( e . g . acid ( e . g . point mutant , loss of function mutation , missense 
point mutant , loss of function mutation , missense mutation , mutation , deletion , or insertion of heterologous nucleic 
deletion , or insertion of heterologous nucleic acid ) . acid ) . 
In embodiments , the protein Acetyl - CoA Carboxylase In embodiments , the protein UGA2 succinate semialde 
( ACC ) is a protein able to be translated from the nucleic acid 5 hyde dehydrogenase ( UGA2 ) is a protein able to be trans 
corresponding to YALIOC11407 of the Genolevures data lated from the nucleic acid corresponding to YALIOF26191 
base ( i . e . found at http : / / www . genolevures . org / ) , wherein of the Genolevures database ( i . e . found at http : / / www . ge 
YALIO stands for Yarrowia lipolytica and A , B , C , D , E , F nolevures . org ) , wherein YALIO stands for Yarrowia lipolytica and A , B , C , D , E , F specifies chromosome . In specifies chromosome . In embodiments , the nucleic acid or 
gene Acetyl - CoA Carboxylase ( ACC ) is the nucleic acid or 10 embodiments , the nucleic acid or gene UGA2 succinate semialdehyde dehydrogenase ( UGA2 ) is the nucleic acid or gene corresponding to YALIOC11407 of the Genolevures gene corresponding to YALIOF26191 of the Genolevures database ( i . e . found at http : / / www . genolevures . org / ) . In database ( i . e . found at http : / / www . genolevures . org / ) . In embodiments , Acetyl - CoA Carboxylase ( ACC ) is a protein embodiments , UGA2 succinate semialdehyde dehydroge 
or nucleic acid gene of a yeast strain corresponding to 15 nase ( UGA2 ) is a protein or nucleic acid / gene of a yeast YALIOC11407 of Yarrowia lipolytica as described above . In strain corresponding to YALIOF26191 of Yarrowia lipolytica 
embodiments , Acetyl - CoA Carboxylase ( ACC ) is a protein as described above . In embodiments , UGA2 succinate semi 
or nucleic acid / gene of an oleaginous organism correspond aldehyde dehydrogenase ( UGA2 ) is a protein or nucleic 
ing to YALIOC11407 of Yarrowia lipolytica as described acid / gene of an oleaginous organism corresponding to 
above . In embodiments , the protein and / or nucleic acid is a 20 YALIOF26191 of Yarrowia lipolytica as described above . In 
wildtype version of the protein or nucleic acid . In embodi - embodiments , the protein and / or nucleic acid is a wildtype 
ments , the protein and / or nucleic acid is a mutant form of the version of the protein or nucleic acid . In embodiments , the 
protein and / or nucleic acid ( e . g . point mutant , loss of func - protein and / or nucleic acid is a mutant form of the protein 
tion mutation , missense mutation , deletion , or insertion of and / or nucleic acid ( e . g . point mutant , loss of function 
heterologous nucleic acid ) . 25 mutation , missense mutation , deletion , or insertion of het 
In embodiments , the protein RME1 zinc - finger transcrip - erologous nucleic acid ) . 
tion factor ( RME1 ) is a protein able to be translated from the In embodiments , the protein OSH6 oxysterol - binding 
nucleic acid corresponding to YALIOE17215 of the Genole protein homolog 6 ( OSHA ) is a protein able to be translated 
vures database ( i . e . found at http : / / www . genolevures . org / ) , from the nucleic acid corresponding to YALIOA02354 of the 
wherein YALIO stands for Yarrowia lipolytica and A , B , C , 30 * 30 Genolevures database ( i . e . found at http : / / www . genolevure s . org / ) , wherein YALIO stands for Yarrowia lipolytica and D , E , F specifies chromosome . In embodiments , the nucleic A , B , C , D , E , F specifies chromosome . In embodiments , the acid or gene RME1 zinc - finger transcription factor ( RME1 ) nucleic acid or gene OSH6 oxysterol - binding protein is the nucleic acid or gene corresponding to YALIOE17215 homolog 6 ( OSH6 ) is the nucleic acid or gene corresponding of the Genolevures database ( i . e . found at http : / / www . ge P : / / www . ge - 35 to YALIOA02354 of the Genolevures database ( i . e . found at nolevures . org / ) . In embodiments , RME1 zinc - finger tran http : / / www . genolevures . org / ) . In embodiments , OSH6 oxys 
scription factor ( RME1 ) is a protein or nucleic acid / gene of terol - binding protein homolog 6 ( OSH6 ) is a protein or 
a yeast strain corresponding to YALIOE17215 of Yarrowia nucleic acid / gene of a veast strain corresponding to 
lipolytica as described above . In embodiments , RME1 zinc - YALIOA02354 of Yarrowia lipolytica as described above . In 
finger transcription factor ( RME1 ) is a protein or nucleic 40 embodiments , OSH6 oxysterol - binding protein homolog 6 
acid / gene of an oleaginous organism corresponding to ( OSH6 ) is a protein or nucleic acid / gene of an oleaginous 
YALIOE17215 of Yarrowia lipolytica as described above . In organism corresponding to YALIOA02354 of Yarrowia 
embodiments , the protein and / or nucleic acid is a wildtype lipolytica as described above . In embodiments , the protein 
version of the protein or nucleic acid . In embodiments , the and / or nucleic acid is a wildtype version of the protein or 
protein and / or nucleic acid is a mutant form of the protein 45 nucleic acid . In embodiments , the protein and / or nucleic 
and / or nucleic acid ( e . g . point mutant , loss of function acid is a mutant form of the protein and / or nucleic acid ( e . g . 
mutation , missense mutation , deletion , or insertion of het point mutant , loss of function mutation , missense mutation , 
erologous nucleic acid ) . deletion , or insertion of heterologous nucleic acid ) . 
In embodiments , the protein YOX1 homeodomain protein In embodiments , the protein IRC20 E3 ubiquitin - protein 
( YOX1 ) is a protein able to be translated from the nucleic 50 ligase and helicase ( IRC20 ) is a protein able to be translated 
acid corresponding to YALIOE20449 of the Genolevures from the nucleic acid corresponding to YALIOC07150 of the 
database ( i . e . found at http : / / www . genolevures . org / ) , Genolevures database ( i . e . found at http : / / www . genolevure 
wherein YALIO stands for Yarrowia lipolytica and A , B , C , s . org / ) , wherein YALIO stands for Yarrowia lipolytica and 
D , E , F specifies chromosome . In embodiments , the nucleic A , B , C , D , E , F specifies chromosome . In embodiments , the 
acid or gene YOX1 homeodomain protein ( YOX1 ) is the 55 nucleic acid or gene IRC20 E3 ubiquitin - protein ligase and 
nucleic acid or gene corresponding to YALIOE20449 of the helicase ( IRC20 ) is the nucleic acid or gene corresponding 
Genolevures database ( i . e . found at http : / / www . genolevure - to YALIOC07150 of the Genolevures database ( i . e . found at 
s . org / ) . In embodiments , YOX1 homeodomain protein http : / / www . genolevures . org / ) . In embodiments , IRC20 E3 
( YOX1 ) is a protein or nucleic acid / gene of a yeast strain ubiquitin - protein ligase and helicase ( IRC20 ) is a protein or 
corresponding to YALIOE20449 of Yarrowia lipolytica as 60 nucleic acid / gene of a yeast strain corresponding to 
described above . In embodiments , YOX1 homeodomain YALIOC07150 of Yarrowia lipolytica as described above . In 
protein ( YOX1 ) is a protein or nucleic acid / gene of an embodiments , IRC20 E3 ubiquitin - protein ligase and heli 
oleaginous organism corresponding to YALIOE20449 of case ( IRC20 ) is a protein or nucleic acid / gene of an oleagi 
Yarrowia lipolytica as described above . In embodiments , the nous organism corresponding to YALIOC07150 of Yarrowia 
protein and / or nucleic acid is a wildtype version of the 65 lipolytica as described above . In embodiments , the protein 
protein or nucleic acid . In embodiments , the protein and / or and / or nucleic acid is a wildtype version of the protein or 
nucleic acid is a mutant form of the protein and / or nucleic nucleic acid . In embodiments , the protein and / or nucleic 
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acid is a mutant form of the protein and / or nucleic acid ( e . g . tide sequence of the protein and / or nucleic acid sequence for 
point mutant , loss of function mutation , missense mutation , Leucine Biosynthesis Gene ( LEU2 ) , Uracil Biosynthesis 
deletion , or insertion of heterologous nucleic acid ) . gene ( URA3 ) , multifunctional enzyme ( MFE1 ) , Transcrip 
As used to describe a protein or nucleic / acid of another tion Factor ( PEX10 ) , AMP Deaminase ( AMPD ) , ATP - Cit 
organism in comparison to a protein or nucleic / acid of 5 rate Lyase ( ACL ) ( e . g . ACL subunit 1 , ACL subunit 2 , or 
Yarrowia lipolytica , the term " corresponds ” or “ correspond subunit 1 and 2 ) , Malic Enzyme ( MAE ) , Acetyl - CoA Car 
ing ” is used according to its ordinary meaning and refers to boxylase ( ACC ) , acyl - CoA : diacylglycerol acyltransferase ( DGA1 ) , acyl - CoA : diacylglycerol acyltransferases a protein or nucleic acid / gene that includes similar or ( DGA2 ) , Mitochondrial 24 O - ribose methyltransferase identical sequence of amino acid or nucleotides respectively 
and / or performs a similar or identical function and / or has a 10 ( MRM2 ) , Lipid synthesis regulator ( MGA2 ) , Chromatin assembly gene ( RLF2 subunit p90 ) , 0 - 6 - methylguanine similar of identical activity as the protein or nucleic acid / DNA methyltransferase ( MGMT ) , Aconitase ( ACO1 ) , Cit gene in Yarrowia lipolytica as described above . In some rate Synthase ( CIT1 ) , RME1 zinc - finger transcription factor 
embodiments , a protein or nucleic acid corresponding to a ( RME1 ) , YOX1 homeodomain protein ( YOX1 ) , UGA2 
protein or nucleic acid from Yarrowia lipolytica is a succinate semialdehyde dehydrogenase ( UGA2 ) , OSH6 
homolog . In embodiments , the protein and / or nucleic acid of 15 oxysterol - binding protein homolog 6 ( OSH6 ) , or IRC20 E3 
Leucine Biosynthesis Gene ( LEU2 ) , Uracil Biosynthesis ubiquitin - protein ligase and helicase ( IRC20 ) respectively , 
gene ( URA3 ) , multifunctional enzyme ( MFE1 ) , Transcrip described herein ( e . g . Examples section and / or sequence 
tion Factor ( PEX10 ) , AMP Deaminase ( AMPD ) , ATP - Cit - listing ) . 
rate Lyase ( ACL ) ( e . g . ACL subunit 1 , ACL subunit 2 , or The term “ wildtype " as used herein when referring to an 
subunit 1 and 2 ) , Malic Enzyme ( MAE ) , Acetyl - CoA Car - 20 oleaginous organism ( e . g . yeast strain or Yarrowia lipolytica 
boxylase ( ACC ) , acyl - CoA : diacylglycerol acyltransferase strain ) means an organism that has not been genetically 
( DGA1 ) , acyl - CoA : diacylglycerol acyltransferases modified to improve production of a lipid ( e . g . increase yield 
( DGA2 ) . Mitochondrial 2 : O - ribose methyltransferase of a lipid , alter the structure of a lipid produced by the 
( MRM2 ) , Lipid synthesis regulator ( MGA2 ) , Chromatin organism , reduce production of one lipid to improve pro 
assembly gene ( RLF2 subunit p90 ) , 0 - 6 - methylguanine - 25 duction of a second lipid , or modulate the production of a 
DNA methyltransferase ( MGMT ) , Aconitase ( ACO1 ) , Cit - lipid ) . In embodiments , a wildtype yeast strain may be 
rate Synthase ( CIT1 ) , RME1 zinc - finger transcription factor auxotrophic for one or more compounds ( e . g . leucine and / or 
( RME1 ) , YOX1 homeodomain protein ( YOX1 ) , UGA2 uracil ) . In embodiments , a wildtype Yarrowia lipolytica strain is Polf ( ATCC # MYA - 2613 ) , a leucine and uracil succinate semialdehyde dehydrogenase ( UGA2 ) , OSHO auxotroph devoid of any secreted protease activity ( Madzak oxysterol - binding protein homolog 6 ( OSH6 ) , or IRC20 E3 30 et al . , 2000 ) . ubiquitin - protein ligase and helicase ( IRC20 ) includes an The term “ oleochemical ” is used herein in accordance amino acid and / or nucleotide sequence included in the with its well known meaning and refers to chemicals or protein and / or nucleic acid sequence for Leucine Biosyn compounds derived from lipids or fats . In embodiments , an 
thesis Gene ( LEU2 ) , Uracil Biosynthesis gene ( URA3 ) , oleochemical is a lipid or fat derived from a different lipid 
multifunctional enzyme ( MFE1 ) , Transcription Factor 35 or fat . In embodiments an oleochemical is a chemical or 
( PEX10 ) , AMP Deaminase ( AMPD ) , ATP - Citrate Lyase compound produced by an oleaginous organism . In embodi 
( ACL ) ( e . g . ACL subunit 1 , ACL subunit 2 , or subunit 1 and ments , an oleochemical is a chemical or compound derived 
2 ) , Malic Enzyme ( MAE ) , Acetyl - CoA Carboxylase ( ACC ) , from a lipid or lipid precursor produced by an oleaginous 
acyl - CoA : diacylglycerol acyltransferase ( DGA1 ) , acyl organism ( e . g . , fatty acid esters such as methyl esters , ethyl 
COA : diacylglycerol acyltransferases ( DGA2 ) , Mitochon - 40 esters , propyl esters , or butyl esters that are derived from a 
drial 2 ' O - ribose methyltransferase ( MRM2 ) , Lipid synthe - fatty acid produced by an oleaginous organism by transes 
sis regulator ( MGA2 ) , Chromatin assembly gene ( RLF2 terification ) . In embodiments , an oleochemical may include 
subunit p90 ) , 0 - 6 - methylguanine - DNA methyltransferase further in vivo or in vitro modification of a lipid or lipid 
( MGMT ) , Aconitase ( ACO1 ) , Citrate Synthase ( CIT1 ) , precursor enabled by endogenous or heterologous modify 
RME1 zinc - finger transcription factor ( RME1 ) . YOX1 45 ing enzymes or chemical reactions . 
homeodomain protein ( YOX1 ) , UGA2 succinate semialde The term “ lipid precursor ” is used in accordance with its 
hyde dehydrogenase ( UGA2 ) , OSH6 oxysterol - binding pro well known meaning and refers to a pathway intermediate ( e . g . , acetyl - CoA or malonyl - CoA ) in the biosynthesis of a tein homolog 6 ( OSH6 ) , or IRC20 E3 ubiquitin - protein lipid . In embodiments , a lipid precursor may be any mol ligase and helicase ( IRC20 ) respectively , described herein ecule along the biosynthetic pathway making triglycerides ( e . g . Examples section and / or sequence listing ) . In embodi - 50 including free citrate , acetyl - CoA , free fatty acids , pyruvate , ments , the protein and / or nucleic acid of Leucine Biosyn citric acid cycle intermediates , diacylglycerides , and / or tria thesis Gene ( LEU2 ) , Uracil Biosynthesis gene ( URA3 ) , cylglycerides . 
The term “ micronutrient ” is used in accordance with its 
( PEX10 ) , AMP Deaminase ( AMPD ) , ATP - Citrate Lyase well known meaning and refers to nutrients used by an 
( ACL ) ( e . g . ACL subunit 1 , ACL subunit 2 , or subunit 1 and 55 organism ( e . g . oleaginous organisms , yeast , oleaginous 
2 ) , Malic Enzyme ( MAE ) , Acetyl - CoA Carboxylase ( ACC ) , yeast ) for growth , proliferation , propagation , survival , one 
acyl - CoArdiacylglycerol acyltransferase ( DGA1 ) , acyl - or more essential biological functions , production of a lipid , 
COA : diacylglycerol acyltransferases ( DGA2 ) , Mitochon - lipid precursor , or oleochemical , which are required for such 
drial 2 ' O - ribose methyltransferase ( MRM2 ) , Lipid synthe - functions in small quantities . Examples of micronutrients 
sis regulator ( MGA2 ) , Chromatin assembly gene ( RLF2 60 include , but are not limited to , minerals , vitamins , and 
subunit p90 ) , 0 - 6 - methylguanine - DNA methyltransferase elements ( e . g . cobalt , iron , magnesium , potassium , zinc , 
( MGMT ) , Aconitase ( ACO1 ) , Citrate Synthase ( CIT1 ) , nickel , molybdenum , manganese , copper , and / or boron ) . 
RME1 zinc - finger transcription factor ( RME1 ) , YOX1 
homeodomain protein ( YOX1 ) , UGA2 succinate semialde II . OLEAGINOUS ORGANISMS 
hyde dehydrogenase ( UGA2 ) , OSH6 oxysterol - binding pro - 65 
tein homolog 6 ( OSH6 ) , or IRC20 E3 ubiquitin - protein In a first aspect is provided a genetically modified ole 
ligase and helicase ( IRC20 ) is the amino acid and / or nucleo aginous organism ( e . g . yeast cell , oleaginous yeast cell , 
27 
US 9 , 896 , 691 B2 
28 
Yarrowia lipolytica , algae , or plant cell ) wherein the dry 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 
weight of the oleaginous organism includes greater than 95 , 96 , 97 , 98 , or 99 % lipids , lipid precursors , and / or 
20 % wt /wt lipids , lipid precursors , and / or oleochemicals oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre 
( e . g . , lipid , lipids , lipid precursors , lipid precursor , oleo cursor , oleochemicals , or oleochemical ) in dry weight . In 
chemicals , or oleochemical ) . 5 embodiments , the oleaginous organism ( e . g . yeast cell , 
In embodiments , the oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or plant 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant cell ) includes greater than 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 
cell ) includes greater than 30 % wt /wt lipids , lipid precur - 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 
sors , and / or oleochemicals ( e . g . , lipid , lipids , lipid precur 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 
sors , lipid precursor , oleochemicals , or oleochemical ) in dry 10 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 
weight . In embodiments , the oleaginous organism ( e . g . yeast 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or 93 , 94 , 95 , 96 , 97 , 98 , or 99 % lipids , lipid precursors , and / or 
plant cell ) includes greater than 40 % wt / wt lipids , lipid oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre 
precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid cursor , oleochemicals , or oleochemical ) in dry weight . 
precursors , lipid precursor , oleochemicals , or oleochemical ) 15 In embodiments , the oleaginous organism ( e . g . yeast cell , 
in dry weight . In embodiments , the oleaginous organism oleaginous yeast cell , Yarrowia lipolytica , algae , or plant 
( e . g . yeast cell , oleaginous yeast cell , Yarrowia lipolytica , cell ) produces about 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 
algae , or plant cell ) includes greater than 50 % wt / wt lipids , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 
lipid precursors , and / or oleochemicals ( e . g . , lipid , lipids , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 
lipid precursors , lipid precursor , oleochemicals , or oleo - 20 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 
chemical ) in dry weight . In embodiments , the oleaginous 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 
organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 
lipolytica , algae , or plant cell ) includes greater than 60 % 94 , 95 , 96 , 97 , 98 , 99 , or 100 g / L culture ( e . g . in a bioreactor ) 
wt / wt lipids , lipid precursors , and / or oleochemicals ( e . g . , of lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , 
lipid , lipids , lipid precursors , lipid precursor , oleochemicals , 25 lipids , lipid precursors , lipid precursor , oleochemicals , or 
or oleochemical ) in dry weight . In embodiments , the ole oleochemical ) . In embodiments , the oleaginous organism 
aginous organism ( e . g . yeast cell , oleaginous yeast cell , ( e . g . yeast cell , oleaginous yeast cell , Yarrowia lipolytica , 
Yarrowia lipolytica , algae , or plant cell ) includes greater algae , or plant cell ) produces at least 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 
than 70 % wt / wt lipids , lipid precursors , and / or oleochemi 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 
cals ( e . g . , lipid , lipids , lipid precursors , lipid precursor , 30 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 
oleochemicals , or oleochemical ) in dry weight . In embodi - 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 
ments , the oleaginous organism ( e . g . yeast cell , oleaginous 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 
yeast cell , Yarrowia lipolytica , algae , or plant cell ) includes 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 
greater than 80 % wt / wt lipids , lipid precursors , and / or 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , or 100 g / L culture ( e . g . 
oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre - 35 in a bioreactor ) of lipids , lipid precursors , and / or oleochemi 
cursor , oleochemicals , or oleochemical ) in dry weight . In cals ( e . g . , lipid , lipids , lipid precursors , lipid precursor , 
embodiments , the oleaginous organism ( e . g . yeast cell , oleochemicals , or oleochemical ) . In embodiments , the ole 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant a ginous organism ( e . g . yeast cell , oleaginous yeast cell , 
cell ) includes greater than 90 % wt / wt lipids , lipid precur - Yarrowia lipolytica , algae , or plant cell ) produces 1 , 2 , 3 , 4 , 
sors , and / or oleochemicals ( e . g . , lipid , lipids , lipid precur - 40 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 
sors , lipid precursor , oleochemicals , or oleochemical ) in dry 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 
weight . In embodiments , the oleaginous organism ( e . g . yeast 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 
plant cell ) includes about 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 
29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , or 100 
45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , g / L culture ( e . g . in a bioreactor ) of lipids , lipid precursors , 
61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 
77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , lipid precursor , oleochemicals , or oleochemical ) . 
93 , 94 , 95 , 96 , 97 , 98 , or 99 % lipids , lipid precursors , and / or In embodiments , the oleaginous organism is a yeast cell . 
oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre - 50 In embodiments , the oleaginous organism is an oleaginous 
cursor , oleochemicals , or oleochemical ) in dry weight . In yeast cell . In embodiments , the yeast cell is selected from the 
embodiments , the oleaginous organism ( e . g . yeast cell , group consisting of the genera Yarrowia , Candida , Rhodoto 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant rula , Rhodosporidium , Cryptococcus , Trichosporon and 
cell ) includes about an average of 20 , 21 , 22 , 23 , 24 , 25 , 26 , Lipomyces . In embodiments , the yeast cell is selected from 
27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 55 the group consisting of Rhodosporidium toruloides , Lipo 
43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , myces starkeyii , Lipomyces lipoferus , Apiotrichum curva 
59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , tum , Candida curvata , Cryptococcus curvatus , Trichos 
75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , poron fermentans , Candida revkaufi , Candida pulcherrima , 
91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , or 99 % lipids , lipid precursors , Candida tropicalis , Candida utilis , Trichosporon pullans , 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 60 Trichosporon cutaneum , Rhodotorula glutinus , Rhodotorula 
lipid precursor , oleochemicals , or oleochemical ) in dry graminis and Yarrowia lipolytica . In embodiments , the yeast 
weight . In embodiments , the oleaginous organism ( e . g . yeast cell is selected from the group consisting of Lipomyces 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or starkeyii , Rhodosporidium toruloides , Apiotrichum curva 
plant cell ) includes 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , tum , Candida curvata , Cryptococcus curvatus , Trichos 
31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 65 poron fermentans , Rhodotorula glutinis , and Yarrowia 
47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , lipolytica . In embodiments , the yeast cell is Yarrowia 
63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , lipolytica . 
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In embodiments , the oleaginous organism ( e . g . yeast cell , plant cell ) including more than about 20 , 21 , 22 , 23 , 24 , 25 , 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 
cell ) is buoyant in an aqueous medium . In embodiments , the 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 
yeast cell includes a greater buoyancy ( i . e . greater tendency 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 
to float , lower density ) than a yeast cell that includes less 5 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 
than about 99 % lipids , lipid precursors , and / or oleochemi 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , or 99 % lipids , lipid 
cals ( e . g . , lipid , lipids , lipid precursors , lipid precursor , precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid 
oleochemicals , or oleochemical ) by dry weight ( e . g . less precursors , lipid precursor , oleochemicals , or oleochemical ) 
than about 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , in dry weight ( e . g . more than 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 
33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 10 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , or 99 % lipids , lipid precursors , 
97 , 98 , or 99 % lipids , lipid precursors , and / or oleochemicals and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors . 
( e . g . , lipid , lipids , lipid precursors , lipid precursor , oleo - 15 lipid precursor , oleochemicals , or oleochemical ) in dry 
chemicals , or oleochemical ) in dry weight ) . In embodi weight ) , included are lipids , lipid precursors , and / or oleo 
ments , the yeast cell includes a greater buoyancy ( i . e . greater chemicals ( e . g . , lipid , lipids , lipid precursors , lipid precur 
tendency to float , lower density ) than a yeast cell that sor , oleochemicals , or oleochemical ) selected from the 
includes less than 99 % lipids , lipid precursors , and / or oleo - group consisting of a fatty acid , wax , sterol , vitamin , mono 
chemicals ( e . g . , lipid , lipids , lipid precursors , lipid precur - 20 glyceride , diglyceride , triglyceride , phospholipid , glycero 
sor , oleochemicals , or oleochemical ) by dry weight ( e . g . less lipid , glycerophospholipid , sphingolipid , saccharolipid , 
than 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , polyketide , sterol lipid , triacylglyceride , wax ester , fatty acid 
35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , ethyl ester , fatty acid methyl ester , component of biodiesel , 
51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , saturated hydrocarbon , unsaturated hydrocarbon , branched 
67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 25 hydrocarbon , and a prenol lipid . In embodiments , the major 
83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , ity lipid , lipid precursor , or oleochemical in the oleaginous 
or 99 % lipids , lipid precursors , and / or oleochemicals ( e . g . , organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia 
lipid , lipids , lipid precursors , lipid precursor , oleochemicals , lipolytica , algae , or plant cell ) is a fatty acid . In embodi 
or oleochemical ) in dry weight ) . In embodiments , the ole - ments , the majority lipid , lipid precursor , or oleochemical in 
aginous organism ( e . g . yeast cell , oleaginous yeast cell , 30 the oleaginous organism ( e . g . yeast cell , oleaginous yeast 
Yarrowia lipolytica , algae , or plant cell ) does not sediment cell , Yarrowia lipolytica , algae , or plant cell ) is a wax . In 
to the bottom of a column of liquid ( e . g . water , buffer , embodiments , the majority lipid , lipid precursor , or oleo 
growth media , minimal media ) that is about 0 . 1 , 0 . 2 , 0 . 3 , chemical in the oleaginous organism ( e . g . yeast cell , oleagi 
0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , 1 . 0 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , nous yeast cell , Yarrowia lipolytica , algae , or plant cell ) is a 
12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 25 , 30 , 35 , 40 , 45 , 50 , 55 , 35 sterol . In embodiments , the majority lipid , lipid precursor , or 
60 , 65 , 70 , 75 , 80 , 85 , 90 , 95 , 96 , 97 , 98 , or 99 mm tall due oleochemical in the oleaginous organism ( e . g . yeast cell , 
to gravitation force alone . The term " about ” when used in oleaginous yeast cell , Yarrowia lipolytica , algae , or plant 
connection with a defined amount refers to an amount up to cell ) is a vitamin . In embodiments , the majority lipid , lipid 
and including greater than and / or less than 10 % of the precursor , or oleochemical in the oleaginous organism ( e . g . 
associated value and includes the associated value . In 40 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
embodiments , the oleaginous organism ( e . g . yeast cell , or plant cell ) is a monoglyceride . In embodiments , the 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant majority lipid , lipid precursor , or oleochemical in the ole 
cell ) does not sediment to the bottom of a column of liquid aginous organism ( e . g . yeast cell , oleaginous yeast cell , 
( e . g . water , buffer , growth media , minimal media ) that is 0 . 1 , Yarrowia lipolytica , algae , or plant cell ) is a diglyceride . In 
0 . 2 , 0 . 3 , 0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , 1 . 0 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 45 embodiments , the majority lipid , lipid precursor , or oleo 
10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 25 , 30 , 35 , 40 , 45 , chemical in the oleaginous organism ( e . g . yeast cell , oleagi 
50 , 55 , 60 , 65 , 70 , 75 , 80 , 85 , 90 , 95 , 96 , 97 , 98 , or 99 mm nous yeast cell , Yarrowia lipolytica , algae , or plant cell ) is a 
tall due to gravitation force alone . In embodiments , the yeast triglyceride . In embodiments , the majority lipid , lipid pre 
cell includes a greater buoyancy ( i . e . greater tendency to cursor , or oleochemical in the oleaginous organism ( e . g . 
float , lower density ) than a yeast cell that does not include 50 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
the same recombinant nucleic acid or combination of recom - or plant cell ) is a phospholipid . In embodiments , the major 
binant nucleic acids as the buoyant yeast cell . In embodi ity lipid , lipid precursor , or oleochemical in the oleaginous 
ments , the yeast cell is buoyant following centrifugation organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia 
( e . g . at about 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , lipolytica , algae , or plant cell ) is a glycerolipid . In embodi 
16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 55 ments , the majority lipid , lipid precursor , or oleochemical in 
32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , the oleaginous organism ( e . g . yeast cell , oleaginous yeast 
48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , cell , Yarrowia lipolytica , algae , or plant cell ) is a glycero 
64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , phospholipid . In embodiments , the majority lipid , lipid 
80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , precursor , or oleochemical in the oleaginous organism ( e . g . 
96 , 97 , 98 , 99 , 100 , 110 , 120 , 130 , 140 , 150 , 160 , 170 , 180 , 60 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
190 , 200 , 250 , 300 , 350 , 400 , 450 , 500 , 550 , 600 , 650 , 700 , or plant cell ) is a sphingolipid . In embodiments , the majority 
750 , 800 , 850 , 900 , 950 . 1000 , 1100 , 1200 , 1300 , 1400 , lipid , lipid precursor , or oleochemical in the oleaginous 
1500 , 1600 , 1700 , 1800 , 1900 , 2000 , 2500 , 3000 , 3500 , organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia 
4000 , 4500 , 5000 , 5500 , 6000 , 6500 , 7000 , 7500 , 8000 , lipolytica , algae , or plant cell ) is a saccharolipid . In embodi 
8500 , 9000 , 9500 , or 10000xg ) . 65 ments , the majority lipid , lipid precursor , or oleochemical in 
In embodiments of the oleaginous organism ( e . g . yeast the oleaginous organism ( e . g . yeast cell , oleaginous yeast 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or cell , Yarrowia lipolytica , algae , or plant cell ) is a polyketide . 
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In embodiments , the majority lipid , lipid precursor , or plant cell ) produces 07 : 0 fatty acid . In embodiments , the 
oleochemical in the oleaginous organism ( e . g . yeast cell , oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant Yarrowia lipolytica , algae , or plant cell ) produces C7 : 1 fatty 
cell ) is a sterol lipid . In embodiments , the majority lipid , acid . In embodiments , the oleaginous organism ( e . g . yeast 
lipid precursor , or oleochemical in the oleaginous organism 5 cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or 
( e . g . yeast cell , oleaginous yeast cell , Yarrowia lipolytica , plant cell ) produces C7 : 2 fatty acid . In embodiments , the 
algae , or plant cell ) is a triacylglyceride . In embodiments , oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
the majority lipid , lipid precursor , or oleochemical in the Yarrowia lipolytica , algae , or plant cell ) produces C7 : 3 fatty acid . In embodiments , the oleaginous organism ( e . g . yeast oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
Yarrowia lipolytica , algae , or plant cell ) is a prenol lipid . In 10 cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or plant cell ) produces C8 : 0 fatty acid . In embodiments , the embodiments , the majority lipid , lipid precursor , or oleo oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , chemical in the oleaginous organism ( e . g . yeast cell , oleagi Yarrowia lipolytica , algae , or plant cell ) produces C8 : 1 fatty nous yeast cell , Yarrowia lipolytica , algae , or plant cell ) is a acid . In embodiments , the oleaginous organism ( e . g . yeast 
wax ester . In embodiments , the majority lipid , lipid precur - 15 cell . oleaginous veast cell . Yarrowia lipolytica , algae , or 
sor , or oleochemical in the oleaginous organism ( e . g . yeast plant cell ) produces C8 : 2 fatty acid . In embodiments , the 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
plant cell ) is a fatty acid ethyl ester . In embodiments , the Yarrowia lipolytica , algae , or plant cell ) produces C8 : 3 fatty 
majority lipid , lipid precursor , or oleochemical in the ole - acid . In embodiments , the oleaginous organism ( e . g . yeast 
aginous organism ( e . g . yeast cell , oleaginous yeast cell , 20 cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or 
Yarrowia lipolytica , algae , or plant cell ) is a fatty acid plant cell ) produces C9 : 0 fatty acid . In embodiments , the 
methyl ester . In embodiments , the majority lipid , lipid oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
precursor , or oleochemical in the oleaginous organism ( e . g . Yarrowia lipolytica , algae , or plant cell ) produces C9 : 1 fatty 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , acid . In embodiments , the oleaginous organism ( e . g . yeast 
or plant cell ) is a component of biodiesel . In embodiments , 25 cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or 
the majority lipid , lipid precursor , or oleochemical in the plant cell ) produces C9 : 2 fatty acid . In embodiments , the 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
Yarrowia lipolytica , algae , or plant cell ) is a saturated Yarrowia lipolytica , algae , or plant cell ) produces C9 : 3 fatty 
hydrocarbon . In embodiments , the majority lipid , lipid pre - acid . In embodiments , the oleaginous organism ( e . g . yeast 
cursor , or oleochemical in the oleaginous organism ( e . g . 30 cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , plant cell ) produces C10 : 0 fatty acid . In embodiments , the 
or plant cell ) is an unsaturated hydrocarbon . In embodi - oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
ments , the majority lipid , lipid precursor , or oleochemical in Yarrowia lipolytica , algae , or plant cell ) produces C10 : 1 
the oleaginous organism ( e . g . yeast cell , oleaginous yeast fatty acid . In embodiments , the oleaginous organism ( e . g . 
cell , Yarrowia lipolytica , algae , or plant cell ) is a branched 35 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
hydrocarbon . In embodiments , the majority lipid , lipid pre or plant cell ) produces C10 : 2 fatty acid . In embodiments , the 
cursor , or oleochemical in the oleaginous organism ( e . g . oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , Yarrowia lipolytica , algae , or plant cell ) produces C10 : 3 
or plant cell ) is a lipid . In embodiments , the majority lipid , fatty acid . In embodiments , the oleaginous organism ( e . g . 
lipid precursor , or oleochemical in the oleaginous organism 40 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
( e . g . yeast cell , oleaginous yeast cell , Yarrowia lipolytica , or plant cell ) produces C11 : 0 fatty acid . In embodiments , the 
algae , or plant cell ) is a lipid precursor . In embodiments , the oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
majority lipid , lipid precursor , or oleochemical in the ole - Yarrowia lipolytica , algae , or plant cell ) produces C11 : 1 
aginous organism ( e . g . yeast cell , oleaginous yeast cell , fatty acid . In embodiments , the oleaginous organism ( e . g . 
Yarrowia lipolytica , algae , or plant cell ) is an oleochemical . 45 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
In embodiments , the oleaginous organism ( e . g . yeast cell , or plant cell ) produces C11 : 2 fatty acid . In embodiments , the 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
cell ) produces C5 : 0 fatty acid . In embodiments , the oleagi Yarrowia lipolytica , algae , or plant cell ) produces C11 : 3 
nous organism ( e . g . yeast cell , oleaginous yeast cell , Yar - fatty acid . In embodiments , the oleaginous organism ( e . g . 
rowia lipolytica , algae , or plant cell ) produces C5 : 1 fatty 50 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
acid . In embodiments , the oleaginous organism ( e . g . yeast or plant cell ) produces C12 : 0 fatty acid . In embodiments , the 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
plant cell ) produces C5 : 2 fatty acid . In embodiments , the Yarrowia lipolytica , algae , or plant cell ) produces C12 : 1 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , fatty acid . In embodiments , the oleaginous organism ( e . g . 
Yarrowia lipolytica , algae , or plant cell ) produces C5 : 3 fatty 55 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
acid . In embodiments , the oleaginous organism ( e . g . yeast or plant cell ) produces C12 : 2 fatty acid . In embodiments , the 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
plant cell ) produces C6 : 0 fatty acid . In embodiments , the Yarrowia lipolytica , algae , or plant cell ) produces C12 : 3 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , fatty acid . In embodiments , the oleaginous organism ( e . g . 
Yarrowia lipolytica , algae , or plant cell ) produces C6 : 1 fatty 60 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
acid . In embodiments , the oleaginous organism ( e . g . yeast or plant cell ) produces C13 : 0 fatty acid . In embodiments , the 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
plant cell ) produces C6 : 2 fatty acid . In embodiments , the Yarrowia lipolytica , algae , or plant cell ) produces C13 : 1 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , fatty acid . In embodiments , the oleaginous organism ( e . g . 
Yarrowia lipolytica , algae , or plant cell ) produces C6 : 3 fatty 65 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
acid . In embodiments , the oleaginous organism ( e . g . yeast or plant cell ) produces C13 : 2 fatty acid . In embodiments , the 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
33 
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Yarrowia lipolytica , algae , or plant cell ) produces C13 : 3 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
fatty acid . In embodiments , the oleaginous organism ( e . g . or plant cell ) produces C20 : 2 fatty acid . In embodiments , the 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
or plant cell ) produces C14 : 0 fatty acid . In embodiments , the Yarrowia lipolytica , algae , or plant cell ) produces C20 : 3 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 5 fatty acid . In embodiments , the oleaginous organism ( e . g . 
Yarrowia lipolytica , algae , or plant cell ) produces C14 : 1 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
fatty acid . In embodiments , the oleaginous organism ( e . g . or plant cell ) produces C21 : 0 fatty acid . In embodiments , the 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
or plant cell ) produces C14 : 2 fatty acid . In embodiments , the Yarrowia lipolytica , algae , or plant cell ) produces C21 : 1 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 10 fatty acid . In embodiments , the oleaginous organism ( e . g . 
Yarrowia lipolytica , algae , or plant cell ) produces C14 : 3 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
fatty acid . In embodiments , the oleaginous organism ( e . g . or plant cell ) produces C21 : 2 fatty acid . In embodiments , the 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
or plant cell ) produces C15 : 0 fatty acid . In embodiments , the Yarrowia lipolytica , algae , or plant cell ) produces C21 : 3 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 15 fatty acid . In embodiments , the oleaginous organism ( e . g . 
Yarrowia lipolytica , algae , or plant cell ) produces C15 : 1 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
fatty acid . In embodiments , the oleaginous organism ( e . g . or plant cell ) produces C22 : 0 fatty acid . In embodiments , the 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
or plant cell ) produces C15 : 2 fatty acid . In embodiments , the Yarrowia lipolytica , algae , or plant cell ) produces C22 : 1 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 20 fatty acid . In embodiments , the oleaginous organism ( e . g . 
Yarrowia lipolytica , algae , or plant cell ) produces C15 : 3 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
fatty acid . In embodiments , the oleaginous organism ( e . g . or plant cell ) produces C22 : 2 fatty acid . In embodiments , the 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
or plant cell ) produces C16 : 0 fatty acid . In embodiments , the Yarrowia lipolytica , algae , or plant cell ) produces C22 : 3 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 25 fatty acid . In embodiments , the oleaginous organism ( e . g . 
Yarrowia lipolytica , algae , or plant cell ) produces C16 : 1 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
fatty acid . In embodiments , the oleaginous organism ( e . g . or plant cell ) produces C23 : 0 fatty acid . In embodiments , the 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
or plant cell ) produces C16 : 2 fatty acid . In embodiments , the Yarrowia lipolytica , algae , or plant cell ) produces C23 : 1 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 30 fatty acid . In embodiments , the oleaginous organism ( e . g . 
Yarrowia lipolytica , algae , or plant cell ) produces C16 : 3 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
fatty acid . In embodiments , the oleaginous organism ( e . g . or plant cell ) produces C23 : 2 fatty acid . In embodiments , the 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
or plant cell ) produces C17 : 0 fatty acid . In embodiments , the Yarrowia lipolytica , algae , or plant cell ) produces C23 : 3 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 35 fatty acid . In embodiments , the oleaginous organism ( e . g . 
Yarrowia lipolytica , algae , or plant cell ) produces C17 : 1 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
fatty acid . In embodiments , the oleaginous organism ( e . g . or plant cell ) produces a fatty acid described herein above at 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , a greater level ( e . g . 1 . 1 , 1 . 2 , 1 . 3 , 1 . 4 , 1 . 5 , 1 . 6 , 1 . 7 , 1 . 8 , 1 . 9 , 
or plant cell ) produces C17 : 2 fatty acid . In embodiments , the 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 40 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 
Yarrowia lipolytica , algae , or plant cell ) produces C17 : 3 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 
fatty acid . In embodiments , the oleaginous organism ( e . g . 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 
or plant cell ) produces C18 : 0 fatty acid . In embodiments , the 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 45 100 , 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , 1000 , 2000 , 
Yarrowia lipolytica , algae , or plant cell ) produces C18 : 1 3000 , 4000 , 5000 , 6000 , 7000 , 8000 , 9000 , 10000 , 100000 , 
fatty acid . In embodiments , the oleaginous organism ( e . g . 1000000 fold ) compared to the same oleaginous organism 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , lacking the genetic modification . In embodiments , the ole 
or plant cell ) produces C18 : 2 fatty acid . In embodiments , the aginous organism ( e . g . yeast cell , oleaginous yeast cell , 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 50 Yarrowia lipolytica , algae , or plant cell ) produces a lipid 
Yarrowia lipolytica , algae , or plant cell ) produces C18 : 3 including a fatty acid selected from the group consisting of 
fatty acid . In embodiments , the oleaginous organism ( e . g . C5 : 0 , C5 : 1 , C5 : 2 , C5 : 3 , C6 : 0 , C6 : 1 , C6 : 2 , C6 : 3 , C7 : 0 , C7 : 1 , 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , C7 : 2 , C7 : 3 , C8 : 0 , C8 : 1 , C8 : 2 , C8 : 3 , C9 : 0 , 19 : 1 , 19 : 2 , C9 : 3 , 
or plant cell ) produces C19 : 0 fatty acid . In embodiments , the C10 : 0 , C10 : 1 , C10 : 2 , C10 : 3 , C11 : 0 , C11 : 1 , C11 : 2 , C11 : 3 , 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 55 C12 : 0 , C12 : 1 , C12 : 2 , C12 : 3 , C13 : 0 , C13 : 1 , C13 : 2 , C13 : 3 , 
Yarrowia lipolytica , algae , or plant cell ) produces C19 : 1 C14 : 0 , C14 : 1 , C14 : 2 , C14 : 3 , C15 : 0 , C15 : 1 , C15 : 2 , C15 : 3 , 
fatty acid . In embodiments , the oleaginous organism ( e . g . C16 : 0 , C16 : 1 , C16 : 2 , C16 : 3 , C17 : 0 , C17 : 1 , C17 : 2 , C17 : 3 , 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , C18 : 0 , C18 : 1 , C18 : 2 , C18 : 3 , C19 : 0 , C19 : 1 , C19 : 2 , C19 : 3 , 
or plant cell ) produces C19 : 2 fatty acid . In embodiments , the C20 : 0 , C20 : 1 , C20 : 2 , C20 : 3 , C21 : 0 , C21 : 1 , C21 : 2 , C21 : 3 , 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 60 C22 : 0 , C22 : 1 , C22 : 2 , C22 : 3 , C23 : 0 , C23 : 1 , C23 : 2 , and 
Yarrowia lipolytica , algae , or plant cell ) produces C19 : 3 C23 : 3 . In embodiments , the oleaginous organism ( e . g . yeast 
fatty acid . In embodiments , the oleaginous organism ( e . g . cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or 
yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , plant cell ) produces a lipid derived from an endogenously 
or plant cell ) produces C20 : 0 fatty acid . In embodiments , the produced fatty acid selected from the group consisting of 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 65 C5 : 0 , C5 : 1 , C5 : 2 , C5 : 3 , C6 : 0 , C6 : 1 , C6 : 2 , C6 : 3 , C7 : 0 , C7 : 1 , 
Yarrowia lipolytica , algae , or plant cell ) produces C20 : 1 C7 : 2 , C7 : 3 , C8 : 0 , C8 : 1 , C8 : 2 , C8 : 3 , 19 : 0 , 19 : 1 , 19 : 2 , 19 : 3 , 
fatty acid . In embodiments , the oleaginous organism ( e . g . C10 : 0 , C10 : 1 , C10 : 2 , C10 : 3 , C11 : 0 , C11 : 1 , C11 : 2 , C11 : 3 , 
36 
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C12 : 0 , C12 : 1 , C12 : 2 , C12 : 3 , C13 : 0 , C13 : 1 , C13 : 2 , C13 : 3 , main protein ( YOX1 ) . In embodiments , the protein is UGA2 
C14 : 0 , C14 : 1 , C14 : 2 , C14 : 3 , C15 : 0 , C15 : 1 , C15 : 2 , C15 : 3 , succinate semialdehyde dehydrogenase ( UGA2 ) . In embodi 
C16 : 0 , C16 : 1 , C16 : 2 , C16 : 3 , C17 : 0 , C17 : 1 , C17 : 2 , C17 : 3 , ments , the protein is OSH6 oxysterol - binding protein 
C18 : 0 , C18 : 1 , C18 : 2 , C18 : 3 , C19 : 0 , C19 : 1 , C19 : 2 , C19 : 3 , homolog 6 ( OSHA ) . In embodiments , the protein is IRC20 
C20 : 0 , C20 : 1 , C20 : 2 , C20 : 3 , C21 : 0 , C21 : 1 , C21 : 2 , C21 : 3 , 5 E3 ubiquitin - protein ligase and helicase ( IRC20 ) . In 
C22 : 0 , C22 : 1 , C22 : 2 , C22 : 3 , C23 : 0 , C23 : 1 , C23 : 2 , and embodiments , modulating the level of activity of a protein in 
C23 : 3 . In embodiments , the oleaginous organism ( e . g . yeast an oleaginous organism ( e . g . yeast cell , oleaginous yeast 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or cell , Yarrowia lipolytica , algae , or plant cell ) is modulating 
plant cell ) produces a lipid , lipid precursor , or oleochemical the function of the protein . In embodiments , modulating the 
( e . g . fatty acid ) described herein at a greater level ( e . g . 1 . 1 , 10 level of activity of a protein in an oleaginous organism ( e . g . 
1 . 2 , 1 . 3 , 1 . 4 , 1 . 5 , 1 . 6 , 1 . 7 , 1 . 8 , 1 . 9 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , or plant cell ) is modulating the amount of the protein . In 
27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , embodiments , modulating the level of activity of a protein in 
43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , an oleaginous organism ( e . g . yeast cell , oleaginous yeast 
59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 15 cell , Yarrowia lipolytica , algae , or plant cell ) is modulating 
75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , the transcription of the mRNA encoding the protein . In 
91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 200 , 300 , 400 , 500 , embodiments , modulating the level of activity of a protein in 
600 , 700 , 800 , 900 , 1000 , 2000 , 3000 , 4000 , 5000 , 6000 , an oleaginous organism ( e . g . yeast cell , oleaginous yeast 
7000 , 8000 , 9000 , 10000 , 100000 , 1000000 fold ) compared cell , Yarrowia lipolytica , algae , or plant cell ) is modulating 
to the same oleaginous organism lacking the genetic modi - 20 the translation of the protein . In embodiments , modulating 
fication . the level of activity of a protein in an oleaginous organism 
In embodiments , the oleaginous organism ( e . g . yeast cell , ( e . g . yeast cell , oleaginous yeast cell , Yarrowia lipolytica , 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant algae , or plant cell ) is modulating the coding sequence of the 
cell ) includes a recombinant nucleic acid , wherein the gene encoding the protein ( e . g . mutating ( e . g . point mutant 
recombinant nucleic acid modulates the level of activity of 25 or missense mutant ) , truncating , inserting into , or deleting ) . 
a protein in the oleaginous organism ( e . g . yeast cell , oleagi - In embodiments , modulating the level of activity of a protein 
nous yeast cell , Yarrowia lipolytica , algae , or plant cell ) in an oleaginous organism ( e . g . yeast cell , oleaginous yeast 
relative to the absence of the recombinant nucleic acid . In cell , Yarrowia lipolytica , algae , or plant cell ) is modulating 
embodiments , the protein is selected from the group con - the regulatory elements ( e . g . promoter ) of the gene encoding 
sisting of Leucine Biosynthesis Gene ( LEU2 ) , Uracil Bio - 30 the protein . In embodiments , modulating the level of activity 
synthesis gene ( URA3 ) , multifunctional enzyme ( MFE1 ) , of a protein in an oleaginous organism ( e . g . yeast cell , 
Transcription Factor ( PEX10 ) , AMP Deaminase ( AMPD ) , oleaginous yeast cell , Yarrowia lipolytica , algae , or plant 
ATP - Citrate Lyase ( ACL ) ( e . g . ACL subunit 1 , ACL subunit cell ) is modulating the stability of the protein . In embodi 
2 , or subunit 1 and 2 ) , Malic Enzyme ( MAE ) , Acetyl - CoA ments , modulating the level of activity of a protein in an 
Carboxylase ( ACC ) , acyl - CoA : diacylglycerol acyltrans - 35 oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
ferase ( DGA1 ) , acyl - CoA : diacylglycerol acyltransferases Yarrowia lipolytica , algae , or plant cell ) is modulating the 
( DGA2 ) , Mitochondrial 2 ' O - ribose methyltransferase stability of the transcript encoding the protein . In embodi 
( MRM2 ) , Lipid synthesis regulator ( MGA2 ) , Chromatin ments , modulating the level of activity of a protein in an 
assembly gene ( RLF2 subunit p90 ) , 0 - 6 - methylguanine - oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , 
DNA methyltransferase ( MGMT ) , Aconitase ( ACO1 ) , Cit - 40 Yarrowia lipolytica , algae , or plant cell ) is reducing the level 
rate Synthase ( CIT1 ) , RME1 zinc - finger transcription factor of activity of the protein . In embodiments , modulating the 
( RME1 ) , YOX1 homeodomain protein ( YOX1 ) , UGA2 level of activity of a protein in an oleaginous organism ( e . g . 
succinate semialdehyde dehydrogenase ( UGA2 ) , OSH6 yeast cell , oleaginous yeast cell , Yarrowia lipolytica , algae , 
oxysterol - binding protein homolog 6 ( OSHO ) , and IRC20 or plant cell ) is increasing the level of activity of the protein . 
E3 ubiquitin - protein ligase and helicase ( IRC20 ) . In 45 In embodiments , the oleaginous organism ( e . g . yeast cell , 
embodiments , the protein is Leucine Biosynthesis Gene oleaginous yeast cell , Yarrowia lipolytica , algae , or plant 
( LEU2 ) . In embodiments , the protein is Uracil Biosynthesis cell ) includes a genetic modification ( e . g . recombinant 
gene ( URA3 ) . In embodiments , the protein is multifunc - nucleic acid ) that modulates ( e . g . reduces or increases ) the 
tional enzyme ( MFE1 ) . In embodiments , the protein is level of activity of a protein in the citric acid cycle in the 
Transcription Factor ( PEX10 ) . In embodiments , the protein 50 oleaginous organism relative to the absence of the genetic 
is AMP Deaminase ( AMPD ) . In embodiments , the protein is modification ( e . g . recombinant nucleic acid ) . In embodi 
ATP - Citrate Lyase ( ACL ) ( e . g . ACL subunit 1 , ACL subunit ments , the oleaginous organism ( e . g . yeast cell , oleaginous 
2 , or subunit 1 and 2 ) . In embodiments , the protein is Malic yeast cell , Yarrowia lipolytica , algae , or plant cell ) includes 
Enzyme ( MAE ) . In embodiments , the protein is Acetyl - CoA a genetic modification ( e . g . recombinant nucleic acid ) that 
Carboxylase ( ACC ) . In embodiments , the protein is acyl - 55 modulates ( e . g . reduces or increases ) the level of activity of 
COA : diacylglycerol acyltransferase ( DGA1 ) . In embodi a protein involved in the Kennedy Pathway in the oleaginous 
ments , the protein is acyl - CoA : diacylglycerol acyltrans - organism relative to the absence of the genetic modification 
ferases ( DGA2 ) . In embodiments , the protein is ( e . g . recombinant nucleic acid ) . In embodiments , the ole 
Mitochondrial 2 O - ribose methyltransferase ( MRM2 ) . In aginous organism ( e . g . yeast cell , oleaginous yeast cell , 
embodiments , the protein is Lipid synthesis regulator 60 Yarrowia lipolytica , algae , or plant cell ) includes a genetic 
( MGA2 ) . In embodiments , the protein is Chromatin assem - modification ( e . g . recombinant nucleic acid ) that modulates 
bly gene ( RLF2 subunit p90 ) . In embodiments , the protein ( e . g . reduces or increases ) the level of activity of a protein 
is 0 - 6 - methylguanine - DNA methyltransferase ( MGMT ) . In involved in fatty acid synthesis in the oleaginous organism 
embodiments , the protein is Aconitase ( ACO1 ) . In embodi - relative to the absence of the genetic modification ( e . g . 
ments , the protein is Citrate Synthase ( CIT1 ) . In embodi - 65 recombinant nucleic acid ) . In embodiments , the oleaginous 
ments , the protein is RME1 zinc - finger transcription factor organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia 
( RME1 ) . In embodiments , the protein is YOX1 homeodo - lipolytica , algae , or plant cell ) includes a genetic modifica 
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tion ( e . g . recombinant nucleic acid ) that modulates ( e . g . absence of the genetic modification ( e . g . recombinant 
reduces or increases ) the level of activity of a protein nucleic acid ) . In embodiments , the oleaginous organism 
involved in fatty acid storage ( e . g . accumulation ) in the ( e . g . yeast cell , oleaginous yeast cell , Yarrowia lipolytica , 
oleaginous organism relative to the absence of the genetic algae , or plant cell ) includes a genetic modification ( e . g . 
modification ( e . g . recombinant nucleic acid ) . In embodi - 5 recombinant nucleic acid ) that modulates ( e . g . reduces or 
ments , the oleaginous organism ( e . g . yeast cell , oleaginous increases the level of activity of a protein involved in 
yeast cell , Yarrowia lipolytica , algae , or plant cell ) includes central carbon metabolism in the oleaginous organism rela 
a genetic modification ( e . g . recombinant nucleic acid ) that tive to the absence of the genetic modification ( e . g . recom 
that modulates ( e . g . reduces or increases the level of binant nucleic acid ) . 
activity of a protein involved in lipid synthesis in the 10 In embodiments , the recombinant nucleic acid increases 
oleaginous organism relative to the absence of the genetic the level of activity of a protein in the oleaginous organism 
modification ( e . g . recombinant nucleic acid ) . In embodi - ( e . g . yeast cell , oleaginous yeast cell , Yarrowia lipolytica , 
ments , the oleaginous organism ( e . g . yeast cell , oleaginous algae , or plant cell ) . In embodiments , the protein is selected 
yeast cell , Yarrowia lipolytica , algae , or plant cell ) includes from the group consisting of Leucine Biosynthesis Gene 
a genetic modification ( e . g . recombinant nucleic acid ) that 15 ( LEU2 ) , Uracil Biosynthesis gene ( URA3 ) , AMP Deami 
modulates ( e . g . reduces or increases ) the level of activity of nase ( AMPD ) , ATP - Citrate Lyase ( ACL ) ( e . g . ACL subunit 
a protein involved in lipid storage ( e . g . accumulation ) in the 1 , ACL subunit 2 , or subunit 1 and 2 ) , Malic Enzyme 
oleaginous organism relative to the absence of the genetic ( MAE ) , Acetyl - CoA Carboxylase ( ACC ) , acyl - CoA : diacyl 
modification ( e . g . recombinant nucleic acid ) . In embodi - glycerol acyltransferase ( DGA1 ) , acyl - CoA : diacylglycerol 
ments , the oleaginous organism ( e . g . yeast cell , oleaginous 20 acyltransferases ( DGA2 ) , Mitochondrial 2 ' O - ribose meth 
yeast cell , Yarrowia lipolytica , algae , or plant cell ) includes y ltransferase ( MRM2 ) , Lipid synthesis regulator ( MGA2 ) , 
a genetic modification ( e . g . recombinant nucleic acid ) that Chromatin assembly gene ( RLF2 subunit p90 ) , 0 - 6 - meth 
modulates ( e . g . reduces or increases ) the level of activity of ylguanine - DNA methyltransferase ( MGMT ) , Citrate Syn 
a protein involved in triacylglyceride storage ( e . g . accumu - thase ( CIT1 ) , RME1 zinc - finger transcription factor 
lation ) in the oleaginous organism relative to the absence of 25 ( RME1 ) , YOX1 homeodomain protein ( YOX1 ) , UGA2 
the genetic modification ( e . g . recombinant nucleic acid ) . In succinate semialdehyde dehydrogenase ( UGA2 ) , OSH6 
embodiments , the oleaginous organism ( e . g . yeast cell , oxysterol - binding protein homolog 6 ( OSH6 ) , and IRC20 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant E3 ubiquitin - protein ligase and helicase ( IRC20 ) . In 
cell ) includes a genetic modification ( e . g . recombinant embodiments , the protein is selected from the group con 
nucleic acid ) that modulates ( e . g . reduces or increases ) the 30 sisting of Leucine Biosynthesis Gene ( LEU2 ) , Uracil Bio 
level of activity of a protein involved in triacylglyceride synthesis gene ( URA3 ) , AMP Deaminase ( AMPD ) , ATP 
synthesis in the oleaginous organism relative to the absence Citrate Lyase ( ACL ) ( e . g . ACL subunit 1 , ACL subunit 2 , or 
of the genetic modification ( e . g . recombinant nucleic acid ) . subunit 1 and 2 ) , Malic Enzyme ( MAE ) , Acetyl - CoA Car 
In embodiments , the oleaginous organism ( e . g . yeast cell , boxylase ( ACC ) , acyl - CoA : diacylglycerol acyltransferase 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant 35 ( DGA1 ) , acyl - CoA : diacylglycerol acyltransferases 
cell ) includes a genetic modification ( e . g . recombinant ( DGA2 ) , Mitochondrial 2 ! O - ribose methyltransferase 
nucleic acid ) that modulates ( e . g . reduces or increases ) the ( MRM2 ) , Lipid synthesis regulator ( MGA2 ) , Chromatin 
level of activity of a protein involved in peroxisomal bio - assembly gene ( RLF2 subunit p90 ) , 0 - 6 - methylguanine 
genesis in the oleaginous organism relative to the absence of DNA methyltransferase ( MGMT ), and Citrate Synthase 
the genetic modification ( e . g . recombinant nucleic acid ) . In 40 ( CIT1 ) . In embodiments , the protein is Leucine Biosynthesis 
embodiments , the oleaginous organism ( e . g . yeast cell , Gene ( LEU2 ) . In embodiments , the protein is Uracil Bio 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant synthesis gene ( URA3 ) . In embodiments , the protein is AMP 
cell ) includes a genetic modification ( e . g . recombinant Deaminase ( AMPD ) . In embodiments , the protein is ATP 
nucleic acid ) that modulates ( e . g . reduces or increases ) the Citrate Lyase ( ACL ) ( e . g . ACL subunit 1 , ACL subunit 2 , or 
level of activity of a protein involved in the beta - oxidation 45 subunit 1 and 2 ) . In embodiments , the protein is Malic 
cycle in the oleaginous organism relative to the absence of Enzyme ( MAE ) . In embodiments , the protein is Acetyl - COA 
the genetic modification ( e . g . recombinant nucleic acid ) . In Carboxylase ( ACC ) . In embodiments , the protein is acyl 
embodiments , the oleaginous organism ( e . g . yeast cell , COA : diacylglycerol acyltransferase ( DGA1 ) . In embodi 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant ments , the protein is acyl - CoA : diacylglycerol acyltrans 
cell ) includes a genetic modification ( e . g . recombinant 50 ferases ( DGA2 ) . In embodiments , the protein is 
nucleic acid ) that modulates ( e . g . reduces or increases ) the Mitochondrial 2 ' O - ribose methyltransferase ( MRM2 ) . In 
level of activity of a protein involved in fatty acid degra - embodiments , the protein is Lipid synthesis regulator 
dation in the oleaginous organism relative to the absence of ( MGA2 ) . In embodiments , the protein is Chromatin assem 
the genetic modification ( e . g . recombinant nucleic acid ) . In bly gene ( RLF2 subunit p90 ) . In embodiments , the protein 
embodiments , the oleaginous organism ( e . g . yeast cell , 55 is 0 - 6 - methylguanine - DNA methyltransferase ( MGMT ) . In 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant embodiments , the protein is Citrate Synthase ( CIT1 ) . In 
cell ) includes a genetic modification ( e . g . recombinant embodiments , the protein is RME1 zinc - finger transcription 
nucleic acid ) that modulates ( e . g . reduces or increases ) the factor ( RME1 ) . In embodiments , the protein is YOX1 home 
level of activity of a protein involved in lipid degradation in odomain protein ( YOX1 ) . In embodiments , the protein is 
the oleaginous organism relative to the absence of the 60 UGA2 succinate semialdehyde dehydrogenase ( UGA2 ) . In 
genetic modification ( e . g . recombinant nucleic acid ) . In embodiments , the protein is OSH6 oxysterol - binding protein 
embodiments , the oleaginous organism ( e . g . yeast cell , homolog 6 ( OSHA ) . In embodiments , the protein is IRC20 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant E3 ubiquitin - protein ligase and helicase ( IRC20 ) . In 
cell ) includes a genetic modification ( e . g . recombinant embodiments , the protein is selected from the group con 
nucleic acid ) that modulates ( e . g . reduces or increases ) the 65 sisting of Leucine Biosynthesis Gene ( LEU2 ) , Uracil Bio 
level of activity of a protein involved in triacylglyceride synthesis gene ( URA3 ) , Malic Enzyme ( MAE ) , Mitochon 
degradation in the oleaginous organism relative to the drial 2 ' O - ribose methyltransferase ( MRM2 ) , Lipid 
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synthesis regulator ( MGA2 ) , and 0 - 6 - methylguanine - DNA ( UGA2 ) , OSH6 oxysterol - binding protein homolog 6 
methyltransferase ( MGMT ) or said nucleic acid decreases ( OSHO ) , or IRC20 E3 ubiquitin - protein ligase and helicase 
the level of activity of Lipid synthesis regulator ( MGA2 ) . ( IRC20 ) . 
In embodiments , the genetic modification ( e . g . recombi In embodiments , the recombinant nucleic acid encodes a 
nant nucleic acid ) decreases the level of activity of a protein 5 mutant of a protein selected from the group consisting of 
in the oleaginous organism ( e . g . yeast cell , oleaginous yeast Leucine Biosynthesis Gene ( LEU2 ) , Uracil Biosynthesis 
cell , Yarrowia lipolytica , algae , or plant cell ) . In embodi gene ( URA3 ) , multifunctional enzyme ( MFE1 ) , Transcrip 
ments , the protein is selected from the group consisting of tion Factor ( PEX10 ) , AMP Deaminase ( AMPD ) , ATP - Cit 
multifunctional enzyme ( MFE1 ) , Lipid synthesis regulator rate Lyase ( ACL ) ( e . g . ACL subunit 1 , ACL subunit 2 , or 
( MGA2 ) , Chromatin assembly gene ( RLF2 subunit p90 ) , 10 subunit 1 and 2 ) , Malic Enzyme ( MAE ) , Acetyl - CoA Car 
Transcription Factor ( PEX10 ) , and Aconitase ( ACO1 ) . In boxylase ( ACC ) , acyl - CoA : diacylglycerol acyltransferase 
embodiments , the protein is multifunctional enzyme ( DGA1 ) , acyl - CoA : diacylglycerol acyltransferases 
( MFE1 ) . In embodiments , the protein is Lipid synthesis ( DGA2 ) , Mitochondrial 2 ' O - ribose methyltransferase 
regulator ( MGA2 ) . In embodiments , the protein is Chroma - ( MRM2 ) , Lipid synthesis regulator ( MGA2 ) , Chromatin 
tin assembly gene ( RLF2 subunit p90 ) . In embodiments , the 15 assembly gene ( RLF2 subunit p90 ) , 0 - 6 - methylguanine 
protein is Transcription Factor ( PEX10 ) . In embodiments , DNA methyltransferase ( MGMT ) , Aconitase ( ACO1 ) , Cit 
the protein is Aconitase ( ACO1 ) . In embodiments , the rate Synthase ( CIT1 ) , RME1 zinc - finger transcription factor 
protein is RME1 zinc - finger transcription factor ( RME1 ) . In ( RME1 ) , YOX1 homeodomain protein ( YOX1 ) , UGA2 
embodiments , the protein is YOX1 homeodomain protein succinate semialdehyde dehydrogenase ( UGA2 ) , OSHO 
( YOX1 ) . In embodiments , the protein is UGA2 succinate 20 oxysterol - binding protein homolog 6 ( OSH6 ) , or IRC20 E3 
semialdehyde dehydrogenase ( UGA2 ) . In embodiments , the ubiquitin - protein ligase and helicase ( IRC20 ) . 
protein is OSH6 oxysterol - binding protein homolog 6 In embodiments , the recombinant nucleic acid is an AMP 
( OSHA ) . In embodiments , the protein is IRC20 E3 ubiquitin - Deaminase ( AMPD ) having the nucleotide sequence of SEQ 
protein ligase and helicase ( IRC20 ) . ID NO . : 33 . In embodiments , the recombinant nucleic acid is 
In embodiments , the oleaginous organism ( e . g . yeast cell , 25 an AMP Deaminase ( AMPD ) having at least 60 % identity 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant ( e . g . at least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , 
cell ) includes a plurality of genetic modifications ( e . g . 69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , 
recombinant nucleic acids ) that collectively modulate one , 79 % , 80 % , 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 
two , three , four , five , six , seven , eight , nine , ten , or more of 89 % , 90 % , 91 % , 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , or 
the group of proteins consisting of Leucine Biosynthesis 30 99 % identity ) over a region of at least 100 nucleotides ( e . g . 
Gene ( LEU2 ) , Uracil Biosynthesis gene ( URA3 ) , multifunc - at least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , 1000 , 1100 , 
tional enzyme ( MFE1 ) , Transcription Factor ( PEX10 ) , AMP 1200 , 1300 , 1400 , 1500 , 1600 , 1700 , 1800 , 1900 , 2000 , or 
Deaminase ( AMPD ) , ATP - Citrate Lyase ( ACL ) ( e . g . ACL the entire sequence ) with SEQ ID NO . : 33 , ( e . g . using the 
subunit 1 , ACL subunit 2 , or subunit 1 and 2 ) , Malic Enzyme same length of nucleotides for comparison or the entirety of 
( MAE ) , Acetyl - CoA Carboxylase ( ACC ) , acyl - CoA : diacyl - 35 both nucleic acids ) . 
glycerol acyltransferase ( DGA1 ) , acyl - CoA : diacylglycerol In embodiments , the recombinant nucleic acid is a Leu 
acyltransferases ( DGA2 ) , Mitochondrial 2 ' O - ribose meth - cine Biosynthesis Gene ( LEU2 ) having the nucleotide 
yltransferase ( MRM2 ) , Lipid synthesis regulator ( MGA2 ) , sequence of SEQ ID NO . : 35 . In embodiments , the recom 
Chromatin assembly gene ( RLF2 subunit p90 ) , 0 - 6 - meth - binant nucleic acid is a Leucine Biosynthesis Gene ( LEU2 ) 
ylguanine - DNA methyltransferase ( MGMT ) , Aconitase 40 having at least 60 % identity ( e . g . at least 61 % , 62 % , 63 % , 
( ACO1 ) , Citrate Synthase ( CIT1 ) , RME1 zinc - finger tran - 64 % , 65 % , 66 % , 67 % , 68 % , 69 % , 70 % , 71 % , 72 % , 73 % , 
scription factor ( RME1 ) , YOX1 homeodomain protein 74 % , 75 % , 76 % , 77 % , 78 % , 79 % , 80 % , 81 % , 82 % , 83 % , 
( YOX1 ) , UGA2 succinate semialdehyde dehydrogenase 84 % , 85 % , 86 % , 87 % , 88 % , 89 % , 90 % , 91 % , 92 % , 93 % , 
( UGA2 ) , OSH6 oxysterol - binding protein homolog 6 94 % , 95 % , 96 % , 97 % , 98 % , or 99 % identity ) over a region 
( OSH6 ) , and IRC20 E3 ubiquitin - protein ligase and helicase 45 of at least 100 nucleotides ( e . g . at least 200 , 300 , 400 , 500 , 
( IRC20 ) . 600 , 700 , 800 , 900 , 1000 , 1100 , 1200 , or the entire 
In embodiments , the recombinant nucleic acid encodes a sequence ) with SEQ ID NO . : 35 , ( e . g . using the same length 
protein comprising a mutation relative to the wildtype of nucleotides for comparison or the entirety of both nucleic 
protein . In embodiments , the mutation is a point mutation . In acids ) . 
embodiments , the mutation is a deletion . In embodiments , 50 In embodiments , the recombinant nucleic acid is a Uracil 
the mutation is an insertion . In embodiments , the mutation Biosynthesis gene ( URA3 ) having the nucleotide sequence 
is a fusion with a second protein . In embodiments , the of SEQ ID NO . : 37 . In embodiments , the recombinant 
recombinant nucleic acid encodes a mutant of a protein nucleic acid is a Uracil Biosynthesis gene ( URA3 ) having at 
selected from the group consisting of Leucine Biosynthesis least 60 % identity ( e . g . at least 61 % , 62 % , 63 % , 64 % , 65 % , 
Gene ( LEU2 ) , Uracil Biosynthesis gene ( URA3 ) , multifunc - 55 66 % , 67 % , 68 % , 69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 
tional enzyme ( MFE1 ) , Transcription Factor ( PEX10 ) , AMP 76 % , 77 % , 78 % , 79 % , 80 % , 81 % , 82 % 83 % , 84 % , 85 % . 
Deaminase ( AMPD ) , ATP - Citrate Lyase ( ACL ) ( e . g . ACL 86 % , 87 % , 88 % , 89 % , 90 % , 91 % 92 % , 93 % , 94 % , 95 % , 
subunit 1 , ACL subunit 2 , or subunit 1 and 2 ) , Malic Enzyme 96 % , 97 % , 98 % , or 99 % identity ) over a region of at least 
( MAE ) , Acetyl - CoA Carboxylase ( ACC ) , acyl - CoA : diacyl - 100 nucleotides ( e . g . at least 200 , 300 , 400 , 500 , 600 , 700 , 
glycerol acyltransferase ( DGA1 ) , acyl - CoA : diacylglycerol 60 800 , or the entire sequence ) with SEQ ID NO . : 37 , ( e . g . using 
acyltransferases ( DGA2 ) , Mitochondrial 2 ' O - ribose meth - the same length of nucleotides for comparison or the entirety 
yltransferase ( MRM2 ) , Lipid synthesis regulator ( MGA2 ) , of both nucleic acids ) . 
Chromatin assembly gene ( RLF2 subunit p90 ) , 0 - 6 - meth In embodiments , the recombinant nucleic acid is an 
ylguanine - DNA methyltransferase ( MGMT ) , Aconitase ATP - Citrate Lyase ( ACL ) ( subunit 1 ) having the nucleotide 
( ACO1 ) , Citrate Synthase ( CIT1 ) , RME1 zinc - finger tran - 65 sequence of SEQ ID NO . : 39 . In embodiments , the recom 
scription factor ( RME1 ) , YOX1 homeodomain protein binant nucleic acid is an ATP - Citrate Lyase ( ACL ) ( subunit 
( YOX1 ) , UGA2 succinate semialdehyde dehydrogenase 1 ) having at least 60 % identity ( e . g . at least 61 % , 62 % , 63 % , 
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64 % , 65 % , 66 % , 67 % , 68 % , 69 % , 70 % , 71 % , 72 % , 73 % , of SEQ ID NO . : 49 . In embodiments , the recombinant 
74 % , 75 % , 76 % , 77 % , 78 % , 79 % , 80 % , 81 % , 82 % , 83 % , nucleic acid is a Lipid synthesis regulator ( MGA2 ) having at 
84 % , 85 % , 86 % , 87 % , 88 % , 89 % , 90 % , 91 % 92 % , 93 % , least 60 % identity ( e . g . at least 61 % , 62 % , 63 % , 64 % , 65 % , 
94 % , 95 % , 96 % , 97 % , 98 % , or 99 % identity ) over a region 66 % , 67 % , 68 % , 69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 
of at least 100 nucleotides ( e . g . at least 200 , 300 , 400 , 500 , 5 76 % , 77 % , 78 % , 79 % , 80 % , 81 % , 82 % 83 % , 84 % , 85 % , 
600 , 700 , 800 , 900 , 1000 , 1100 , 1200 , 1300 , 1400 , 1500 , 86 % , 87 % , 88 % , 89 % , 90 % , 91 % , 92 % , 93 % , 94 % , 95 % , 
1600 , 1700 , 1800 , 1900 , or the entire sequence ) with SEQ 96 % , 97 % , 98 % , or 99 % identity ) over a region of at least 
ID NO . : 39 , ( e . g . using the same length of nucleotides for 100 nucleotides ( e . g . at least 200 , 300 , 400 , 500 , 600 , 700 , 
comparison or the entirety of both nucleic acids ) . 800 , 900 , 1000 , 1100 , 1200 , 1300 , 1400 , 1500 , 1600 , 1700 , 
In embodiments , the recombinant nucleic acid is an 10 1800 , 1900 , 2000 , 2100 , 2200 , 2300 , 2400 , 2500 , 2600 , 
ATP - Citrate Lyase ( ACL ) ( subunit 2 ) having the nucleotide 2700 , 2800 , 2900 , 3000 , 3100 , 3200 , 3300 , 3400 , 3500 , 
sequence of SEQ ID NO . : 41 . In embodiments , the recom - 3600 , 3700 , 3800 , or the entire sequence ) with SEQ ID 
binant nucleic acid is an ATP - Citrate Lyase ( ACL ) ( subunit NO . : 49 , ( e . g . using the same length of nucleotides for 
2 ) having at least 60 % identity ( e . g . at least 61 % , 62 % , 63 % , comparison or the entirety of both nucleic acids ) . 
64 % , 65 % , 66 % , 67 % , 68 % , 69 % , 70 % , 71 % , 72 % , 73 % , 15 In embodiments , the recombinant nucleic acid is a mutant 
74 % , 75 % , 76 % , 77 % , 78 % , 79 % , 80 % , 81 % , 82 % , 83 % , Lipid synthesis regulator ( MGA2 - L36 mutant ) having the 
84 % , 85 % , 86 % , 87 % , 88 % , 89 % , 90 % , 91 % , 92 % , 93 % , nucleotide sequence of SEQ ID NO . : 51 . In embodiments , 
94 % , 95 % , 96 % , 97 % , 98 % , or 99 % identity ) over a region the recombinant nucleic acid is a mutant Lipid synthesis 
of at least 100 nucleotides ( e . g . at least 200 , 300 , 400 , 500 , regulator ( MGA2 - L36 mutant ) having at least 60 % identity 
600 , 700 , 800 , 900 , 1000 , 1100 , 1200 , 1300 , 1400 , or the 20 ( e . g . at least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , 
entire sequence ) with SEQ ID NO . : 41 , ( e . g . using the same 69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , 
length of nucleotides for comparison or the entirety of both 79 % , 80 % , 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 
nucleic acids ) . 89 % , 90 % , 91 % 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , or 
In embodiments , the recombinant nucleic acid is a Malic 99 % identity ) over a region of at least 100 nucleotides ( e . g . 
Enzyme ( MEA , MAE , MEA1 ) having the nucleotide 25 at least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , 1000 , 1100 , 
sequence of SEQ ID NO . : 43 . In embodiments , the recom - 1200 , 1300 , 1400 , 1500 , 1600 , 1700 , 1800 , 1900 , 2000 , 
binant nucleic acid is a Malic Enzyme ( MEA , MAE , MEA1 ) 2100 , 2200 , 2300 , 2400 , 2500 , 2600 , 2700 , 2800 , 2900 , 
having at least 60 % identity ( e . g . at least 61 % , 62 % , 63 % , 3000 , 3100 , 3200 , 3300 , 3400 , 3500 , 3600 , 3700 , 3800 , or 
64 % , 65 % , 66 % , 67 % , 68 % , 69 % , 70 % , 71 % , 72 % , 73 % , the entire sequence ) with SEQ ID NO . : 51 , ( e . g . using the 
74 % , 75 % , 76 % , 77 % , 78 % , 79 % , 80 % , 81 % , 82 % , 83 % , 30 same length of nucleotides for comparison or the entirety of 
84 % , 85 % , 86 % , 87 % , 88 % , 89 % , 90 % , 91 % , 92 % , 93 % , both nucleic acids ) . 
94 % , 95 % , 96 % , 97 % , 98 % , or 99 % identity ) over a region In embodiments , the recombinant nucleic acid is a trun 
of at least 100 nucleotides ( e . g . at least 200 , 300 , 400 , 500 , cated Lipid synthesis regulator ( MGA2 - truncated ) having 
600 , 700 , 800 , 900 , 1000 , 1100 , 1200 , 1300 , 1400 , 1500 , the nucleotide sequence of SEQ ID NO . : 53 . In embodi 
1600 , 1700 , 1800 , or the entire sequence ) with SEQ ID 35 ments , the recombinant nucleic acid is a truncated Lipid 
NO . : 43 , ( e . g . using the same length of nucleotides for synthesis regulator ( MGA2 - truncated ) having at least 60 % 
comparison or the entirety of both nucleic acids ) . identity ( e . g . at least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 
In embodiments , the recombinant nucleic acid is a acyl 68 % , 69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 
COA : diacylglycerol acyltransferase ( DGA1 ) having the 78 % , 79 % , 80 % , 81 % , 82 % 83 % 84 % , 85 % , 86 % , 87 % , 
nucleotide sequence of SEQ ID NO . : 45 . In embodiments , 40 88 % , 89 % , 90 % , 91 % 92 % 93 % , 94 % , 95 % , 96 % , 97 % , 
the recombinant nucleic acid is a acyl - CoA : diacylglycerol 98 % , or 99 % identity ) over a region of at least 100 nucleo 
acyltransferase ( DGA1 ) having at least 60 % identity ( e . g . at tides ( e . g . at least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , 
least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , 69 % , 1000 , 1100 , 1200 , 1300 , 1400 , 1500 , 1600 , 1700 , 1800 , 
70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , 79 % , 1900 , 2000 , 2100 , 2200 , 2300 , 2400 , 2500 , 2600 , 2700 , 
80 % , 81 % , 82 % 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 89 % , 45 2800 , 2900 , 3000 , 3100 , 3200 , 3300 , 3400 , 3500 , 3600 , 
90 % , 91 % 92 % 93 % 94 % , 95 % , 96 % , 97 % , 98 % , or 99 % 3700 , 3800 , or the entire sequence ) with SEQ ID NO . : 53 , 
identity ) over a region of at least 100 nucleotides ( e . g . at ( e . g . using the same length of nucleotides for comparison or 
least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , 1000 , 1100 , the entirety of both nucleic acids ) . 
1200 , 1300 , 1400 , 1500 , or the entire sequence ) with SEO In embodiments , the recombinant nucleic acid is a Chro 
ID NO . : 45 , ( e . g . using the same length of nucleotides for 50 matin assembly gene ( RLF2 subunit p90 ) having the nucleo 
comparison or the entirety of both nucleic acids ) . tide sequence of SEO ID NO . : 58 . In embodiments , the 
In embodiments , the recombinant nucleic acid is a acyl - recombinant nucleic acid is a Chromatin assembly gene 
COA : diacylglycerol acyltransferase ( DGA2 ) having the ( RLF2 subunit p90 ) having at least 60 % identity ( e . g . at least 
nucleotide sequence of SEQ ID NO . : 47 . In embodiments , 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , 69 % , 70 % , 
the recombinant nucleic acid is a acyl - CoA : diacylglycerol 55 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , 79 % , 80 % , 
acyltransferase ( DGA2 ) having at least 60 % identity ( e . g . at 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 89 % , 90 % , 
least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , 69 % , 91 % , 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , or 99 % 
70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , 79 % , identity ) over a region of at least 100 nucleotides ( e . g . at 
80 % , 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 89 % , least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , 1000 , 1100 , 
90 % , 91 % 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , or 99 % 60 1200 , 1300 , 1400 , 1500 , or the entire sequence ) with SEQ 
identity ) over a region of at least 100 nucleotides ( e . g . at ID NO . : 58 , ( e . g . using the same length of nucleotides for 
least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , 1000 , 1100 , comparison or the entirety of both nucleic acids ) . 
1200 , 1300 , 1400 , 1500 , or the entire sequence ) with SEQ In embodiments , the recombinant nucleic acid is a Mito 
ID NO . : 47 , ( e . g . using the same length of nucleotides for chondrial 2 ' O - ribose methyltransferase ( MRM2 ) having the 
comparison or the entirety of both nucleic acids ) . 65 nucleotide sequence of SEQ ID NO . : 63 . In embodiments , 
In embodiments , the recombinant nucleic acid is a Lipid the recombinant nucleic acid is a Mitochondrial 2 ' O - ribose 
synthesis regulator ( MGA2 ) having the nucleotide sequence methyltransferase ( MRM2 ) having at least 60 % identity 
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( e . g . at least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , 69 % , 70 % , 
69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , 79 % , 80 % , 
79 % , 80 % , 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 89 % , 90 % , 
89 % , 90 % , 91 % , 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , or 91 % 92 % 93 % 94 % , 95 % , 96 % , 97 % , 98 % , or 99 % 
99 % identity ) over a region of at least 100 nucleotides ( e . g . 5 identity ) over a region of at least 100 nucleotides ( e . g . at 
at least 200 , 300 , 400 , 500 , 600 , 700 , or the entire sequence ) least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , 1000 , 1100 , 
with SEQ ID NO . : 63 , ( e . g . using the same length of nucleo - 1200 , 1300 , 1400 , 1500 , 1600 , 1700 , 1800 , 1900 , 2000 , 
tides for comparison or the entirety of both nucleic acids ) . 2100 , 2200 , 2300 , 2400 , 2500 , 2600 , or the entire sequence ) 
In embodiments , the recombinant nucleic acid is a Citrate with SEQ ID NO . : 75 , ( e . g . using the same length of nucleo 
Synthase ( CIT1 ) having the nucleotide sequence of SEQ ID 10 tides for comparison or the entirety of both nucleic acids ) . 
NO . : 67 . In embodiments , the recombinant nucleic acid is a In embodiments , the recombinant nucleic acid is a YOX1 
Citrate Synthase ( CIT1 ) having at least 60 % identity ( e . g . at homeodomain protein ( YOX1 ) having the nucleotide 
least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , 69 % , sequence of SEQ ID NO . : 77 . In embodiments , the recom 
70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , 79 % , binant nucleic acid is a YOX1 homeodomain protein 
80 % , 81 % , 82 % 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 89 % , 15 ( YOX1 ) having at least 60 % identity ( e . g . at least 61 % , 62 % , 
90 % , 91 % , 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , or 99 % 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , 69 % , 70 % , 71 % , 72 % , 
identity ) over a region of at least 100 nucleotides ( e . g . at 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , 79 % , 80 % , 81 % , 82 % , 
least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , 1000 , 1100 , 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 89 % , 90 % , 91 % , 92 % , 
1200 , 1300 , 1400 , 1500 , 1600 , 1700 , or the entire sequence ) 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , or 99 % identity ) over a 
with SEQ ID NO . : 67 , ( e . g . using the same length of nucleo - 20 region of at least 100 nucleotides ( e . g . at least 200 , 300 , 400 , 
tides for comparison or the entirety of both nucleic acids ) . 500 , 600 , 700 , 800 , 900 , 1000 , 1100 , 1200 , 1300 , 1400 , or 
In embodiments , the recombinant nucleic acid is a Acetyl - the entire sequence ) with SEQ ID NO . : 77 , ( e . g . using the 
COA Carboxylase ( ACC ) having the nucleotide sequence of same length of nucleotides for comparison or the entirety of 
SEO ID NO . : 69 . In embodiments , the recombinant nucleic both nucleic acids ) . 
acid is a Acetyl - COA Carboxylase ( ACC ) having at least 25 In embodiments , the recombinant nucleic acid is a UGA2 
60 % identity ( e . g . at least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , succinate semialdehyde dehydrogenase ( UGA2 ) having the 
67 % , 68 % , 69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , nucleotide sequence of SEQ ID NO . : 78 . In embodiments , 
77 % , 78 % , 79 % , 80 % , 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , the recombinant nucleic acid is a UGA2 succinate semial 
87 % , 88 % , 89 % , 90 % , 91 % , 92 % , 93 % , 94 % , 95 % , 96 % , dehyde dehydrogenase ( UGA2 ) having at least 60 % identity 
97 % , 98 % , or 99 % identity ) over a region of at least 100 30 ( e . g . at least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , 
nucleotides ( e . g . at least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , 
900 , 1000 , 1100 , 1200 , 1300 , 1400 , 1500 , 1600 , 1700 , 1800 , 79 % , 80 % , 81 % , 82 % 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 
1900 , 2000 , 3000 , 4000 , 5000 , 6000 , 7000 , or the entire 89 % , 90 % , 91 % , 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , or 
sequence ) with SEQ ID NO . : 69 , ( e . g . using the same length 99 % identity ) over a region of at least 100 nucleotides ( e . g . 
of nucleotides for comparison or the entirety of both nucleic 35 at least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , 1000 , 1100 , 
acids ) . 1200 , 1300 , 1400 , or the entire sequence ) with SEQ ID 
In embodiments , the recombinant nucleic acid is a Tran - NO . : 78 , ( e . g . using the same length of nucleotides for 
scription Factor ( PEX10 ) having the nucleotide sequence of comparison or the entirety of both nucleic acids ) . 
SEQ ID NO . : 71 . In embodiments , the recombinant nucleic In embodiments , the recombinant nucleic acid is a RME1 
acid is a Transcription Factor ( PEX10 ) having at least 60 % 40 zinc - finger transcription factor ( RMEI ) having the nucleo 
identity ( e . g . at least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , tide sequence of SEQ ID NO . : 79 . In embodiments , the 
68 % , 69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , recombinant nucleic acid is a RME1 zinc - finger transcrip 
78 % , 79 % , 80 % , 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , 87 % , tion factor ( RME1 ) having at least 60 % identity ( e . g . at least 
88 % , 89 % , 90 % , 91 % 92 % 93 % 94 % , 95 % , 96 % , 97 % , 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , 69 % , 70 % , 
98 % , or 99 % identity ) over a region of at least 100 nucleo - 45 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , 79 % , 80 % , 
tides ( e . g . at least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 89 % , 90 % , 
1000 , 1100 , or the entire sequence ) with SEQ ID NO . : 71 , 91 % 92 % 93 % 94 % , 95 % , 96 % , 97 % , 98 % , or 99 % 
( e . g . using the same length of nucleotides for comparison or identity ) over a region of at least 100 nucleotides ( e . g . at 
the entirety of both nucleic acids ) . least 200 , 300 , 400 , 500 , 600 , or the entire sequence ) with 
In embodiments , the recombinant nucleic acid is a mul - 50 SEQ ID NO . : 79 , ( e . g . using the same length of nucleotides 
tifunctional enzyme ( MFE1 ) having the nucleotide sequence for comparison or the entirety of both nucleic acids ) . 
of SEQ ID NO . : 73 . In embodiments , the recombinant In embodiments , the recombinant nucleic acid is a OSH6 
nucleic acid is a multifunctional enzyme ( MFE1 ) having at oxysterol - binding protein homolog 6 ( OSH6 ) having the 
least 60 % identity ( e . g . at least 61 % , 62 % , 63 % , 64 % , 65 % , nucleotide sequence of SEQ ID NO . : 80 . In embodiments , 
66 % , 67 % , 68 % , 69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 55 the recombinant nucleic acid is a OSH6 oxysterol - binding 
76 % , 77 % , 78 % , 79 % , 80 % , 81 % , 82 % , 83 % , 84 % , 85 % , protein homolog 6 ( OSH6 ) having at least 60 % identity ( e . g . 
86 % , 87 % , 88 % , 89 % , 90 % , 91 % , 92 % , 93 % , 94 % , 95 % at least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , 68 % , 69 % , 
96 % , 97 % , 98 % , or 99 % identity ) over a region of at least 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 78 % , 79 % , 
100 nucleotides ( e . g . at least 200 , 300 , 400 , 500 , 600 , 700 , 80 % , 81 % , 82 % 83 % 84 % , 85 % , 86 % , 87 % , 88 % , 89 % , 
800 , 900 , 1000 , 1100 , 1200 , 1300 , 1400 , 1500 , 1600 , 1700 , 60 90 % , 91 % 92 % 93 % 94 % , 95 % , 96 % , 97 % , 98 % , or 99 % 
1800 , 1900 , 2000 , 2100 , 2200 , 2300 , or the entire sequence ) identity ) over a region of at least 100 nucleotides ( e . g . at 
with SEQ ID NO . : 73 , ( e . g . using the same length of nucleo - least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , 1000 , 1100 , 
tides for comparison or the entirety of both nucleic acids ) . 1200 , 1300 , 1400 , 1500 , 1600 , or the entire sequence ) with 
In embodiments , the recombinant nucleic acid is a Aco - SEQ ID NO . : 80 , ( e . g . using the same length of nucleotides 
nitase ( ACO1 ) having the nucleotide sequence of SEQ ID 65 for comparison or the entirety of both nucleic acids ) . 
NO . : 75 . In embodiments , the recombinant nucleic acid is a In embodiments , the recombinant nucleic acid is a IRC20 
Aconitase ( ACO1 ) having at least 60 % identity ( e . g . at least E3 ubiquitin - protein ligase and helicase ( IRC20 ) having the 
46 
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nucleotide sequence of SEQ ID NO . : 81 . In embodiments , Acetyl - CoA Carboxylase ( ACC ) , acyl - CoA : diacylglycerol 
the recombinant nucleic acid is a IRC20 E3 ubiquitin acyltransferase ( DGA1 ) , acyl - CoA : diacylglycerol acyltrans 
protein ligase and helicase ( IRC20 ) having at least 60 % ferases ( DGA2 ) , Mitochondrial 2 ' O - ribose methyltrans 
identity ( e . g . at least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , ferase ( MRM2 ) , Lipid synthesis regulator ( MGA2 ) , Chro 
68 % , 69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 5 matin assembly gene ( RLF2 subunit p90 ) , 0 - 6 
78 % , 79 % , 80 % , 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , 87 % , methylguanine - DNA methyltransferase ( MGMT ) , 
88 % , 89 % , 90 % , 91 % , 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , Aconitase ( ACO1 ) , Citrate Synthase ( CIT1 ) , RME1 zinc 98 % , or 99 % identity ) over a region of at least 100 nucleo finger transcription factor ( RME1 ) , YOX1 homeodomain tides ( e . g . at least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , protein ( YOX1 ) , UGA2 succinate semialdehyde dehydro 
1000 , 1100 , 1200 , 1300 , 1400 , 1500 , 1600 , 1700 , 1800 , 10 genase ( UGA2 ) , OSH6 oxysterol - binding protein homolog 6 1900 , 2000 , 3000 , 4000 , 5000 , or the entire sequence ) with ( OSH6 ) , IRC20 E3 ubiquitin - protein ligase and helicase SEQ ID NO . : 81 , ( e . g . using the same length of nucleotides ( IRC20 ) , a wildtype version thereof , or a mutant version for comparison or the entirety of both nucleic acids ) . 
thereof ) . In embodiments , the extra - chromosomal recombi In embodiments , the recombinant nucleic acid is a 0 - 6 
methylguanine - DNA methyltransferase ( MGMT ) having 15 nant nucleic acid includes a gene that is also included in the 
the nucleotide sequence of SEO ID NO . : 65 . In embodi - genome of the oleaginous organism ( e . g . yeast cell , oleagi 
ments , the recombinant nucleic acid is a 0 - 6 - methylgua - nous yeast cell , Yarrowia lipolytica , algae , or plant cell ) ( e . g . 
nine - DNA methyltransferase ( MGMT ) having at least 60 % Leucine Biosynthesis Gene ( LEU2 ) , Uracil Biosynthesis 
identity ( e . g . at least 61 % , 62 % , 63 % , 64 % , 65 % , 66 % , 67 % , gene ( URA3 ) , AMP Deaminase ( AMPD ) , ATP - Citrate 
68 % , 69 % , 70 % , 71 % , 72 % , 73 % , 74 % , 75 % , 76 % , 77 % , 20 Lyase ( ACL ) ( e . g . ACL subunit 1 , ACL subunit 2 , or subunit 
78 % , 79 % , 80 % , 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , 87 % , 1 and 2 ) , Malic Enzyme ( MAE ) , Acetyl - CoA Carboxylase 
88 % , 89 % , 90 % , 91 % , 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , ( ACC ) , acyl - CoA : diacylglycerol acyltransferase ( DGA1 ) , 
98 % , or 99 % identity ) over a region of at least 100 nucleo - acyl - CoA : diacylglycerol acyltransferases ( DGA2 ) , Mito 
tides ( e . g . at least 200 , 300 , 400 , 500 , 600 , 700 , 800 , 900 , chondrial 2 ' O - ribose methyltransferase ( MRM2 ) , Lipid 
1000 , 1100 , 1200 , 1300 , 1400 , 1500 , or the entire sequence ) 25 synthesis regulator ( MGA2 ) , Chromatin assembly gene 
with SEQ ID NO . : 65 , ( e . g . using the same length of nucleo - ( RLF2 subunit p90 ) , 0 - 6 - methylguanine - DNA methyltrans 
tides for comparison or the entirety of both nucleic acids ) . ferase ( MGMT ) , Citrate Synthase ( CIT1 ) , RME1 zinc - finger 
In embodiments , the oleaginous organism ( e . g . yeast cell , transcription factor ( RME1 ) , YOX1 homeodomain protein 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant ( YOX1 ) , UGA2 succinate semialdehyde dehydrogenase 
cell ) includes a recombinant nucleic acid that decreases the 30 ( UGA2 ) , OSH6 - oxysterol - binding protein homolog 6 
level of activity of multifunctional enzyme ( MFE1 ) protein ( OSH6 ) , IRC20 E3 ubiquitin - protein ligase and helicase 
and Transcription Factor ( PEX10 ) protein , increases the ( IRC20 ) , a wildtype version thereof , or a mutant version 
level of activity of acyl - CoA : diacylglycerol acyltransferase thereof ) . In embodiments , a recombinant nucleic acid inte 
( DGA1 ) protein , or increases the level of activity of Leucine grated into the oleaginous organism ( e . g . yeast cell , oleagi 
Biosynthesis Gene ( LEU2 ) protein relative to a oleaginous 35 nous yeast cell , Yarrowia lipolytica , algae , or plant cell ) 
organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia genome replaces ( e . g . partially or completely ) a promoter 
lipolytica , algae , or plant cell ) that does not include the included in the oleaginous organism ( e . g . yeast cell , oleagi 
recombinant nucleic acid . In embodiments , the oleaginous nous yeast cell , Yarrowia lipolytica , algae , or plant cell ) 
organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia genome pror to integration of the recombinant nucleic acid . 
lipolytica , algae , or plant cell ) includes recombinant nucleic 40 In embodiments , the yeast cell is a yeast cell including 
acids that decrease the level of activity of multifunctional one or more genetic modifications ( e . g . recombinant nucleic 
enzyme ( MFE1 ) protein and Transcription Factor ( PEX10 ) acids ) , as described herein ( including in the Examples 
protein , increase the level of activity of acyl - CoA : diacyl - section below , the tables , the figures , and the claims herein ) . 
glycerol acyltransferase ( DGA1 ) protein , and increase the In embodiments , the yeast cell is a yeast cell described 
level of activity of Leucine Biosynthesis Gene ( LEU2 ) 45 herein , including in an example , table , figure , or claim . In 
protein relative to a oleaginous organism ( e . g . yeast cell , embodiments , the oleaginous yeast cell is L36 as described 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant herein ( e . g . examples , tables , and figures ) . In embodiments , 
cell ) that does not include the recombinant nucleic acids . In the oleaginous yeast cell is derived from L36 as described 
embodiments , the level of activity is the level of expression herein ( e . g . examples , tables , and figures ) . In embodiments , 
of the protein . 50 the oleaginous yeast cell is E26 as described herein ( e . g . 
In embodiments , the oleaginous organism ( e . g . yeast cell , examples , tables , and figures ) . In embodiments , the oleagi 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant nous yeast cell is E13 as described herein ( e . g . examples , 
cell ) includes an extra - chromosomal recombinant nucleic tables , and figures ) . In embodiments , the oleaginous yeast 
acid . In embodiments , the oleaginous organism ( e . g . yeast cell is derived from E26 or E13 . 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or 55 In embodiments , the dry weight of the genetically modi 
plant cell ) includes a recombinant nucleic acid integrated fied yeast cell described herein includes greater than about 
into the oleaginous organism ( e . g . yeast cell , oleaginous 20 % wt / wt lipids , lipid precursors , and / or oleochemicals 
yeast cell , Yarrowia lipolytica , algae , or plant cell ) genome . ( e . g . , greater than about 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 
In embodiments , the extra - chromosomal recombinant 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 
nucleic acid includes a gene that is also included in the 60 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 
genome of the yeast cell oleaginous organism ( e . g . yeast 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 
plant cell ) ( e . g . Leucine Biosynthesis Gene ( LEU2 ) , Uracil 94 , 95 , 96 , 97 , 98 , or 99 % ; greater than 20 , 21 , 22 , 23 , 24 , 
Biosynthesis gene ( URA3 ) , multifunctional enzyme 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 
( MFE1 ) , Transcription Factor ( PEX10 ) , AMP Deaminase 65 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 
( AMPD ) , ATP - Citrate Lyase ( ACL ) ( e . g . ACL subunit 1 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 
ACL subunit 2 , or subunit 1 and 2 ) , Malic Enzyme ( MAE ) , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 
ge 
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89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , or 99 % ; of lipid ; lipids ; the genetically modified yeast cell described herein includes 
lipid precursors ; lipid precursor , oleochemical , and / or oleo - a recombinant Acetyl - CoA Carboxylase ( ACC ) protein . In 
chemicals ) . embodiments , the genetic modification increases the level of 
In embodiments , the genetically modified yeast cell activity of the Acetyl - CoA Carboxylase ( ACC ) protein rela 
described herein includes a recombinant Leucine Biosyn - 5 tive to an otherwise identical yeast cell lacking the genetic 
thesis Gene ( LEU2 ) . In embodiments , the genetic modifi modification . In embodiments , the genetically modified 
cation increases the level of activity of the Leucine Biosyn - yeast cell described herein includes a recombinant acyl 
thesis Gene ( LEU2 ) protein relative to an otherwise identical COA : diacylglycerol acyltransferase 1 ( DGA1 ) protein . In 
yeast cell lacking the genetic modification . In embodiments , embodiments , the genetic modification increases the level of 
the genetically modified yeast cell described herein is 10 activity of the acyl - CoA : diacylglycerol acyltransferase 1 
capable of de novo synthesis of leucine ( e . g . at sufficient ( DGA1 ) protein relative to an otherwise identical yeast cell 
levels to meet the leucine requirements of the yeast cell ) . In lacking the genetic modification . In embodiments , the 
embodiments , the genetically modified yeast cell described genetically modified yeast cell described herein includes a 
herein is capable of de novo synthesis of leucine indepen recombinant acyl - CoA : diacylglycerol acyltransferase 2 
dent of the genetic modification . In embodiments , the 15 ( DGA2 ) protein . In embodiments , the genetic modification 
genetically modified yeast cell described herein includes a increases the level of activity of the acyl - CoA : diacylglycerol 
recombinant Uracil Biosynthesis gene ( URA3 ) . In embodi - acyltransferase 2 ( DGA2 ) protein relative to an otherwise 
ments , the genetic modification increases the level of activ - identical yeast cell lacking the genetic modification . In 
ity of the Uracil Biosynthesis gene ( URA3 ) protein relative embodiments , the genetically modified yeast cell described 
to an otherwise identical yeast cell lacking the genetic 20 herein includes a recombinant Mitochondrial 2 ' O - ribose 
modification . In embodiments , the genetically modified methyltransferase ( MRM2 ) protein . In embodiments , the 
yeast cell described herein is capable of de novo synthesis of genetic modification increases the level of activity of the 
uracil ( e . g . at sufficient levels to meet the uracil requirements Mitochondrial 2 ' O - ribose methyltransferase ( MRM2 ) pro 
of the yeast cell ) . In embodiments , the genetically modified tein relative to an otherwise identical yeast cell lacking the 
yeast cell described herein is capable of de novo synthesis of 25 genetic modification . In embodiments , the genetically modi 
uracil independent of the genetic modification . In embodi fied yeast cell described herein includes a recombinant Lipid 
ments , the genetically modified yeast cell described herein synthesis regulator ( MGA2 ) protein . In embodiments , the 
includes a genetically modified multifunctional enzyme genetically modified yeast cell described herein includes a 
( MFE1 ) gene . In embodiments , the genetic modification genetically modified Lipid synthesis regulator ( MGA2 ) 
decreases the level of activity of the multifunctional enzyme 30 gene . In embodiments , the genetically modified yeast cell 
( MFE1 ) protein relative to an otherwise identical yeast cell described herein includes at least one nucleotide deletion in 
lacking the genetic modification . In embodiments , the the genomic Lipid synthesis regulator ( MGA2 ) gene and 
genetically modified yeast cell described herein includes a expression of a Lipid synthesis regulator ( MGA2 ) protein 
genetically modified PEX10 Transcription Factor ( PEX10 ) including a mutation corresponding to G643R in Yarrowia 
gene . In embodiments , the genetic modification decreases 35 lipolytica Lipid synthesis regulator ( MGA2 ) In embodi 
the level of activity of the PEX10 Transcription Factor ments , the genetic modification decreases the level of activ 
( PEX10 ) protein relative to an otherwise identical yeast cell ity of the Lipid synthesis regulator ( MGA2 ) protein relative 
lacking the genetic modification . In embodiments , the to an otherwise identical yeast cell lacking the genetic 
genetically modified yeast cell described herein includes a modification . In embodiments , the genetically modified 
recombinant AMP Deaminase ( AMPD ) protein . In embodi - 40 yeast cell described herein includes a genetically modified 
ments , the genetic modification increases the level of activ . Chromatin assembly gene ( RLF2 subunit p90 ) gene . In 
ity of the AMP Deaminase ( AMPD ) protein relative to an embodiments , the genetic modification decreases the level 
otherwise identical yeast cell lacking the genetic modifica of activity of the Chromatin assembly gene ( RLF2 subunit 
tion . In embodiments , the genetically modified yeast cell p90 ) protein relative to an otherwise identical yeast cell 
described herein includes a recombinant ATP - Citrate Lyase 45 lacking the genetic modification . In embodiments , the 
1 ( ACL1 ) protein . In embodiments , the genetic modification genetically modified yeast cell described herein includes a 
increases the level of activity of the ATP - Citrate Lyase 1 recombinant 0 - 6 - methylguanine - DNA methyltransferase 
( ACL1 ) protein relative to an otherwise identical yeast cell ( MGMT ) protein . In embodiments , the genetic modification 
lacking the genetic modification . In embodiments , the increases the level of activity of the 0 - 6 - methylguanine 
genetically modified yeast cell described herein includes a 50 DNA methyltransferase ( MGMT ) protein relative to an 
recombinant ATP - Citrate Lyase 2 ( ACL2 ) protein . In otherwise identical yeast cell lacking the genetic modifica 
embodiments , the genetic modification increases the level of tion . In embodiments , the genetically modified yeast cell 
activity of the ATP - Citrate Lyase 2 ( ACL2 ) protein relative described herein includes a genetically modified Aconitase 
to an otherwise identical yeast cell lacking the genetic ( ACO1 ) gene . In embodiments , the genetic modification 
modification . In embodiments , the genetically modified 55 decreases the level of activity of the Aconitase ( ACO1 ) 
yeast cell described herein includes a recombinant ATP protein relative to an otherwise identical yeast cell lacking 
Citrate Lyase 1 ( ACL1 ) protein and ATP - Citrate Lyase 2 the genetic modification . In embodiments , the genetically 
( ACL2 ) protein . In embodiments , the genetic modification modified yeast cell described herein includes a recombinant 
increases the level of activity of the ATP - Citrate Lyase 1 Citrate Synthase ( CIT1 ) gene . In embodiments , the genetic 
( ACL1 ) protein and ATP - Citrate Lyase 2 ( ACL2 ) protein 60 modification increases the level of activity of the Citrate 
relative to an otherwise identical yeast cell lacking the Synthase ( CIT1 ) protein relative to an otherwise identical 
genetic modification . In embodiments , the genetically modi - yeast cell lacking the genetic modification . In embodiments , 
fied yeast cell described herein includes a recombinant the genetically modified yeast cell described herein includes 
Malic Enzyme ( MAE ) protein . In embodiments , the genetic a genetically modified RME1 zinc - finger transcription factor 
modification increases the level of activity of the Malic 65 ( RME1 ) gene . In embodiments , the genetic modification 
Enzyme ( MAE ) protein relative to an otherwise identical decreases the level of activity of the RME1 zinc - finger 
yeast cell lacking the genetic modification . In embodiments , transcription factor ( RME1 ) protein relative to an otherwise 
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identical yeast cell lacking the genetic modification . In lipid , lipid precursor , or oleochemical . In embodiments , the 
embodiments , the genetically modified yeast cell described genetic modification increases the level of activity of a 
herein includes a genetically modified YOX1 homeodomain component of a lipid biosynthetic pathway . In embodiments , 
protein ( YOX1 ) gene . In embodiments , the genetic modifi the genetic modification increases the level of activity of a 
cation decreases the level of activity of the YOX1 home - 5 component of a lipid precursor biosynthetic pathway . In 
odomain protein ( YOX1 ) protein relative to an otherwise embodiments , the genetic modification increases the level of 
identical yeast cell lacking the genetic modification . In activity of a component of an oleochemical biosynthetic 
embodiments , the genetically modified yeast cell described pathway . In embodiments , the genetic modification 
herein includes a genetically modified UGA2 succinate increases the level of activity of a component of a pathway 
semialdehyde dehydrogenase ( UGA2 ) gene . In embodi - 10 incorporating acetyl - CoA into a lipid , lipid precursor , or 
ments , the genetic modification decreases the level of activ - oleochemical . In embodiments , the genetic modification 
ity of the UGA2 succinate semialdehyde dehydrogenase increases the level of activity of a component of a pathway 
( UGA2 ) protein relative to an otherwise identical yeast cell incorporating malonyl - CoA into a lipid , lipid precursor , or 
lacking the genetic modification . In embodiments , the oleochemical . In embodiments , the genetic modification 
genetically modified yeast cell described herein includes a 15 modulates the level of activity of a component of a lipid , or 
genetically modified OSH6 oxysterol - binding protein lipid precursor , metabolic pathway . In embodiments , the 
homolog 6 ( OSH6 ) gene . In embodiments , the genetic genetic modification decreases the level of activity of a 
modification decreases the level of activity of the OSH6 component of a lipid , or lipid precursor , metabolic pathway . 
oxysterol - binding protein homolog 6 ( OSH6 ) protein rela - In embodiments , the genetic modification decreases the 
tive to an otherwise identical yeast cell lacking the genetic 20 level of activity of a component of a lipid , or lipid precursor , 
modification . In embodiments , the genetically modified metabolic pathway . In embodiments , the genetic modifica 
yeast cell described herein includes a genetically modified tion increases the level of acetyl - CoA in the genetically 
IRC20 E3 ubiquitin - protein ligase and helicase ( IRC20 ) modified oleaginous organism ( e . g . yeast cell , oleaginous 
gene . In embodiments , the genetic modification decreases yeast cell , Yarrowia lipolytica , algae , or plant cell ) relative 
the level of activity of the IRC20 E3 ubiquitin - protein ligase 25 to a genetically unmodified oleaginous organism ( e . g . yeast 
and helicase ( IRC20 ) protein relative to an otherwise iden - cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or 
tical yeast cell lacking the genetic modification . In embodi - plant cell ) that is otherwise identical ( e . g . genetically ) to the 
ments , the gene or protein described herein is a Yarrowia genetically modified oleaginous organism ( e . g . yeast cell , 
lipolytica gene or protein . In embodiments , the gene or oleaginous yeast cell , Yarrowia lipolytica , algae , or plant 
protein is a yeast gene or protein corresponding to the 30 cell ) . In embodiments , the genetic modification increases the 
Yarrowia lipolytica gene or protein . In embodiments , the level of malonyl - CoA in the genetically modified oleaginous 
gene or protein is a gene or protein from an oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia 
organism corresponding to the Yarrowia lipolytica gene or lipolytica , algae , or plant cell ) relative to a genetically 
protein . In embodiments , the gene or protein is the Yarrowia unmodified oleaginous organism ( e . g . yeast cell , oleaginous 
lipolytica gene or protein identified by sequence herein . In 35 yeast cell , Yarrowia lipolytica , algae , or plant cell ) that is 
embodiments , the gene or protein is a mutant gene or protein otherwise identical ( e . g . genetically ) to the genetically modi 
of a wildtype gene or protein corresponding to the Yarrowia fied oleaginous organism ( e . g . yeast cell , oleaginous yeast 
lipolytica gene or protein . In embodiments , the gene or cell , Yarrowia lipolytica , algae , or plant cell ) . In embodi 
protein is a mutant gene or protein of a wildtype yeast gene m ents , the genetic modification increases the level of tri 
or protein corresponding to the Yarrowia lipolytica gene or 40 glyceride production in the genetically modified oleaginous 
protein . In embodiments , the gene or protein is a homolog of organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia 
the Yarrowia lipolytica gene or protein . In embodiments , the lipolytica , algae , or plant cell ) relative to a genetically 
gene or protein is a homolog of the Yarrowia lipolytica gene unmodified oleaginous organism ( e . g . yeast cell , oleaginous 
or protein identified by sequence herein . In embodiments , yeast cell , Yarrowia lipolytica , algae , or plant cell ) that is 
the gene or protein is a mutant of the Yarrowia lipolytica 45 otherwise identical ( e . g . genetically , to the genetically modi 
gene or protein . In embodiments , the gene or protein fied oleaginous organism ( e . g . yeast cell , oleaginous yeast 
described in this paragraph is LEU2 , URA3 , MFE1 , PEX10 , cell , Yarrowia lipolytica , algae , or plant cell ) . In embodi 
AMPD , ACL , ACL1 , ACL2 , MAE , ACC , DGA , DGA1 , ments , the genetic modification decreases the level of beta 
DGA2 , MRM2 , MGA2 , RLF2 subunit p90 , MGMT , ACO1 , oxidation activity in the genetically modified oleaginous 
CIT1 , RME1 , YOX1 , UGA2 , OSH6 , or IRC20 ) . In embodi - 50 organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia 
ments , the gene or protein described in this paragraph is lipolytica , algae , or plant cell ) relative to a genetically 
LEU2 , URA3 , MFE1 , PEX10 , AMPD , ACL , ACL1 , ACL2 , unmodified oleaginous organism ( e . g . yeast cell , oleaginous 
MAE , ACC , DGA , DGA1 , DGA2 , MRM2 , MGA2 , RLF2 yeast cell , Yarrowia lipolytica , algae , or plant cell ) that is 
subunit p90 , MGMT , ACO1 , CIT1 , RMEI , YOX1 , UGA2 , otherwise identical ( e . g . genetically ) to the genetically modi 
OSH6 , or IRC20 ) , having the sequence identified herein . 55 fied oleaginous organism ( e . g . yeast cell , oleaginous yeast 
In embodiments , the genetic modification modulates the cell , Yarrowia lipolytica , algae , or plant cell ) . In embodi 
level of activity of a component of a lipid biosynthetic ments , the genetic modification decreases the level of fatty 
pathway . In embodiments , the genetic modification modu acid catabolism in the genetically modified oleaginous 
lates the level of activity of a component of a lipid precursor organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia 
biosynthetic pathway . In embodiments , the genetic modifi - 60 lipolytica , algae , or plant cell ) relative to a genetically 
cation modulates the level of activity of a component of an unmodified oleaginous organism ( e . g . yeast cell , oleaginous 
oleochemical biosynthetic pathway . In embodiments , the yeast cell , Yarrowia lipolytica , algae , or plant cell ) that is 
genetic modification modulates the level of activity of a otherwise identical ( e . g . genetically ) to the genetically modi 
component of a pathway incorporating Acetyl - CoA into a fied oleaginous organism ( e . g . yeast cell , oleaginous yeast 
lipid , lipid precursor , or oleochemical . In embodiments , the 65 cell , Yarrowia lipolytica , algae , or plant cell ) . In embodi 
genetic modification modulates the level of activity of a ments , the genetic modification decreases the level of per 
component of a pathway incorporating malonyl - CoA into a oxisome biogenesis activity in the genetically modified 
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oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , In embodiments , the genetic modification is an engi 
Yarrowia lipolytica , algae , or plant cell ) relative to a geneti neered genetic modification . In embodiments , the engi 
cally unmodified oleaginous organism ( e . g . yeast cell , ole neered genetic modification includes modulated expression 
aginous yeast cell , Yarrowia lipolytica , algae , or plant cell ) of a protein . In embodiments , the engineered genetic modi 
that is otherwise identical ( e . g . genetically ) to the genetically 5 fication includes increased expression of a protein . In 
modified oleaginous organism ( e . g . yeast cell , oleaginous embodiments , the engineered genetic modification includes 
yeast cell , Yarrowia lipolytica , algae , or plant cell ) . In decreased expression of a protein . In embodiments , the 
embodiments , the genetic modification produces a lipid , genetic modification is associated with exposure to a muta 
lipid precursor , or oleochemical at a higher level than by a gen . In embodiments , the genetic modification includes 
genetically unmodified oleaginous organism ( e . g . yeast cell , 11 10 modulated expression of a protein in a lipid , or lipid pre 
oleaginous yeast cell , Yarrowia lipolytica , algae , or plant cursor , or oleochemical biosynthetic pathway . 
cell ) that is otherwise identical to the genetically modified III . METHODS OF MAKING AND PURIFYING oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , LIPIDS , LIPID PRECURSORS , AND / OR Yarrowia lipolytica , algae , or plant cell ) . In embodiments , 15 . OLEOCHEMICALS the genetically modified oleaginous organism ( e . g . yeast 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or Lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , 
plant cell ) produces a lipid , lipid precursor , or oleochemical lipids , lipid precursors , lipid precursor , oleochemicals , or 
at a higher level than by a genetically unmodified oleaginous oleochemical ) produced by cells of the invention can be 
organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia 20 harvested , or otherwise collected , by any convenient method 
lipolytica , algae , or plant cell ) that is otherwise identical ( e . g . centrifugation of extracellular secreted lipids , exposure 
( e . g . genetically ) to the genetically modified oleaginous to solvent , whole cell extraction ( e . g . cell disruption and 
organism ( e . g . yeast cell , oleaginous yeast cell , Yarrowia collection ) , hydrophobic solvent extraction ( e . g . hexane ) , 
lipolytica , algae , or plant cell ) . In embodiments , the genetic liquefaction , supercritical carbon dioxide extraction , freeze 
modification modulates the level of activity of a component 25 drying , mechanical pulverization , secretion ( e . g . by addition 
of the citric acid cycle . In embodiments , the genetic modi - of effective exporter proteins ) , or combinations thereof ) . 
fication modulates the level of activity of a component of the In embodiments , reduced nitrogen conditions promote 
TCA cycle . In embodiments , the genetic modification modu accumulation of lipids , lipid precursors , and / or oleochemi 
lates the level of activity of a component of the Kennedy cals ( e . g . , lipid , lipids , lipid precursors , lipid precursor , 
pathway . In embodiments , the genetic modification reduces 30 oleochemicals , or oleochemical ) . In embodiments , cells ( e . g . 
the level of activity of the TCA cycle . In embodiments , the oleaginous organisms or oleaginous yeast ) are first cultured 
genetic modification increases the level of activity of the in standard conditions and then cultured in low nitrogen 
Kennedy pathway . conditions where harvesting is desired . In embodiments , 
In embodiments , the lipid , lipid precursor , or oleochemi - oleaginous yeast species are grown in a medium including a 
cal produced at a higher level by the genetically modified 35 carbon substrate and / or nitrogen source , optionally in the 
oleaginous organism ( e . g . yeast cell , oleaginous yeast cell , absence of light , optionally in an aerobic environment . In 
Yarrowia lipolytica , algae , or plant cell ) is a fatty acid , wax , embodiments , media for culturing oleaginous yeast may 
sterol , vitamin , monoglyceride , diglyceride , triglyceride , include a carbon substrate , a fixed nitrogen source , trace 
phospholipid , glycerolipid , glycerophospholipid , sphingo elements , a buffer for pH maintenance , phosphate , or a 
lipid , saccharolipid , polyketide , sterol lipid , triacylglyceride , 40 combination thereof . 
prenol lipid , fatty acid ester , fatty acid methyl ester , fatty In embodiments , the carbon substrate may be selected 
acid ethyl ester , fatty acid propyl ester , fatty acid butyl ester , from the group consisting of monosaccharides , oligosaccha 
fatty alcohol , fatty amine , glycerol , alcohol ethoxylate , rides , polysaccharides , alkanes , fatty acids , esters of fatty 
alcohol sulfate , or alcohol ether sulfate . In embodiments , the acids , monoglycerides , carbon dioxide , methanol , formal 
genetic modification includes a mutation relative to the wild 45 dehyde , formate , carbon - containing amines , glucose , fruc 
type gene . In embodiments , the genetic modification tose , sucrose , lactose , galactose , xylose , mannose , rham 
includes a deletion of a portion of a gene . In embodiments , nose , arabinose , glycerol , acetate , depolymerized sugar beet 
the genetically modified oleaginous organism ( e . g . yeast pulp , black liquor , corn starch , depolymerized cellulosic 
cell , oleaginous yeast cell , Yarrowia lipolytica , algae , or material , corn stover , sugar beet pulp , switchgrass , milk 
plant cell ) includes an increased level of a fatty acid selected 50 whey , molasses , potato , rice , sorghum , sugar cane , wheat , 
from the group consisting of C5 : 0 , C5 : 1 , C5 : 2 , C5 : 3 , C6 : 0 , thick cane juice , sugar beet juice , wheat , lignocellulosic 
C6 : 1 , C6 : 2 , C6 : 3 , C7 : 0 , C7 : 1 , C7 : 2 , C7 : 3 , C8 : 0 , C8 : 1 , C8 : 2 , biomass , and combinations thereof . 
C8 : 3 , C9 : 0 , C9 : 1 , C9 : 2 , C9 : 3 , C10 : 0 , C10 : 1 , C10 : 2 , C10 : 3 , Examples of cellulosic material that may be depolymer 
C11 : 0 , C11 : 1 , C11 : 2 , C11 : 3 , C12 : 0 , C12 : 1 , C12 : 2 , C12 : 3 , ized and used as a carbon substrate ( e . g . fixed carbon source ) 
C13 : 0 , C13 : 1 , C13 : 2 , C13 : 3 , C14 : 0 , C14 : 1 , C14 : 2 , C14 : 3 , 55 include sugarcane bagasse , rice hulls , corn fiber ( including 
C15 : 0 , C15 : 1 , C15 : 2 , C15 : 3 , C16 : 0 , C16 : 1 , C16 : 2 , C16 : 3 , stalks , leaves , husks , and cobs ) , wheat straw , rice straw , 
C17 : 0 , C17 : 1 , C17 : 2 , C17 : 3 , C18 : 0 , C18 : 1 , C18 : 2 , C18 : 3 , sugar beet pulp , citrus pulp , citrus peels ; hardwood and 
C19 : 0 , C19 : 1 , C19 : 2 , C19 : 3 , C20 : 0 , C20 : 1 , C20 : 2 , C20 : 3 , softwood thinnings ; hardwood and softwood residues ; saw 
C21 : 0 , C21 : 1 , C21 : 2 , C21 : 3 , C22 : 0 , C22 : 1 , C22 : 2 , C22 : 3 , mill wastes ( wood chips , sawdust ) and pulp mill waste ; 
C23 : 0 , C23 : 1 , C23 : 2 , and C23 : 3 , relative to a genetically 60 paper fractions of municipal solid waste ; municipal grass 
unmodified oleaginous organism ( e . g . yeast cell , oleaginous clippings ; wood construction waste ; and cellulosic crops 
yeast cell , Yarrowia lipolytica , algae , or plant cell ) that is such as switchgrass , hybrid poplar wood , and miscanthus , 
otherwise identical ( e . g . genetically ) to the genetically modi - fiber cane , and fiber sorghum . 
fied oleaginous organism ( e . g . yeast cell , oleaginous yeast Oleaginous yeast cultures may yield oleaginous yeast 
cell , Yarrowia lipolytica , algae , or plant cell ) . In embodi - 65 biomass in fermentation media . To extract lipids , lipid 
ments , the fatty acid is ?17 : 0 C17 : 1 . In embodiments , the precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid 
fatty acid is C16 : 1n9 . precursors , lipid precursor , oleochemicals , or oleochemical ) 
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from the biomass , the biomass may be harvested , concen - source is at a concentration at least 12 - fold greater than the 
trated , dewatered ( i . e . separation of the biomass from the concentration of the nitrogen source . In embodiments , the 
liquid medium ) ( e . g . through centrifugation , filtration , use of carbon source is at a concentration at least 13 - fold greater 
mechanical pressure , simple sedimentation , or sedimenta than the concentration of the nitrogen source . In embodi 
tion ) , or combinations thereof . Centrifugation does not 5 ments , the carbon source is at a concentration at least 14 - fold 
always remove significant amounts of intracellular water greater than the concentration of the nitrogen source . In 
from the oleaginous yeast and so is often considered a embodiments , the carbon source is at a concentration at least 
dewatering , not a drying , step . The biomass can optionally 15 - fold greater than the concentration of the nitrogen source . 
be dried ( oven dried , lyophilized , and the like ) and condi - In embodiments , the carbon source is at a concentration at 
tioned prior to cell disruption ( lysis ) . 10 least 16 - fold greater than the concentration of the nitrogen 
In a second aspect is provided a method of producing a source . In embodiments , the carbon source is at a concen 
lipid , lipid precursor , or oleochemical ( e . g . , lipid , lipid tration at least 17 - fold greater than the concentration of the 
precursor , oleochemical ) including : 1 ) culturing a yeast cell nitrogen source . In embodiments , the carbon source is at a 
as described herein ( including embodiments or as described concentration at least 18 - fold greater than the concentration 
in the examples , tables , figures , and / or claims ) in a growth 15 of the nitrogen source . In embodiments , the carbon source is 
medium ; and 2 ) isolating the lipid , lipid precursor , or at a concentration at least 19 - fold greater than the concen 
oleochemical ( e . g . , lipid , lipid precursor , oleochemical ) ( e . g . tration of the nitrogen source . In embodiments , the carbon 
from the medium or yeast cell ) . source is at a concentration at least 20 - fold greater than the 
In embodiments , the lipid , lipid precursor , or oleochemi - concentration of the nitrogen source . In embodiments , the 
cal ( e . g . , lipid , lipid precursor , oleochemical ) is isolated 20 ratio of the carbon source to the nitrogen source ( wt / wt ) is 
from the yeast cell . In embodiments , the lipid , lipid precur about 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 
sor , or oleochemical ( e . g . , lipid , lipid precursor , oleochemi - 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 
cal ) is isolated from the medium . In embodiments , the or 40 . In embodiments , the ratio of the carbon source to the 
growth medium includes a majority carbon source selected nitrogen source ( wt /wt ) is 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 
from the group consisting of glucose , glycerol , xylose , 25 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 
fructose , mannose , ribose , sucrose , and lignocellulosic bio 35 , 36 , 37 , 38 , 39 , or 40 . In embodiments , the ratio of the 
mass . In embodiments , the majority carbon source is glu carbon source to the nitrogen source ( wt / wt ) is about 
cose . In embodiments , the majority carbon source is glyc 0 . 03125 , 0 . 0625 , 0 . 125 , 0 . 25 , 0 . 5 , 1 . 0 , 2 . 0 , 4 . 0 , 8 . 0 , 16 , 32 , 
erol . In embodiments , the majority carbon source is xylose . 64 , 128 , 256 , 512 , 1024 , 1600 , 2048 , 4096 , 8192 , or 16284 . 
In embodiments , the majority carbon source is fructose . In 30 In embodiments , the ratio of the carbon source to the 
embodiments , the majority carbon source is mannose . In nitrogen source ( wt /wt ) is about 0 . 001 , 0 . 002 , 0 . 003 , 0 . 004 , 
embodiments , the majority carbon source is ribose . In 0 . 005 , 0 . 006 , 0 . 007 , 0 . 008 , 0 . 009 , 0 . 01 , 0 . 02 , 0 . 03 , 0 . 04 , 
embodiments , the majority carbon source is sucrose . In 0 . 05 , 0 . 06 , 0 . 07 , 0 . 08 , 0 . 09 , 0 . 1 , 0 . 2 , 0 . 3 , 0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 
embodiments , the majority carbon source is lignocellulosic 0 . 8 , 0 . 9 , 1 . 0 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 
biomass . In embodiments , the carbon source is glucose . In 35 17 , 18 , 19 , 20 , 25 , 30 , 35 , 40 , 45 , 50 , 55 , 60 , 65 , 70 , 75 , 80 , 
embodiments , the carbon source is glycerol . In embodi 85 , 90 , 95 , 100 , 110 , 120 , 130 , 140 , 150 , 160 , 170 , 180 , 190 , 
ments , the carbon source is xylose . In embodiments , the 200 , 250 , 300 , 350 , 400 , 500 , 550 , 600 , 650 , 700 , 750 , 800 , 
carbon source is fructose . In embodiments , the carbon 850 , 900 , 950 , 1000 , 2000 , 3000 , 4000 , 5000 , 6000 , 7000 , 
source is mannose . In embodiments , the carbon source is 8000 , 9000 , or 10000 . In embodiments , the ratio of the 
ribose . In embodiments , the carbon source is sucrose . In 40 carbon source to the nitrogen source ( wt /wt ) is 0 . 001 , 0 . 002 , 
embodiments , the carbon source is lignocellulosic biomass . 0 . 003 , 0 . 004 , 0 . 005 , 0 . 006 , 0 . 007 , 0 . 008 , 0 . 009 , 0 . 01 , 0 . 02 , 
In embodiments , the majority carbon source is not glucose . 0 . 03 , 0 . 04 , 0 . 05 , 0 . 06 , 0 . 07 , 0 . 08 , 0 . 09 , 0 . 1 , 0 . 2 , 0 . 3 , 0 . 4 , 0 . 5 , 
In embodiments , the majority nitrogen source is ammonium 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , 1 . 0 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 
sulfate ( ( NH4 ) , SOA ) . 15 , 16 , 17 , 18 , 19 , 20 , 25 , 30 , 35 , 40 , 45 , 50 , 55 , 60 , 65 , 70 , 
In embodiments , the growth medium includes a carbon 45 75 , 80 , 85 , 90 , 95 , 100 , 110 , 120 , 130 , 140 , 150 , 160 , 170 , 
source and a nitrogen source wherein the carbon source is at 180 , 190 , 200 , 250 , 300 , 350 , 400 , 500 , 550 , 600 , 650 , 700 , 
a concentration at least 2 - fold greater than the concentration 750 , 800 , 850 , 900 , 950 , 1000 , 2000 , 3000 , 4000 , 5000 , 
of the nitrogen source . In embodiments , the carbon source is 6000 , 7000 , 8000 , 9000 , or 10000 . In embodiments , the ratio 
at a concentration at least 3 - fold greater than the concen - of the carbon source to the nitrogen source ( wt / wt ) is at least 
tration of the nitrogen source . In embodiments , the carbon 50 0 . 001 , 0 . 002 , 0 . 003 , 0 . 004 , 0 . 005 , 0 . 006 , 0 . 007 , 0 . 008 , 
source is at a concentration at least 4 - fold greater than the 0 . 009 , 0 . 01 , 0 . 02 , 0 . 03 , 0 . 04 , 0 . 05 , 0 . 06 , 0 . 07 , 0 . 08 , 0 . 09 , 0 . 1 , 
concentration of the nitrogen source . In embodiments , the 0 . 2 , 0 . 3 , 0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , 1 . 0 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 
carbon source is at a concentration at least 5 - fold greater 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 25 , 30 , 35 , 40 , 45 , 
than the concentration of the nitrogen source . In embodi - 50 , 55 , 60 , 65 , 70 , 75 , 80 , 85 , 90 , 95 , 100 , 110 , 120 , 130 , 
ments , the carbon source is at a concentration at least 6 - fold 55 140 , 150 , 160 , 170 , 180 , 190 , 200 , 250 , 300 , 350 , 400 , 500 , 
greater than the concentration of the nitrogen source . In 550 , 600 , 650 , 700 , 750 , 800 , 850 , 900 , 950 , 1000 , 2000 , 
embodiments , the carbon source is at a concentration at least 3000 , 4000 , 5000 , 6000 , 7000 , 8000 , 9000 , or 10000 . In 
7 - fold greater than the concentration of the nitrogen source . embodiments , the carbon source to nitrogen source ratio 
In embodiments , the carbon source is at a concentration at corresponds to a ratio calculated from one or more of the 
least 8 - fold greater than the concentration of the nitrogen 60 ratios described above when the ratios described above are 
source . In embodiments , the carbon source is at a concen - for a carbon source of glucose ( g / L ) and a nitrogen source 
tration at least 9 - fold greater than the concentration of the of ammonium sulfate ( g / L ) for a carbon source that may not 
nitrogen source . In embodiments , the carbon source is at a be glucose and a nitrogen source that may not be ammonium 
concentration at least 10 - fold greater than the concentration sulfate . In embodiments , the ratio of the concentration of the 
of the nitrogen source . In embodiments , the carbon source is 65 carbon source to the concentration of the nitrogen source is 
at a concentration at least 11 - fold greater than the concen - as described herein , including in embodiments , examples , 
tration of the nitrogen source . In embodiments , the carbon tables , figures , and claims . In embodiments , the amount and 
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ratio of the carbon source to the nitrogen source ( wt / wt ) is growth medium includes cobalt . In embodiments , the 
equivalent to 160 : 0 . 2 glucose : ammonium sulfate . In growth medium includes iron . In embodiments , the growth 
embodiments , the amount and ratio of the carbon source to medium includes magnesium . In embodiments , the growth 
the nitrogen source ( wt / wt ) is equivalent to 80 : 5 glucose : medium includes potassium . In embodiments , the growth 
ammonium sulfate . 5 medium includes zinc . In embodiments , the growth medium 
In embodiments , the carbon source is at a concentration includes nickel . In embodiments , the growth medium 
( g / L ) of about 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , includes molybdenum . In embodiments , the growth medium 
16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , includes manganese . In embodiments , the growth medium 
32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , includes copper . In embodiments , the growth medium 
48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 10 includes boron . In embodiments , the growth medium is 
64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , supplemented with cobalt , iron , magnesium , potassium , 
80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , zinc , nickel , molybdenum , manganese , copper , and / or 
96 , 97 , 98 , 99 , 100 , 110 , 120 , 130 , 140 , 150 , 160 , 170 , 180 , boron . In embodiments , the growth medium is supple 
190 , 200 , 210 , 220 , 230 , 240 , 250 , 260 , 270 , 280 , 290 , 300 , mented with iron and copper or molybdenum . In embodi 
310 , 320 , 330 , 340 , 350 , 360 , 370 , 380 , 390 , 100 , 410 , 420 , 15 ments , the growth medium is supplemented with copper and 
430 , 440 , 450 , 460 , 470 , 480 , 490 , or 500 . In embodiments , nickel . In embodiments , the growth medium is supple 
the carbon source is at a concentration ( g / L ) of 1 , 2 , 3 , 4 , 5 , mented with copper , iron , and either molybdenum or nickel . 
6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , In embodiments , the growth medium is supplemented with 
23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , copper , iron , molybdenum , and nickel . In embodiments , the 
39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 20 growth medium is supplemented with cobalt . In embodi 
55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , ments , the growth medium is supplemented with iron . In 
71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , embodiments , the growth medium is supplemented with 
87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 110 , magnesium . In embodiments , the growth medium is supple 
120 , 130 , 140 , 150 , 160 , 170 , 180 , 190 , 200 , 210 , 220 , 230 , mented with potassium . In embodiments , the growth 
240 , 250 , 260 , 270 , 280 , 290 , 300 , 310 , 320 , 330 , 340 , 350 , 25 medium is supplemented with zinc . In embodiments , the 
360 , 370 , 380 , 390 , 100 , 410 , 420 , 430 , 440 , 450 , 460 , 470 , growth medium is supplemented with nickel . In embodi 
480 , 490 , or 500 . In embodiments , the carbon source , which ments , the growth medium is supplemented with molybde 
is optionally not glucose , is at a concentration for the carbon num . In embodiments , the growth medium is supplemented 
source that would provide an equal amount of carbon as one with manganese . In embodiments , the growth medium is 
of the amounts described above where the amount described 30 supplemented with copper . In embodiments , the growth 
above is for glucose . medium is supplemented with boron . In embodiments , the 
In embodiments , the nitrogen source is at a concentration growth medium includes CoCl2 at a concentration of about 
( g / L ) of about 0 . 001 , 0 . 002 , 0 . 003 , 0 . 004 , 0 . 005 , 0 . 006 , 15 mg / L . In embodiments , the growth medium includes 
0 . 007 , 0 . 008 , 0 . 009 , 0 . 01 , 0 . 02 , 0 . 03 , 0 . 04 , 0 . 05 , 0 . 06 , 0 . 07 , MgSO4 at a concentration of about 250 mg / L . In embodi 
0 . 08 , 0 . 09 , 0 . 1 , 0 . 2 , 0 . 3 , 0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , 1 , 2 , 3 , 35 ments , the growth medium includes KI at a concentration of 
4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , about 15 mg / L . In embodiments , the growth medium 
22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , includes ZnSO4 . 7H2O at a concentration of about 20 mg / L . 
38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , In embodiments , the growth medium includes MnSO2 . H , O 
54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , at a concentration of about 12 . 5 mg / L . In embodiments , the 
70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 40 growth medium includes Boric acid at a concentration of 
86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 . In about 12 . 5 mg / L . In embodiments , the growth medium 
embodiments , the nitrogen source is at a concentration ( g / L ) includes ( NHL ) , Mo . 4H , O at a concentration of about 15 
of 0 . 001 , 0 . 002 , 0 . 003 , 0 . 004 , 0 . 005 , 0 . 006 , 0 . 007 , 0 . 008 , mg / L . In embodiments , the growth medium includes 
0 . 009 , 0 . 01 , 0 . 02 , 0 . 03 , 0 . 04 , 0 . 05 , 0 . 06 , 0 . 07 , 0 . 08 , 0 . 09 , 0 . 1 , NISO2 . 6H , O at a concentration of about 12 . 5 mg / L . In 
0 . 2 , 0 . 3 , 0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 45 embodiments , the growth medium includes FeSO4 . 7H20 at 
10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , a concentration of about 20 mg / L . In embodiments , the 
26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , growth medium includes CuSO4 at a concentration of about 
42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 15 mg / L . In embodiments , the growth medium includes 
58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , COCl , at a concentration of 15 mg / L . In embodiments , the 
74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 50 growth medium includes MgSO4 at a concentration of 250 
90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 . In embodiments , mg / L . In embodiments , the growth medium includes KI at a 
the nitrogen source , which is optionally not ammonium concentration of 15 mg / L . In embodiments , the growth 
sulfate , is at a concentration for the nitrogen source that medium includes ZnSO4 . 7H , O at a concentration of 20 
would provide an equal amount of nitrogen as one of the mg / L . In embodiments , the growth medium includes 
amounts described above where the amount described above 55 MnSO2 . H , O at a concentration of 12 . 5 mg / L . In embodi 
is for ammonium sulfate . ments , the growth medium includes Boric acid at a concen 
In embodiments , the growth medium includes a micro - tration of 12 . 5 mg / L . In embodiments , the growth medium 
nutrient . In embodiments , the growth medium includes a includes ( NHL ) , Mo . 4H , O at a concentration of 15 mg / L . In 
plurality of micronutrients . In embodiments , the growth embodiments , the growth medium includes NiSO4 . 6H2O at 
medium includes cobalt , iron , magnesium , potassium , zinc , 60 a concentration of 12 . 5 mg / L . In embodiments , the growth 
nickel , molybdenum , manganese , copper , and / or boron . In medium includes FeSO4 . 7H , O at a concentration of 20 
embodiments , the growth medium includes iron and copper mg / L . In embodiments , the growth medium includes CuSO4 
or molybdenum . In embodiments , the growth medium at a concentration of 15 mg / L . In embodiments , the growth 
includes copper and nickel . In embodiments , the growth medium is supplemented with CoCl , at a concentration of 
medium includes copper , iron , and either molybdenum or 65 about 15 mg / L . In embodiments , the growth medium is 
nickel . In embodiments , the growth medium includes cop - supplemented with MgSO , at a concentration of about 250 
per , iron , molybdenum , and nickel . In embodiments , the mg / L . In embodiments , the growth medium is supplemented 
57 
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with KI at a concentration of about 15 mg / L . In embodi with CoC1 , at a concentration of about 7 . 5 to 22 . 5 mg / L . In 
ments , the growth medium is supplemented with embodiments , the growth medium is supplemented with 
ZnSO4 . 7H20 at a concentration of about 20 mg / L . In MgSO4 at a concentration of about 125 to 375 mg / L . In 
embodiments , the growth medium is supplemented with embodiments , the growth medium is supplemented with KI 
MnSO4 . H20 at a concentration of about 12 . 5 mg / L . In 5 at a concentration of about 7 . 5 to 22 . 5 mg / L . In embodi 
embodiments , the growth medium is supplemented with ments , the growth medium is supplemented with 
Boric acid at a concentration of about 12 . 5 mg / L . In embodi ZnSO4 . 7H20 at a concentration of about 10 to 30 mg /L . In ments , the growth medium is supplemented with ( NH4 ) 2 embodiments , the growth medium is supplemented with Mo . 4H , O at a concentration of about 15 mg / L . In embodi MnSO4 . H2O at a concentration of about 6 to 18 mg / L . In ments , the growth medium is supplemented with 10 embodiments , the growth medium is supplemented with NiSO4 . 6H , O at a concentration of about 12 . 5 mg / L . In Boric acid at a concentration of about 6 to 18 mg / L . In embodiments , the growth medium is supplemented with embodiments , the growth medium is supplemented with FeSO4 . 7H2O at a concentration of about 20 mg / L . In 
embodiments , the growth medium is supplemented with ( NH4 ) 2Mo .4H20 at a concentration of about 7 . 5 to 22 . 5 
Cuso . at a concentration of about 15 mg / L . In embodi . 15 mg / L . In embodiments , the growth medium is supplemented 
ments , the growth medium is supplemented with CoCl , at a with NiSO4 . 6H2O at a concentration of about 6 to 18 mg / L . 
concentration of 15 mg / L . In embodiments , the growth In embodiments , the growth medium is supplemented with 
medium is supplemented with MgSO , at a concentration of FeSO4 . 7H2O at a concentration of about 10 to 30 mg / L . In 
250 mg / L . In embodiments , the growth medium is supple - embodiments , the growth medium is supplemented with 
mented with KI at a concentration of 15 mg / L . In embodi - 20 CuSO4 at a concentration of about 7 . 5 to 22 . 5 mg / L . In 
ments , the growth medium is supplemented with embodiments , the growth medium is supplemented with 
ZnSO4 . 7H20 at a concentration of 20 mg / L . In embodi - CoCl , at a concentration of 7 . 5 to 22 . 5 mg / L . In embodi 
ments , the growth medium is supplemented with ments , the growth medium is supplemented with MgSO , at 
MnSO . . H , O at a concentration of 12 . 5 mg / L . In embodi - a concentration of 125 to 375 mg / L . In embodiments , the 
ments , the growth medium is supplemented with Boric acid 25 growth medium is supplemented with KI at a concentration 
at a concentration of 12 . 5 mg / L . In embodiments , the growth of 7 . 5 to 22 . 5 mg / L . In embodiments , the growth medium is 
medium is supplemented with ( NH4 ) Mo . 4H20 at a con - supplemented with ZnSO4 . 7H2O at a concentration of 10 to 
centration of 15 mg / L . In embodiments , the growth medium 30 mg / L . In embodiments , the growth medium is supple 
is supplemented with NiSO2 . 6H , O at a concentration of mented with MnSO2 . H , O at a concentration of 6 to 18 mg / L . 
12 . 5 mg / L . In embodiments , the growth medium is supple - 30 In embodiments , the growth medium is supplemented with 
mented with FeSO4 . 7H2O at a concentration of 20 mg / L . In Boric acid at a concentration of 6 to 18 mg / L . In embodi 
embodiments , the growth medium is supplemented with ments , the growth medium is supplemented with ( NH4 ) 2 
CuSO4 at a concentration of 15 mg / L . In embodiments , the Mo . 4H , O at a concentration of 7 . 5 to 22 . 5 mg / L . In embodi 
growth medium includes CoCl2 at a concentration of about ments , the growth medium is supplemented with 
7 . 5 to 22 . 5 mg / L . In embodiments , the growth medium 35 NiSO4 . 6H2O at a concentration of 6 to 18 mg / L . In embodi 
includes MgSO4 at a concentration of about 125 to 375 ments , the growth medium is supplemented with 
mg / L . In embodiments , the growth medium includes KI at a FeSO4 . 7H , O at a concentration of 10 to 30 mg / L . In 
concentration of about 7 . 5 to 22 . 5 mg / L . In embodiments , embodiments , the growth medium is supplemented with 
the growth medium includes ZnSO4 . 7H , O at a concentra - CuSO4 at a concentration of 7 . 5 to 22 . 5 mg / L . 
tion of about 10 to 30 mg / L . In embodiments , the growth 40 In embodiments , the method does not include nitrogen 
medium includes MnSO4 .H20 at a concentration of about 6 starvation of the oleaginous organism ( e . g . oleaginous yeast 
to 18 mg / L . In embodiments , the growth medium includes cell ) . 
Boric acid at a concentration of about 6 to 18 mg / L . In In embodiments , the oleaginous yeast is cultured for 
embodiments , the growth medium includes ( NH4 ) , about 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 
Mo . 4H20 at a concentration of about 7 . 5 to 22 . 5 mg / L . In 45 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 
embodiments , the growth medium includes NiSO4 . 6H , O at 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 
a concentration of about 6 to 18 mg / L . In embodiments , the 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 
growth medium includes FeSO4 . 7H2O at a concentration of 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 
about 10 to 30 mg / L . In embodiments , the growth medium 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 
includes CuSO4 at a concentration of about 7 . 5 to 22 . 5 mg / L . 50 98 , 99 , 100 , 110 , 120 , 130 , 140 , 150 , 160 , 170 , 180 , 190 , 
In embodiments , the growth medium includes CoCl , at a 200 , 250 , 300 , 350 , 400 , or 500 hours . In embodiments , the 
concentration of 7 . 5 to 22 . 5 mg / L . In embodiments , the oleaginous yeast is cultured for 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 
growth medium includes MgSO4 at a concentration of 125 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 
to 375 mg / L . In embodiments , the growth medium includes 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 
KI at a concentration of 7 . 5 to 22 . 5 mg / L . In embodiments , 55 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 
the growth medium includes ZnSO4 . 7H2O at a concentra 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 
tion of 10 to 30 mg / L . In embodiments , the growth medium 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 
includes MnSO4 . H2O at a concentration of 6 to 18 mg / L . In 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 110 , 120 , 130 , 140 , 
embodiments , the growth medium includes Boric acid at a 150 , 160 , 170 , 180 , 190 , 200 , 250 , 300 , 350 , 400 , or 500 
concentration of 6 to 18 mg / L . In embodiments , the growth 60 hours . In embodiments , the oleaginous yeast is cultured for 
medium includes ( NH4 ) 2M0 . 4H20 at a concentration of 7 . 5 about 48 , 96 , 144 , or 192 hours . In embodiments , the 
to 22 . 5 mg / L . In embodiments , the growth medium includes oleaginous yeast is cultured for 48 , 96 , 144 , or 192 hours . In 
NiSO4 . 6H , O at a concentration of 6 to 18 mg / L . In embodi - embodiments , the oleaginous yeast is cultured for about 0 . 5 , 
ments , the growth medium includes FeSO4 . 7H20 at a con - 1 , 1 . 5 , 2 , 2 . 5 , 3 , 3 . 5 , 4 , 4 . 5 , 5 , 5 . 5 , 6 , 6 . 5 , 7 , 7 . 5 , 8 , 8 . 5 , 9 , 
centration of 10 to 30 mg / L . In embodiments , the growth 65 9 . 5 , or 10 days . In embodiments , the oleaginous yeast is 
medium includes CuSO4 at a concentration of 7 . 5 to 22 . 5 cultured for 0 . 5 , 1 , 1 . 5 , 2 , 2 . 5 , 3 , 3 . 5 , 4 , 4 . 5 , 5 , 5 . 5 , 6 , 6 . 5 , 
mg / L . In embodiments , the growth medium is supplemented 7 , 7 . 5 , 8 , 8 . 5 , 9 , 9 . 5 , or 10 days . 
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In an aspect is provided a method of producing a lipid , 3 . 76x10 - 5 M to 1 . 10x10 - 4M molybdenum . In embodiments , 
lipid precursor , or oleochemical including culturing a yeast the growth medium includes about 2 . 28x10 - 5 M to 6 . 84x 
cell described herein in a growth medium ; and isolating the 10 - 5 M nickel . In embodiments , the growth medium 
lipid , lipid precursor , or oleochemical . includes about 3 . 60x10 - 5 M to 1 . 08x10 - 4M iron . In embodi 
In embodiments , the lipid , lipid precursor , or oleochemi - 5 ments , the growth medium includes about 4 . 70x10 - 5 M to 
cal is isolated from the yeast cell . In embodiments , the lipid , 1 . 41x10 - 4M copper . In embodiments , the growth medium 
lipid precursor , or oleochemical is isolated from the growth includes 5 . 77x10 - 5 M to 1 . 73x10 - 4 M cobalt . In embodi 
medium . In embodiments , the growth medium includes a ments , the growth medium includes 0 . 001 M to 0 . 003 M 
majority carbon source selected from the group consisting of magnesium . In embodiments , the growth medium includes 
glucose , glycerol , Xylose , fructose , mannose , ribose , 10 4 . 52x10 - M to 1 . 35x10 - 4 M potassium . In embodiments , 
sucrose , and lignocellulosic biomass . In embodiments , the the growth medium includes 4 . 05x10 - 5 M to 1 . 22x10 - 4 M 
growth medium includes lignocellulosic biomass as the zinc . In embodiments , the growth medium includes 3 . 55x 
majority carbon source . In embodiments , the growth 10 - 9 to 1 . 06x10 - 4 M manganese . In embodiments , the 
medium includes a carbon source and a nitrogen source growth medium includes 9 . 07x10 - 5 M to 2 . 91x10 - 4 M 
wherein the carbon source is at a concentration at least 15 boron . In embodiments , the growth medium includes 3 . 76x 
10 - fold greater than the concentration of the nitrogen source 10 - 5 M to 1 . 10x10 - 4 M molybdenum . In embodiments , the 
( wt / wt ). In embodiments , the growth medium includes a growth medium includes 2 . 28x10 - 4 M to 6 . 84x10 - 5 M 
carbon source and a nitrogen source wherein the carbon nickel . In embodiments , the growth medium includes 3 . 60x 
source is at a concentration at least 16 - fold greater than the 10 - 5 M to 1 . 08x10 - 4 M iron . In embodiments , the growth 
concentration of the nitrogen source ( wt / wt ) . In embodi - 20 medium includes 4 . 70x10 - 5 M to 1 . 41x10 - 4 M copper . In 
ments , the growth medium includes a carbon source and a embodiments , the growth medium includes iron , copper , and 
nitrogen source wherein the carbon source is at a concen - molybdenum . In embodiments , the growth medium includes 
tration at least 320 - fold greater than the concentration of the molybdenum in an amount equivalent to 7 . 5 to 22 . 5 mg / L 
nitrogen source ( wt / wt ) . ( NHL ) , Mo . 41 , 0 , iron in an amount equivalent to 10 to 30 
In embodiments , the growth medium includes cobalt , 25 mg / L FeSO4 . 7H , O , or copper in an amount equivalent to 7 . 5 
iron , magnesium , potassium , zinc , nickel , molybdenum , to 22 . 5 mg / L CuSO4 . In embodiments , the growth medium 
manganese , copper , or boron . In embodiments , the growth includes 3 . 76x10 - M to 1 . 10x10 - 4 M molybdenum , 3 . 60x 
medium includes any combination of two or more of cobalt , 10 - 5 M to 1 . 08x10 - 4 M iron , or 4 . 70x10 - 5 M to 1 . 41x10 - 4 
iron , magnesium , potassium , zinc , nickel , molybdenum , M copper . In embodiments , the growth medium includes 
manganese , copper , or boron . In embodiments , the growth 30 copper and nickel . In embodiments , the growth medium 
medium includes cobalt in an amount equivalent to 7 . 5 to includes nickel in an amount equivalent to 6 to 18 mg / L 
22 . 5 mg / L COC1 , , magnesium in an amount equivalent to NISO2 . 6H , O or copper in an amount equivalent to 7 . 5 to 
125 to 375 mg / L MgSO , potassium in an amount equivalent 22 . 5 mg / L CuSO4 . In embodiments , the growth medium 
to 7 . 5 to 22 . 5 mg / L KI , zinc in an amount equivalent to 10 includes 2 . 28x10 - 5 M to 6 . 84x10 - 5 M nickel or 4 . 70x10 - 5 
to 30 mg / L ZnSO4 . 7H , O , manganese in an amount equiva - 35 M to 1 . 41x10 - 4 M copper . In embodiments , the growth 
lent to 6 to 18 mg / L MnSO4 . H , O , boron in an amount medium includes copper , iron , and either molybdenum or 
equivalent to 6 to 18 mg / L Boric acid , molybdenum in an nickel . In embodiments , the growth medium includes 
amount equivalent to 7 . 5 to 22 . 5 mg / L ( NH4 ) 2M0 . 4H20 , molybdenum in an amount equivalent to 7 . 5 to 22 . 5 mg / L 
nickel in an amount equivalent to 6 to 18 mg / L ( NH4 ) Mo . 4H20 , nickel in an amount equivalent to 6 to 18 
NiSO4 . 6H , O , iron in an amount equivalent to 10 to 30 mg / L 40 mg / L NISO2 . 6H , O , iron in an amount equivalent to 10 to 30 
FeSO4 . 7H , O , or copper in an amount equivalent to 7 . 5 to mg / L FeSO4 . 7H , O , or copper in an amount equivalent to 7 . 5 
22 . 5 mg / L CuSO4 . In embodiments , the growth medium to 22 . 5 mg / L CuSO4 . In embodiments , the growth medium 
includes about 5 . 77x10 - 5 M to 1 . 73x10 - 4M cobalt , about includes 3 . 76x10 - 5 M to 1 . 10x10 - 4 M molybdenum , 2 . 28x 
0 . 001 M to 0 . 003 M magnesium , about 4 . 52x10 - 5 M to 10 - 5 M to 6 . 84x10 - 5 M nickel , 3 . 60x10 - 5 Mto 1 . 08x10 - 4 M 
1 . 35x10 - 4 M potassium , about 4 . 05x10 - 5 M to 1 . 22x10 - 4 M 45 iron , or 4 . 70x10 - 5 M to 1 . 41x10 - 4 M copper . In embodi 
zinc , about 3 . 55x10 - 5 to 1 . 06x10 - 4M manganese , about ments , the growth medium includes copper , iron , molybde 
9 . 07x10 - 5 M to 2 . 91x10 - 4 M boron , about 3 . 76x10 - 5 M to num , and nickel . 
1 . 10x10 - 4M molybdenum , about 2 . 28x10 - 5M to 6 . 84x10 - 5 In another aspect is provided a method of isolating a yeast 
M nickel , about 3 . 60x10 - 5 M to 1 . 08x10 - 4M iron , or about cell including greater than 20 % wt / wt lipids , lipid precur 
4 . 70x10 - S M to 1 . 41x10 - 4 M copper . In embodiments , the 50 sors , and / or oleochemicals ( e . g . , lipid , lipids , lipid precur 
growth medium includes 5 . 77x10 - 5 M to 1 . 73x10 - 4 M sors , lipid precursor , oleochemicals , or oleochemical ) in dry 
cobalt , 0 . 001 M to 0 . 003 M magnesium , 4 . 52x10 - 5 M to weight from a plurality of yeast cells , including allowing a 
1 . 35x10 - 4 M potassium , 4 . 05x10 - M to 1 . 22x10 - 4 M zinc , yeast cell including greater than 20 % wt / wt lipids , lipid 
3 . 55x10 - 5 to 1 . 06x10 - 4 M manganese , 9 . 07x10 - 5 M to precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid 
2 . 91x10 - 4 M boron , 3 . 76x10 - 5 M to 1 . 10x10 - 4 M molyb - 55 precursors , lipid precursor , oleochemicals , or oleochemical ) 
denum , 2 . 28x10 - 5 M to 6 . 84x10 - 5 M nickel , 3 . 60x10 - 5M to to separate from a population of yeast cells within the 
1 . 08x10 - 4 M iron , or 4 . 70x10 - M to 1 . 41x10 - 4 M copper . plurality of yeast cells by floating above the population of 
In embodiments , the growth medium includes about 5 . 77x yeast cells within an aqueous medium thereby isolating the 
10 - 5 M to 1 . 73x10 - 4M cobalt . In embodiments , the growth yeast cell including greater than 20 % wt / wt lipids , lipid 
medium includes about 0 . 001 M to 0 . 003 M magnesium . In 60 precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid 
embodiments , the growth medium includes about 4 . 52x10 - 5 precursors , lipid precursor , oleochemicals , or oleochemical ) , 
M to 1 . 35x10 - 4 M potassium . In embodiments , the growth wherein the population of yeast cells includes a lower 
medium includes about 4 . 05x10 - 5 M to 1 . 22x10 - 4 M zinc . percentage wt /wt of lipids , lipid precursors , and / or oleo 
In embodiments , the growth medium includes about 3 . 55x chemicals ( e . g . , lipid , lipids , lipid precursors , lipid precur 
10 - 5 to 1 . 06x10 - 4 M manganese . In embodiments , the 65 sor , oleochemicals , or oleochemical ) than the yeast cell 
growth medium includes about 9 . 07x10 - 5 M to 2 . 91x10 - 4 M including greater than 20 % wt /wt lipids , lipid precursors , 
boron . In embodiments , the growth medium includes about and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 
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lipid precursor , oleochemicals , or oleochemical ) . In another 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 
aspect is provided a method of isolating a genetically 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 
modified yeast cell from a plurality of yeast cells including or 99 % lipids , lipid precursors , and / or oleochemicals ( e . g . , 
greater than 20 % wt /wt lipids , lipid precursors , and / or lipid , lipids , lipid precursors , lipid precursor , oleochemicals , 
oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre - 5 or oleochemical ) in dry weight ) is floating on the top surface 
cursor , oleochemicals , or oleochemical ) in dry weight of the aqueous medium . In embodiments , the yeast cell ( e . g . 
including allowing a genetically modified yeast cell to genetically modified yeast cell ) including greater than 20 % 
separate from a population of yeast cells within the plurality wt / wt lipids , lipid precursors , and / or oleochemicals ( e . g . , 
of yeast cells by floating above the population of yeast cells lipid , lipids , lipid precursors , lipid precursor , oleochemicals , 
within an aqueous medium thereby isolating the genetically 10 or oleochemical ) in dry weight ( e . g . greater than 20 , 21 , 22 , 
modified yeast cell , wherein the population of yeast cells 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 
includes a lower percentage wt / wt of lipids , lipid precursors , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 
lipid precursor , oleochemicals , or oleochemical ) than the 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 
genetically modified yeast cell . 15 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , or 99 % lipids , 
In embodiments is a method of isolating a yeast cell ( e . g . lipid precursors , and / or oleochemicals ( e . g . , lipid , lipids , 
genetically modified yeast cell ) , including greater than 20 % lipid precursors , lipid precursor , oleochemicals , or oleo 
wt / wt lipids , lipid precursors , and / or oleochemicals ( e . g . , chemical ) in dry weight ) is above the bottom of a vessel 
lipid , lipids , lipid precursors , lipid precursor , oleochemicals , containing the aqueous medium . In embodiments , the yeast 
or oleochemical ) in dry weight , from a plurality of yeast 20 cell ( e . g . genetically modified yeast cell ) including greater 
cells , including allowing a yeast cell ( e . g . genetically modi - than 20 % wt /wt lipids , lipid precursors , and / or oleochemi 
fied yeast cell ) to separate from a population of yeast cells cals ( e . g . , lipid , lipids , lipid precursors , lipid precursor , 
within the plurality of yeast cells by floating above the oleochemicals , or oleochemical ) in dry weight ( e . g . greater 
population of yeast cells within an aqueous medium thereby than 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 
isolating the yeast cell ( e . g . genetically modified yeast cell ) , 25 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 
wherein the population of yeast cells includes a lower 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 
percentage wt / wt of lipids , lipid precursors , and / or oleo - 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 
chemicals ( e . g . , lipid , lipids , lipid precursors , lipid precur - 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 
sor , oleochemicals , or oleochemical ) than the genetically or 99 % lipids , lipid precursors , and / or oleochemicals ( e . g . , 
modified yeast cell . 30 lipid , lipids , lipid precursors , lipid precursor , oleochemicals , 
In embodiments , the yeast cell ( e . g . genetically modified or oleochemical ) in dry weight ) is floating above the popu 
yeast cell ) includes greater than 30 % wt / wt lipids , lipid lation of yeast cells including a lower percentage wt / wt of 
precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , 
precursors , lipid precursor , oleochemicals , or oleochemical ) lipids , lipid precursors , lipid precursor , oleochemicals , or 
in dry weight . In embodiments , the yeast cell ( e . g . geneti - 35 oleochemical ) than the yeast cell ( e . g . genetically modified 
cally modified yeast cell ) includes greater than 40 % wt / wt yeast cell ) including greater than 20 % wt / wt lipids , lipid 
lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid 
lipids , lipid precursors , lipid precursor , oleochemicals , or precursors , lipid precursor , oleochemicals , or oleochemical ) 
oleochemical ) in dry weight . In embodiments , the yeast cell in dry weight by about 0 . 1 , 0 . 2 , 0 . 3 , 0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 
( e . g . genetically modified yeast cell ) includes greater than 40 0 . 9 , 1 . 0 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 
50 % wt / wt lipids , lipid precursors , and / or oleochemicals 18 , 19 , 20 , 25 , 30 , 35 , 40 , 45 , 50 , 55 , 60 , 65 , 70 , 75 , 80 , 85 , 
( e . g . , lipid , lipids , lipid precursors , lipid precursor , oleo - 90 , 95 , 96 , 97 , 98 , or 99 mm in the aqueous medium . In 
chemicals , or oleochemical ) in dry weight . In embodiments , embodiments , the yeast cell ( e . g . genetically modified yeast 
the yeast cell ( e . g . genetically modified yeast cell ) includes cell ) including greater than 20 % wt / wt lipids , lipid precur 
greater than 60 % wt / wt lipids , lipid precursors , and / or 45 sors , and / or oleochemicals ( e . g . , lipid , lipids , lipid precur 
oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre - sors , lipid precursor , oleochemicals , or oleochemical ) in dry 
cursor , oleochemicals , or oleochemical ) in dry weight . In weight ( e . g . greater than 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 
embodiments , the yeast cell ( e . g . genetically modified yeast 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 
cell ) includes greater than 70 % wt /wt lipids , lipid precur 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 
sors , and / or oleochemicals ( e . g . , lipid , lipids , lipid precur - 50 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 
sors , lipid precursor , oleochemicals , or oleochemical ) in dry 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 
weight . In embodiments , the yeast cell ( e . g . genetically 93 , 94 , 95 , 96 , 97 , 98 , or 99 % lipids , lipid precursors , and / or 
modified yeast cell ) includes greater than 80 % wt / wt lipids , oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre 
lipid precursors , and / or oleochemicals ( e . g . , lipid , lipids , cursor , oleochemicals , or oleochemical ) in dry weight ) is 
lipid precursors , lipid precursor , oleochemicals , or oleo - 55 floating above the population of yeast cells including a lower 
chemical ) in dry weight . In embodiments , the yeast cell ( e . g . percentage wt /wt of lipids , lipid precursors , and / or oleo 
genetically modified yeast cell ) includes greater than 90 % chemicals ( e . g . , lipid , lipids , lipid precursors , lipid precur 
wt / wt lipids , lipid precursors , and / or oleochemicals ( e . g . , sor , oleochemicals , or oleochemical ) than the yeast cell ( e . g . 
lipid , lipids , lipid precursors , lipid precursor , oleochemicals , genetically modified yeast cell ) including greater than 20 % 
or oleochemical ) in dry weight . In embodiments , the yeast 60 wt /wt lipids , lipid precursors , and / or oleochemicals ( e . g . , 
cell ( e . g . genetically modified yeast cell ) including greater lipid , lipids , lipid precursors , lipid precursor , oleochemicals , 
than 20 % wt / wt lipids , lipid precursors , and / or oleochemi - or oleochemical ) in dry weight by at least 0 . 1 , 0 . 2 , 0 . 3 , 0 . 4 , 
cals ( e . g . , lipid , lipids , lipid precursors , lipid precursor , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , 1 . 0 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 
oleochemicals , or oleochemical ) in dry weight ( e . g . greater 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 25 , 30 , 35 , 40 , 45 , 50 , 55 , 60 , 
than 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 65 65 , 70 , 75 , 80 , 85 , 90 , 95 , 96 , 97 , 98 , or 99 mm in the 
35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , aqueous medium . In embodiments , the genetically modified 
51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , yeast cell including greater than 20 % wt / wt lipids , lipid 
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precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid 0 . 5 vvm ( volume per volume per minute ) . In embodiments 
precursors , lipid precursor , oleochemicals , or oleochemical ) of the method , the plurality of yeast cells are in a bioreactor 
in dry weight ( e . g . greater than 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , with agitation and aeration rates of about 1 . 0 vvm ( volume 
28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , per volume per minute ) . In embodiments of the method , the 
44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 5 plurality of yeast cells are in a bioreactor with agitation and 
60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , aeration rates of about 2 . 0 vvm ( volume per volume per 
76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , minute ) . In embodiments of the method , the plurality of 
92 , 93 , 94 , 95 , 96 , 97 , 98 , or 99 % lipids , lipid precursors , yeast cells are in a bioreactor with agitation and aeration 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , rates of about 2 . 5 vvm ( volume per volume per minute ) . In 
lipid precursor , oleochemicals , or oleochemical ) in dry 10 embodiments of the method , the plurality of yeast cells are 
weight ) floating above the population of yeast cells includ - in a bioreactor with agitation and aeration rates of about 3 . 0 
ing a lower percentage wt / wt of lipids , lipid precursors , vvm ( volume per volume per minute ) . In embodiments of 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , the method , the plurality of yeast cells are in a bioreactor 
lipid precursor , oleochemicals , or oleochemical ) than the with agitation and aeration rates of about 4 . 0 vvm ( volume 
yeast cell ( e . g . genetically modified yeast cell ) including 15 per volume per minute ) . In embodiments of the method , the 
greater than 20 % wt / wt lipids , lipid precursors , and / or plurality of yeast cells are in a bioreactor with agitation and 
oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre - aeration rates of 0 . 5 vvm ( volume per volume per minute ) . 
cursor , oleochemicals , or oleochemical ) in dry weight has a In embodiments of the method , the plurality of yeast cells 
buoyant density greater than the buoyant density of the are in a bioreactor with agitation and aeration rates of 1 . 0 
population of yeast cells including a lower percentage wt / wt 20 vvm ( volume per volume per minute ) . In embodiments of 
of lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , the method , the plurality of yeast cells are in a bioreactor 
lipids , lipid precursors , lipid precursor , oleochemicals , or with agitation and aeration rates of 2 . 0 vvm ( volume per 
oleochemical ) than yeast cell ( e . g . genetically modified volume per minute ) . In embodiments of the method , the 
yeast cell ) including greater than 20 % wt / wt lipids , lipid plurality of yeast cells are in a bioreactor with agitation and 
precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid 25 aeration rates of 2 . 5 vvm ( volume per volume per minute ) . 
precursors , lipid precursor , oleochemicals , or oleochemical ) In embodiments of the method , the plurality of yeast cells 
in dry weight by about 0 . 001 , 0 . 002 , 0 . 003 , 0 . 004 , 0 . 005 , are in a bioreactor with agitation and aeration rates of 3 . 0 
0 . 006 , 0 . 007 , 0 . 008 , 0 . 009 , 0 . 01 , 0 . 02 , 0 . 03 , 0 . 04 , 0 . 05 , 0 . 06 , vvm ( volume per volume per minute ) . In embodiments of 
0 . 07 , 0 . 08 , 0 . 09 , 0 . 1 , 0 . 2 , 0 . 3 , 0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , the method , the plurality of yeast cells are in a bioreactor 
g / mL . In embodiments , the yeast cell ( e . g . genetically modi - 30 with agitation and aeration rates of 4 . 0 vvm ( volume per 
fied yeast cell ) including greater than 20 % wt /wt lipids , lipid volume per minute ) . 
precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid In embodiments of the method , the aqueous medium 
precursors , lipid precursor , oleochemicals , or oleochemical ) includes a yeast growth medium , minimal media , complete 
in dry weight ( e . g . greater than 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , supplement media , or greater than 50 g / L carbon source ( e . g . 
28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 35 glucose ) and less than 5 g / L of a nitrogen source ( e . g . 
44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , ammonium sulfate ) . In embodiments of the method , the 
60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , aqueous medium includes a yeast growth medium . In 
76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , embodiments of the method , the aqueous medium includes 
92 , 93 , 94 , 95 , 96 , 97 , 98 , or 99 % lipids , lipid precursors , a minimal media . In embodiments of the method , the 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 40 aqueous medium includes a complete supplement media . In 
lipid precursor , oleochemicals , or oleochemical ) in dry embodiments of the method , the aqueous medium includes 
weight ) floating above the population of yeast cells includ - greater than 50 g / L carbon source ( e . g . glucose ) and less 
ing a lower percentage wt / wt of lipids , lipid precursors , than 5 g / L of a nitrogen source ( e . g . ammonium sulfate ) . In 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , embodiments of the method , the aqueous medium is a yeast 
lipid precursor , oleochemicals , or oleochemical ) than the 45 growth medium . In embodiments of the method , the aqueous 
yeast cell ( e . g . genetically modified yeast cell ) including medium is a minimal media . In embodiments of the method , 
greater than 20 % wt / wt lipids , lipid precursors , and / or the aqueous medium is a complete supplement media . 
oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre - In embodiments of the method of isolating a yeast cell 
cursor , oleochemicals , or oleochemical ) in dry weight has a ( e . g . genetically modified yeast cell ) including greater than 
buoyant density greater than the buoyant density of the 50 20 % wt / wt lipids , lipid precursors , and / or oleochemicals 
population of yeast cells including a lower percentage wt /wt ( e . g . , lipid , lipids , lipid precursors , lipid precursor , oleo 
of lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , chemicals , or oleochemical ) in dry weight , including allow 
lipids , lipid precursors , lipid precursor , oleochemicals , or i ng a yeast cell ( e . g . genetically modified yeast cell ) includ 
oleochemical ) than the yeast cell ( e . g . genetically modified ing greater than 20 % wt / wt lipids , lipid precursors , and / or 
yeast cell ) including greater than 20 % wt / wt lipids , lipid 55 oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre 
precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid cursor , oleochemicals , or oleochemical ) in dry weight to 
precursors , lipid precursor , oleochemicals , or oleochemical ) separate from a population of yeast cells within the plurality 
in dry weight by 0 . 001 , 0 . 002 , 0 . 003 , 0 . 004 , 0 . 005 , 0 . 006 , of yeast cells by floating above the population of yeast cells 
0 . 007 , 0 . 008 , 0 . 009 , 0 . 01 , 0 . 02 , 0 . 03 , 0 . 04 , 0 . 05 , 0 . 06 , 0 . 07 , within an aqueous medium , the allowing is performed by 
0 . 08 , 0 . 09 , 0 . 1 , 0 . 2 , 0 . 3 , 0 . 4 , 0 . 5 , 0 . 6 , 0 . 7 , 0 . 8 , 0 . 9 , g / mL . In 60 centrifugation or simple sedimentation . In embodiments of 
embodiments , the yeast cell ( e . g . genetically modified yeast the method of isolating a yeast cell ( e . g . genetically modified 
cell ) including greater than 20 % wt / wt lipids , lipid precur - yeast cell ) including greater than 20 % wt / wt lipids , lipid 
sors , and / or oleochemicals ( e . g . , lipid , lipids , lipid precur precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid 
sors , lipid precursor , oleochemicals , or oleochemical ) , precursors , lipid precursor , oleochemicals , or oleochemical ) 
includes a mutation created by natural genetic drift . 65 in dry weight , including allowing a yeast cell ( e . g . geneti 
In embodiments of the method , the plurality of yeast cells cally modified yeast cell ) including greater than 20 % wt / wt 
are in a bioreactor with agitation and aeration rates of about lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , 
i  
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65 
lipids , lipid precursors , lipid precursor , oleochemicals , or 6p . The yeast cell of embodiment lp comprising greater than 
oleochemical ) in dry weight to separate from a population of 70 % wt / wt lipid . 
yeast cells within the plurality of yeast cells by floating 7p . The yeast cell of embodiment lp comprising greater than 
above the population of yeast cells within an aqueous 80 % wt /wt lipid . 
medium , the allowing is performed by centrifugation . In 5 Sp . The yeast cell of embodiment lp comprising greater than 
embodiments of the method of isolating a yeast cell ( e . g . 90 % wt / wt lipid . 
genetically modified yeast cell ) including greater than 20 % 9p . The yeast cell of any one of embodiments lp to 8p , 
wt / wt lipids , lipid precursors , and / or oleochemicals ( e . g . , selected from the group consisting of the genera Yarrowia , 
lipid , lipids , lipid precursors , lipid precursor , oleochemicals , Candida , Rhodotorula , Rhodosporidium , Cryptococcus , or oleochemical ) in dry weight , including allowing a yeast 10 Trichosporon and Lipomyces . cell ( e . g . genetically modified yeast cell ) including greater 10p . The yeast cell of any one of embodiments 1p to 8p , than 20 % wt /wt lipids , lipid precursors , and / or oleochemi selected from the group consisting of Rhodosporidium toru cals ( e . g . , lipid , lipids , lipid precursors , lipid precursor , loides , Lipomyces starkeyii , Lipomyces lipoferus , Apiotri oleochemicals , or oleochemical ) in dry weight to separate 
from a population of yeast cells within the plurality of yeast 15 chum curvatum , Candida curvata , Cryptococcus curvatus , 
cells by floating above the population of yeast cells within Trichosporon fermentans , Candida revkaufi , Candida pul 
an aqueous medium , the allowing is performed by simple cherrima , Candida tropicalis , Candida utilis , Trichosporon 
sedimentation . In embodiments of the method of isolating a pullans , Trichosporon cutaneum , Rhodotorula glutinus , 
yeast cell ( e . g . genetically modified yeast cell ) including Rhodotorula graminis and Yarrowia lipolytica . 
greater than 20 % wt / wt lipids , lipid precursors , and / or 20 11p . The yeast cell of any one of embodiments 1p to 8p , 
oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre selected from the group consisting of Lipomyces starkeyii , 
cursor , oleochemicals , or oleochemical ) in dry weight , Rhodosporidium toruloides , Apiotrichum curvatum , Can 
including allowing a yeast cell ( e . g . genetically modified dida curvata , Cryptococcus curvatus , Trichosporon fermen 
yeast cell ) including greater than 20 % wt / wt lipids , lipid tans , Rhodotorula glutinis , and Yarrowia lipolytica . 
precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid 25 12p . The yeast cell of any one of embodiments 1p to 8p , 
precursors , lipid precursor , oleochemicals , or oleochemical ) wherein said yeast cell is Yarrowia lipolytica . 
in dry weight to separate from a population of yeast cells 13p . The yeast cell of any one of embodiments lp to 12p , 
within the plurality of yeast cells by floating above the wherein said yeast cell is buoyant in an aqueous medium . 
population of yeast cells within an aqueous medium , the 14p . The yeast cell of any one of embodiments lp to 13p , 
allowing is performed by sedimentation . In embodiments of 30 wherein said lipid is selected from the group consisting of a 
the method of isolating a yeast cell ( e . g . genetically modified fatty acid , wax , sterol , vitamin , monoglyceride , diglyceride , 
yeast cell ) including greater than 20 % wt /wt lipids , lipid triglyceride , phospholipid , glycerolipid , glycerophospho 
precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid lipid , sphingolipid , saccharolipid , polyketide , sterol lipid , 
precursors , lipid precursor , oleochemicals , or oleochemical ) triacylglyceride , and a prenol lipid . 
in dry weight , including allowing a yeast cell ( e . g . geneti - 35 15p . A yeast cell comprising a recombinant nucleic acid , 
cally modified yeast cell ) including greater than 20 % wt / wt wherein said recombinant nucleic acid modulates the level 
lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , of activity of a protein in said yeast cell relative to the 
lipids , lipid precursors , lipid precursor , oleochemicals , or absence of the recombinant nucleic acid , and wherein said 
oleochemical ) in dry weight to separate from a population of protein is selected from the group consisting of Leucine 
yeast cells within the plurality of yeast cells by floating 40 Biosynthesis Gene ( LEU2 ) , Uracil Biosynthesis gene 
above the population of yeast cells within an aqueous ( URA3 ) , multifunctional enzyme ( MFE1 ) , Transcription 
medium , the allowing is performed by sedimentation due to Factor ( PEX10 ) , AMP Deaminase ( AMPD ) , ATP - Citrate 
gravity . Lyase ( ACL ) , Malic Enzyme ( MAE ) , Acetyl - CoA Carboxy 
In embodiments of the method , the genetically modified lase ( ACC ) , acyl - CoA : diacylglycerol acyltransferase 
yeast cell is formed by transforming a yeast cell with a 45 ( DGA1 ) , acyl - CoA : diacylglycerol acyltransferases 
recombinant nucleic acid ( e . g . as described herein , including ( DGA2 ) , Mitochondrial 2 " O - ribose methyltransferase 
in embodiments , examples , tables , figures , and / or claims ) . In ( MRM2 ) , Lipid synthesis regulator ( MGA2 ) , Chromatin 
embodiments , the genetically modified yeast cell is formed assembly gene ( RLF2 subunit p90 ) , and 0 - 6 - methylgua 
by mutagenizing a yeast cell . In embodiments , the yeast cell nine - DNA methyltransferase ( MGMT ) . 
( e . g . genetically modified yeast cell includes a mutation 50 16p . The yeast cell of embodiment 15p , wherein said recom 
created by natural genetic drift . binant nucleic acid increases the level of activity of a protein 
In embodiments , the method is a method described herein , in said yeast cell selected from the group consisting of 
including in embodiments , examples , tables , figures , and Leucine Biosynthesis Gene ( LEU2 ) , Uracil Biosynthesis 
claims . gene ( URA3 ) , AMP Deaminase ( AMPD ) , ATP - Citrate 
55 Lyase ( ACL ) , Malic Enzyme ( MAE ) , Acetyl - CoA Carboxy 
IV . ADDITIONAL EMBODIMENTS lase ( ACC ) , acyl - CoA : diacylglycerol acyltransferase 
( DGA1 ) , acyl - CoA : diacylglycerol acyltransferases 
1p . A genetically modified yeast cell wherein the dry weight ( DGA2 ) , Mitochondrial 2 ' O - ribose methyltransferase 
of said yeast cell comprises greater than 20 % wt /wt lipid . ( MRM2 ) , Lipid synthesis regulator ( MGA2 ) , Chromatin 
2p . The yeast cell of embodiment lp comprising greater than 60 assembly gene ( RLF2 subunit p90 ) , and 0 - 6 - methylgua 
30 % wt / wt lipid . nine - DNA methyltransferase ( MGMT ) . 
3p . The yeast cell of embodiment lp comprising greater than 17p . The yeast cell of any one of embodiments 15p to 16p , 
40 % wt / wt lipid . wherein said recombinant nucleic acid decreases the level of 
4p . The yeast cell of embodiment 1p comprising greater than activity of a protein in said yeast cell selected from the group 
50 % wt / wt lipid . 65 consisting of multifunctional enzyme ( MFE1 ) , Lipid syn 
5p . The yeast cell of embodiment lp comprising greater than thesis regulator ( MGA2 ) , Chromatin assembly gene ( RLF2 
60 % wt / wt lipid . subunit p90 ) , and Transcription Factor ( PEX10 ) . 
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18p . The yeast cell of any one of embodiments 15p to 17p , 33p . The method of embodiment 30p , wherein the growth 
wherein said recombinant nucleic acid increases the level of medium comprises copper , iron , and either molybdenum or 
activity of a protein in said yeast cell selected from the group nickel . 
consisting of Leucine Biosynthesis Gene ( LEU2 ) , Uracil 34p . The method of embodiment 30p , wherein the growth 
Biosynthesis gene ( URA3 ) , Malic Enzyme ( MAE ) , Mito - 5 medium comprises copper , iron , molybdenum , and nickel . 
chondrial 2 ' O - ribose methyltransferase ( MRM2 ) , Lipid 35p . A method of isolating a genetically modified yeast cell 
synthesis regulator ( MGA2 ) , and 0 - 6 - methylguanine - DNA from a plurality of yeast cells comprising greater than 20 % 
methyltransferase ( MGMT ) or said nucleic acid decrease the wt / wt lipids in dry weight , comprising allowing a geneti 
level of activity of Lipid synthesis regulator ( MGA2 ) . cally modified yeast cell to separate from a population of 
19p . The yeast cell of any one of embodiments 15p to 18p , yeast cells within said plurality of yeast cells by floating 
wherein said recombinant nucleic acid encodes a protein above said population of yeast cells within an aqueous 
comprising a mutation relative to the wildtype protein . medium thereby isolating said genetically modified yeast 
20p . The yeast cell of any one of embodiments 15p to 18p , cell , wherein said population of yeast cells comprises a 
wherein said nucleic acid modulates the level of expression 15 lower percentage wt / wt of lipids than said genetically modi 
of a protein . fied yeast cell . 
21p . The yeast cell of embodiment 15p , wherein said yeast 36p . The method of any embodiment 35p , wherein said 
cell comprises a recombinant nucleic acid that decreases the genetically modified yeast cell comprises greater than 30 % 
level of activity of multifunctional enzyme ( MFE1 ) protein wt / wt lipids in dry weight . 
and Transcription Factor ( PEX10 ) protein , increases the 20 37p . The method of embodiment 35p , wherein said geneti 
level of activity of acyl - CoA : diacylglycerol acyltransferase cally modified yeast cell comprises greater than 40 % wt / wt 
( DGA1 ) protein , or increases the level of activity of Leucine lipids in dry weight . 
Biosynthesis Gene ( LEU2 ) protein relative to a yeast cell 38p . The method of embodiment 35p , wherein said geneti 
that does not comprise said recombinant nucleic acids . cally modified yeast cell comprises greater than 50 % wt /wt 
22p . The yeast cell of any one of embodiments 1p to 21p , 25 lipids in dry weight . 
wherein said yeast cell comprises a fatty acid selected from 39p . The method of embodiment 35p , wherein said geneti 
the group consisting of C5 : 0 , C5 : 1 , C5 : 2 , C5 : 3 , C6 : 0 , C6 : 1 , cally modified yeast cell comprises greater than 60 % wt / wt 
C6 : 2 , C6 : 3 , C7 : 0 , C7 : 1 , C7 : 2 , C7 : 3 , C8 : 0 , C8 : 1 , C8 : 2 , C8 : 3 , lipids in dry weight . 
C9 : 0 , C9 : 1 , C9 : 2 , C9 : 3 , C10 : 0 , C10 : 1 , C10 : 2 , C10 : 3 , C11 : 0 , 40p . The method of any one of embodiments 35p to 39p , 
C11 : 1 , C11 : 2 , C11 : 3 , C12 : 0 , C12 : 1 , C12 : 2 , C12 : 3 , C13 : 0 , 30 wherein said plurality of yeast cells are in a bioreactor with 
C13 : 1 , C13 : 2 , C13 : 3 , C14 : 0 , C14 : 1 , C14 : 2 , C14 : 3 , C15 : 0 , agitation and aeration rates of about 0 . 5 vvm ( volume per 
C15 : 1 , C15 : 2 , C15 : 3 , C16 : 0 , C16 : 1 , C16 : 2 , C16 : 3 , C17 : 0 , volume per minute ) . 
C17 : 1 , C17 : 2 , C17 : 3 , C18 : 0 , C18 : 1 , C18 : 2 , C18 : 3 , C19 : 0 , 41p . The method of any one of embodiments 35p to 39p , 
C19 : 1 , C19 : 2 , C19 : 3 , C20 : 0 , C20 : 1 , C20 : 2 , C20 : 3 , C21 : 0 , wherein said plurality of yeast cells are in a bioreactor with 
C21 : 1 , C21 : 2 , C21 : 3 , C22 : 0 , C22 : 1 , C22 : 2 , C22 : 3 , C23 : 0 , 35 agitation and aeration rates of about 1 . 0 vvm ( volume per 
C23 : 1 , C23 : 2 , and C23 : 3 . volume per minute ) . 
23p . The yeast cell of any one of embodiments 1p to 21p , 42p . The method of any one of embodiments 35p to 39p , 
wherein said yeast cell comprises a fatty acid selected from wherein said plurality of yeast cells are in a bioreactor with 
the group consisting of C17 : 0 and C17 : 1 . agitation and aeration rates of about 2 . 0 vvm ( volume per 
24p . A method of producing a lipid comprising : 40 volume per minute ) . 
1 ) culturing a yeast cell of any one of embodiments 1p to 23p 43p . The method of any one of embodiments 35p to 39p , 
in a growth medium ; wherein said plurality of yeast cells are in a bioreactor with 
2 ) isolating said lipid . agitation and aeration rates of about 3 . 0 vvm ( volume per 
25p . The method of embodiment 24p , wherein said lipid is volume per minute ) . 
isolated from said yeast cell . 26p . The method of embodi - 45 44p . The method of any one of embodiments 35p to 39p , 
ment 24p , wherein said lipid is isolated from the medium . wherein said plurality of yeast cells are in a bioreactor with 
27p . The method of any one of embodiments 24p to 26p , agitation and aeration rates of about 4 . 0 vvm ( volume per 
wherein said growth medium comprises a majority carbon volume per minute ) . 
source selected from the group consisting of glucose , glyc 45p . The method of any one of embodiments 35p to 44p , 
erol , xylose , fructose , mannose , ribose , sucrose , and ligno - 50 wherein said aqueous medium comprises a yeast growth 
cellulosic biomass . medium , minimal media , complete supplement media , or 
28p . The method of any one of embodiments 24p to 26p , greater than 50 g / L glucose and less than 5 g / L of a nitrogen 
wherein said growth medium comprises lignocellulosic bio source . 
mass as the majority carbon source . 46p . The method of any one of embodiments 35p to 45p , 
29p . The method of any one of embodiments 24p to 28p , 55 wherein said allowing is performed by centrifugation or 
wherein said growth medium comprises a carbon source and simple sedimentation . 
a nitrogen source wherein said carbon source is at a con 47p . The method of any one of embodiments 35p to 46p , 
centration at least 10 - fold greater than the concentration of wherein said genetically modified yeast cell was formed by 
the nitrogen source . transforming a yeast cell with a recombinant nucleic acid . 
30p . The method of any one of embodiments 24p to 29p , 60 48p . The method of any one of embodiments 35p to 4 ' 7p , 
wherein said growth medium comprises cobalt , iron , mag - wherein said genetically modified yeast cell was formed by 
nesium , potassium , zinc , nickel , molybdenum , manganese , mutagenizing a yeast cell . 
copper , or boron . 1 . A genetically modified yeast cell wherein the dry weight 
31p . The method of embodiment 30p , wherein the growth of said yeast cell comprises greater than 20 % wt / wt lipids , 
medium comprises iron , copper , and molybdenum . 65 lipid precursors , and / or oleochemicals ( e . g . , lipid , lipids , 
32p . The method of embodiment 30p , wherein the growth lipid precursors , lipid precursor , oleochemicals , or oleo 
medium comprises copper and nickel . chemical ) . 
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2 . The genetically modified yeast cell of embodiment 1 the level of activity of the Uracil Biosynthesis gene ( URA3 ) 
comprising greater than 30 % wt / wt lipids , lipid precursors , protein relative to an otherwise identical yeast cell lacking 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , said genetic modification . 
lipid precursor , oleochemicals , or oleochemical ) . 18 . The genetically modified yeast cell of one of embodi 
3 . The genetically modified yeast cell of embodiment 1 5 ments 1 to 17 , comprising a genetically modified multifunc 
comprising greater than 40 % wt / wt lipids , lipid precursors , tional enzyme ( MFE1 ) gene . 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 19 . The genetically modified yeast cell of one of embodi 
lipid precursor , oleochemicals , or oleochemical ) . ments 1 to 17 , wherein said genetic modification decreases 
4 . The genetically modified yeast cell of embodiment 1 the level of activity of the multifunctional enzyme ( MFE1 ) 
comprising greater than 50 % wt / wt lipids , lipid precursors , 10 protein relative to an otherwise identical yeast cell lacking 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , said genetic modification . 20 . The genetically modified yeast cell of one of embodi lipid precursor , oleochemicals , or oleochemical ) . ments 1 to 19 , comprising a genetically modified PEX10 5 . The genetically modified yeast cell of embodiment 1 Transcription Factor ( PEX10 ) gene . 
comprising greater than 60 % wt / wt lipids , lipid precursors , 15 21 . The genetically modified veast cell of one of embodi 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , ments 1 to 19 , wherein said genetic modification decreases 
lipid precursor , oleochemicals , or oleochemical ) . the level of activity of the PEX10 Transcription Factor 
6 . The genetically modified yeast cell of embodiment 1 ( PEX10 ) protein relative to an otherwise identical yeast cell 
comprising greater than 70 % wt / wt lipids , lipid precursors , lacking said genetic modification . 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 20 22 . The genetically modified yeast cell of one of embodi 
lipid precursor , oleochemicals , or oleochemical ) . ments 1 to 21 , comprising a recombinant AMP Deaminase 
7 . The genetically modified yeast cell of embodiment 1 ( AMPD ) protein . 
comprising greater than 80 % wt / wt lipids , lipid precursors , 23 . The genetically modified yeast cell of one of embodi 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , ments 1 to 21 , wherein said genetic modification increases 
lipid precursor , oleochemicals , or oleochemical ) . 25 the level of activity of the AMP Deaminase ( AMPD ) protein 
8 . The genetically modified yeast cell of embodiment 1 relative to an otherwise identical yeast cell lacking said 
comprising greater than 90 % wt / wt lipids , lipid precursors , genetic modification . 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 24 . The genetically modified yeast cell of one of embodi 
lipid precursor , oleochemicals , or oleochemical ) . ments 1 to 23 , comprising a recombinant ATP - Citrate Lyase 
9 . The genetically modified yeast cell of any one of embodi - 30 ( ACL1 ) protein . 
ments 1 to 8 , selected from the group consisting of the 25 . The genetically modified yeast cell of one of embodi 
genera Yarrowia , Candida , Rhodotorula , Rhodosporidium , ments 1 to 23 , wherein said genetic modification increases 
Cryptococcus , Trichosporon and Lipomyces . the level of activity of the ATP - Citrate Lyase ( ACL1 ) protein 
10 . The genetically modified yeast cell of any one of relative to an otherwise identical yeast cell lacking said 
embodiments 1 to 8 , selected from the group consisting of 35 genetic modification . 
Rhodosporidium toruloides , Lipomyces starkeyii , Lipomy 26 . The genetically modified yeast cell of one of embodi 
ces lipoferus , Apiotrichum curvatum , Candida curvata , ments 1 to 25 , comprising a recombinant ATP - Citrate Lyase 
Cryptococcus curvatus , Trichosporon fermentans , Candida ( ACL2 ) protein . 
revkaufi , Candida pulcherrima , Candida tropicalis , Can 27 . The genetically modified yeast cell of one of embodi 
dida utilis , Trichosporon pullans , Trichosporon cutaneum , 40 ments 1 to 25 , wherein said genetic modification increases 
the level of activity of the ATP - Citrate Lyase ( ACL2 ) protein 
lipolytica . relative to an otherwise identical yeast cell lacking said 
11 . The genetically modified yeast cell of any one of genetic modification . 
embodiments 1 to 8 , selected from the group consisting of 28 . The genetically modified yeast cell of one of embodi 
Lipomyces starkeyii , Rhodosporidium toruloides , Apiotri - 45 ments 1 to 27 , comprising a recombinant Malic Enzyme 
chum curvatum , Candida curvata , Cryptococcus curvatus , ( MAE ) protein . 
Trichosporon fermentans , Rhodotorula glutinis , and Yar - 29 . The genetically modified yeast cell of one of embodi 
rowia lipolytica . ments 1 to 27 , wherein said genetic modification increases 
12 . The genetically modified yeast cell of any one of the level of activity of the Malic Enzyme ( MAE ) protein 
embodiments 1 to 8 , wherein said yeast cell is Yarrowia 50 relative to an otherwise identical yeast cell lacking said 
lipolytica . genetic modification . 
13 . The genetically modified yeast cell of any one of 30 . The genetically modified yeast cell of one of embodi 
embodiments 1 to 12 , wherein said yeast cell is buoyant in ments 1 to 29 , comprising a recombinant Acetyl - CoA Car 
an aqueous medium . boxylase ( ACC ) protein . 
14 . The genetically modified yeast cell of one of embodi - 55 31 . The genetically modified yeast cell of one of embodi 
ments 1 to 13 , comprising a recombinant Leucine Biosyn - ments 1 to 29 , wherein said genetic modification increases 
thesis Gene ( LEU2 ) . the level of activity of the Acetyl - CoA Carboxylase ( ACC ) 
15 . The genetically modified yeast cell of one of embodi protein relative to an otherwise identical yeast cell lacking 
ments 1 to 13 , wherein said genetic modification increases said genetic modification . 
the level of activity of the Leucine Biosynthesis Gene 60 32 . The genetically modified yeast cell of one of embodi 
( LEU2 ) protein relative to an otherwise identical yeast cell m ents 1 to 31 , comprising a recombinant acyl - CoA : diacyl 
lacking said genetic modification . glycerol acyltransferase 1 ( DGA1 ) protein . 
16 . The genetically modified yeast cell of one of embodi 33 . The genetically modified yeast cell of one of embodi 
ments 1 to 15 , comprising a recombinant Uracil Biosynthe - ments 1 to 31 , wherein said genetic modification increases 
sis gene ( URA3 ) . 65 the level of activity of the acyl - CoA : diacylglycerol acyl 
17 . The genetically modified yeast cell of one of embodi - transferase 1 ( DGA1 ) protein relative to an otherwise iden 
ments 1 to 15 , wherein said genetic modification increases tical yeast cell lacking said genetic modification . 
71 
US 9 , 896 , 691 B2 
72 
34 . The genetically modified yeast cell of one of embodi 50 . The genetically modified yeast cell of one of embodi 
ments 1 to 33 , comprising a recombinant acyl - CoA : diacyl - ments 1 to 49 , comprising a genetically modified RMEI 
glycerol acyltransferase 2 ( DGA2 ) protein . zinc - finger transcription factor ( RME1 ) gene . 
35 . The genetically modified yeast cell of one of embodi 51 . The genetically modified yeast cell of one of embodi 
ments 1 to 33 , wherein said genetic modification increases 5 ments 1 to 49 , wherein said genetic modification decreases 
the level of activity of the acyl - CoA : diacylglycerol acyl the level of activity of the RME1 zinc - finger transcription 
transferase 2 ( DGA2 ) protein relative to an otherwise iden - factor ( RME1 ) protein relative to an otherwise identical 
tical yeast cell lacking said genetic modification . yeast cell lacking said genetic modification . 
36 . The genetically modified yeast cell of one of embodi 52 . The genetically modified yeast cell of one of embodi 
ments 1 to 35 , comprising a recombinant Mitochondrial 2 10 ments 1 to 51 , comprising a genetically modified YOX1 
O - ribose methyltransferase ( MRM2 ) protein . homeodomain protein ( YOX1 ) gene . 
37 . The genetically modified yeast cell of one of embodi - 53 . The genetically modified yeast cell of one of embodi 
ments 1 to 35 , wherein said genetic modification increases ments 1 to 51 , wherein said genetic modification decreases 
the level of activity of the Mitochondrial 2 ' O - ribose meth - 15 the level of activity of the YOX1 homeodomain protein 
yltransferase ( MRM2 ) protein relative to an otherwise iden ( YOX1 ) protein relative to an otherwise identical yeast cell 
Gotion tical yeast cell lacking said genetic modification . lacking said genetic modification . 
38 . The genetically modified yeast cell of one of embodi 54 . The genetically modified yeast cell of one of embodi 
ments 1 to 37 , comprising a recombinant Lipid synthesis ments 1 to 53 , comprising a genetically modified UGA2 
regulator ( MGA2 ) protein . 20 succinate semialdehyde dehydrogenase ( UGA2 ) gene . 
39 . The genetically modified yeast cell of one of embodi 55 . The genetically modified yeast cell of one of embodi 
ments 1 to 37 , comprising a genetically modified Lipid ments 1 to 53 , wherein said genetic modification decreases 
synthesis regulator ( MGA2 ) gene . the level of activity of the UGA2 succinate semialdehyde 
40 . The genetically modified yeast cell of one of embodi - dehydrogenase ( UGA2 ) protein relative to an otherwise 
ments 1 to 37 , comprising at least one nucleotide deletion in 25 identical yeast cell lacking said genetic modification . 
the genomic Lipid synthesis regulator ( MGA2 ) gene and 56 . The genetically modified yeast cell of one of embodi 
expression of a Lipid synthesis regulator ( MGA2 ) protein ments 1 to 55 , comprising a genetically modified OSH6 
comprising a mutation corresponding to G643R in Yarrowia oxysterol - binding protein homolog 6 ( OSH6 ) gene . 
lipolytica . Lipid synthesis regulator ( MGA2 ) 57 . The genetically modified yeast cell of one of embodi 
41 . The genetically modified yeast cell of one of embodi - 30 ments 1 to 55 , wherein said genetic modification decreases 
ments 1 to 37 , wherein said genetic modification decreases the level of activity of the OSH6 oxysterol - binding protein 
the level of activity of the Lipid synthesis regulator ( MGA2 ) homolog 6 ( OSH6 ) protein relative to an otherwise identical 
protein relative to an otherwise identical yeast cell lacking yeast cell lacking said genetic modification . 
said genetic modification . 35 58 . The genetically modified yeast cell of one of embodi 
42 . The genetically modified yeast cell of one of embodi m ents 1 to 57 , comprising a genetically modified IRC20 E3 
ments 1 to 41 , comprising a genetically modified Chromatin ubiquitin - protein ligase and helicase ( IRC20 ) gene . 
assembly gene ( RLF2 subunit p90 ) gene . 59 . The genetically modified yeast cell of one of embodi 
43 . The genetically modified yeast cell of one of embodi - ments 1 to 57 , wherein said genetic modification decreases 
ments 1 to 41 , wherein said genetic modification decreases 40 the level of activity of the IRC20 E3 ubiquitin - protein ligase 
the level of activity of the Chromatin assembly gene ( RLF2 and helicase ( IRC20 ) protein relative to an otherwise iden 
subunit p90 ) protein relative to an otherwise identical yeast tical yeast cell lacking said genetic modification . 
cell lacking said genetic modification . 60 . The genetically modified yeast cell of any one of 
44 . The genetically modified yeast cell of one of embodi embodiments 1 to 59 , wherein said genetic modification 
ments 1 to 43 , comprising a recombinant 0 - 6 - methylgua - 45 modulates the level of activity of a component of a lipid 
nine - DNA methyltransferase ( MGMT ) protein . biosynthetic pathway . 
45 . The genetically modified yeast cell of one of embodi - 61 . The genetically modified yeast cell of any one of 
ments 1 to 43 , wherein said genetic modification increases embodiments 1 to 59 , wherein said genetic modification 
the level of activity of the O - 6 - methylguanine - DNA meth - modulates the level of activity of a component of a pathway 
yltransferase ( MGMT ) protein relative to an otherwise iden - 50 incorporating Acetyl - CoA into a lipid , lipid precursor , or 
tical yeast cell lacking said genetic modification . oleochemical . 
46 . The genetically modified yeast cell of one of embodi - 62 . The genetically modified yeast cell of any one of 
ments 1 to 45 , comprising a genetically modified Aconitase embodiments 1 to 59 , wherein said genetic modification 
( ACO1 ) gene . modulates the level of activity of a component of a pathway 
47 . The genetically modified yeast cell of one of embodi - 55 incorporating malonyl - CoA into a lipid , lipid precursor , or 
ments 1 to 45 , wherein said genetic modification decreases oleochemical . 
the level of activity of the Aconitase ( ACO1 ) protein relative 63 . The genetically modified yeast cell of any one of 
to an otherwise identical yeast cell lacking said genetic embodiments 1 to 59 , wherein said genetic modification 
modification . increases the level of activity of a component of a lipid 
48 . The genetically modified yeast cell of one of embodi - 60 biosynthetic pathway . 
ments 1 to 47 , comprising a recombinant Citrate Synthase 64 . The genetically modified yeast cell of any one of 
( CIT1 ) gene . embodiments 1 to 59 , wherein said genetic modification 
49 . The genetically modified yeast cell of one of embodi increases the level of activity of a component of a pathway 
ments 1 to 47 , wherein said genetic modification increases incorporating acetyl - CoA into a lipid , lipid precursor , or 
the level of activity of the Citrate Synthase ( CIT1 ) protein 65 Oleochemical . 
relative to an otherwise identical yeast cell lacking said 6 5 . The genetically modified yeast cell of any one of 
genetic modification . embodiments 1 to 59 , wherein said genetic modification 
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cell . 
increases the level of activity of a component of a pathway 77 . The genetically modified yeast cell of any one of 
incorporating malonyl - CoA into a lipid , lipid precursor , or embodiments 1 to 76 , wherein said genetic modification 
oleochemical . comprises a mutation relative to the wild type gene . 
66 . The genetically modified yeast cell of any one of 78 . The genetically modified yeast cell of any one of 
embodiments 1 to 59 , wherein said genetic modification 5 embodiments 1 to 76 , wherein said genetic modification 
modulates the level of activity of a component of a lipid , comprises a deletion of a portion of a gene . 
lipid precursor , or oleochemical , metabolic pathway . 79 . The genetically modified yeast cell of one of embodi 
67 . The genetically modified yeast cell of any one of ments 1 to 78 , wherein said yeast cell comprises an increased level of a fatty acid selected from the group embodiments 1 to 59 , wherein said genetic modification 
decreases the level of activity of a component of a lipid , lipid 10 consisting of C5 : 0 , C5 : 1 , C5 : 2 , C5 : 3 , C6 : 0 , C6 : 1 , C6 : 2 , C6 : 3 , C7 : 0 , C7 : 1 , C7 : 2 , C7 : 3 , C8 : 0 , C8 : 1 , C8 : 2 , 18 : 3 , C9 : 0 , precursor , or oleochemical , metabolic pathway . C9 : 1 , C9 : 2 , C9 : 3 , C10 : 0 , C10 : 1 , C10 : 2 , C10 : 3 , C11 : 0 , 68 . The genetically modified yeast cell of any one of C11 : 1 , C11 : 2 , C11 : 3 , C12 : 0 , C12 : 1 , C12 : 2 , C12 : 3 , C13 : 0 , embodiments 1 to 59 , wherein said genetic modification C13 : 1 , C13 : 2 , C13 : 3 , C14 : 0 , C14 : 1 , C14 : 2 , C14 : 3 , C15 : 0 , 
decreases the level of activity of a component of a lipid , lipid 15 C15 : 1 . C15 : 2 . C15 : 3 . C16 : 0 . C16 : 1 . C16 : 2 . C16 : 3 . C17 : 0 . 
precursor , or oleochemical , metabolic pathway . C17 : 1 , C17 : 2 , C17 : 3 , C18 : 0 , C18 : 1 , C18 : 2 , C18 : 3 , C19 : 0 , 
69 . The genetically modified yeast cell of any one of C19 : 1 , C19 : 2 , C19 : 3 , C20 : 0 , C20 : 1 , C20 : 2 , C20 : 3 , C21 : 0 , 
embodiments 1 to 59 , wherein said genetic modification C21 : 1 , C21 : 2 , C21 : 3 , C22 : 0 , C22 : 1 , C22 : 2 , C22 : 3 , C23 : 0 , 
increases the level of acetyl - CoA in the genetically modified C23 : 1 , C23 : 2 , and C23 : 3 , relative to a genetically unmodi 
yeast cell relative to a genetically unmodified yeast cell that 20 fied yeast cell that is otherwise identical to said genetically 
is otherwise identical to said genetically modified yeast cell . modified yeast cell . 
70 . The genetically modified yeast cell of any one of 80 . The genetically modified yeast cell of embodiment 79 , 
embodiments 1 to 59 , wherein said genetic modification wherein said fatty acid is ?17 : 0 C17 : 1 . 
increases the level of malonyl - CoA in the genetically modi - 81 . The genetically modified yeast cell of embodiment 79 , 
fied yeast cell relative to a genetically unmodified yeast cell 25 wherein said fatty acid is C16 : 1n9 . 
that is otherwise identical to said genetically modified yeast 82 . The genetically modified yeast cell of one of embodi 
ments 1 to 81 , wherein said genetic modification is an 
71 . The genetically modified yeast cell of any one of engineered genetic modification . 
embodiments 1 to 59 , wherein said genetic modification 83 . The genetically modified yeast cell of embodiment 82 , 
increases the level of triglyceride production in the geneti - 30 wherein said engineered genetic modification comprises 
cally modified yeast cell relative to a genetically unmodified modulated expression of a protein . 
yeast cell that is otherwise identical to said genetically 84 . The genetically modified yeast cell of embodiment 82 , 
modified yeast cell . wherein said engineered genetic modification comprises 
72 . The genetically modified yeast cell of any one of increased expression of a protein . 
embodiments 1 to 59 , wherein said genetic modification 35 85 . The genetically modified yeast cell of embodiment 82 , 
decreases the level of beta - oxidation activity in the geneti - wherein said engineered genetic modification comprises 
cally modified yeast cell relative to a genetically unmodified decreased expression of a protein . 
yeast cell that is otherwise identical to said genetically 86 . The genetically modified yeast cell of one of embodi 
modified yeast cell . ments 1 to 81 , wherein said genetic modification is associ 
73 . The genetically modified yeast cell of any one of 40 ated with exposure to a mutagen . 
embodiments 1 to 59 , wherein said genetic modification 87 . The genetically modified yeast cell of one of embodi 
decreases the level of fatty acid catabolism in the genetically ments 1 to 86 , wherein said genetic modification comprises 
modified yeast cell relative to a genetically unmodified yeast modulated expression of a protein in a lipid , or lipid pre 
cell that is otherwise identical to said genetically modified cursor , biosynthetic pathway . 
yeast cell . 45 88 . A method of producing a lipid , lipid precursor , or 
74 . The genetically modified yeast cell of any one of oleochemical comprising : 
embodiments 1 to 59 , wherein said genetic modification 1 ) culturing a yeast cell of any one of embodiments 1 to 87 
decreases the level of peroxisome biogenesis activity in the in a growth medium ; and 
genetically modified yeast cell relative to a genetically 2 ) isolating said lipid , lipid precursor , or oleochemical . 
unmodified yeast cell that is otherwise identical to said 50 89 . The method of embodiment 88 , wherein said lipid , lipid 
genetically modified yeast cell . precursor , or oleochemicalis isolated from said yeast cell . 
75 . The genetically modified yeast cell of any one of 90 . The method of embodiment 88 , wherein said lipid , lipid 
embodiments 1 to 59 , wherein said genetic modification precursor , or oleochemical is isolated from the growth 
produces a lipid , lipid precursor , or oleochemical at a higher medium . 
level than by a genetically unmodified yeast cell that is 55 91 . The method of any one of embodiments 88 to 90 , 
otherwise identical to said genetically modified yeast cell . wherein said growth medium comprises a majority carbon 
76 . The genetically modified yeast cell of embodiment 75 , source selected from the group consisting of glucose , glyc 
wherein said lipid , lipid precursor , or oleochemical pro erol , xylose , fructose , mannose , ribose , sucrose , and ligno 
duced at a higher level by said genetically modified yeast cellulosic biomass . 
cell is a fatty acid , wax , sterol , vitamin , monoglyceride , 60 92 . The method of any one of embodiments 88 to 90 , 
diglyceride , triglyceride , phospholipid , glycerolipid , glyc - wherein said growth medium comprises lignocellulosic bio 
erophospholipid , sphingolipid , saccharolipid , polyketide , mass as the majority carbon source . 
sterol lipid , triacylglyceride , prenol lipid , fatty acid ester , 93 . The method of any one of embodiments 88 to 92 , 
fatty acid methyl ester , fatty acid ethyl ester , fatty acid wherein said growth medium comprises a carbon source and 
propyl ester , fatty acid butyl ester , fatty alcohol , fatty amine , 65 a nitrogen source wherein said carbon source is at a con 
glycerol , alcohol ethoxylate , alcohol sulfate , or alcohol ether centration at least 10 - fold greater than the concentration of 
sulfate . the nitrogen source ( wt / wt ) . 
genen 
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94 . The method of any one of embodiments 88 to 92 , NISO4 . 6H , O , iron in an amount equivalent to 10 to 30 mg / L 
wherein said growth medium comprises a carbon source and FeSO4 . 7H2O , or copper in an amount equivalent to 7 . 5 to 
a nitrogen source wherein said carbon source is at a con - 22 . 5 mg / L CuSO4 . 
centration at least 16 - fold greater than the concentration of 107 . The method of any one of embodiments 88 to 95 , 
the nitrogen source ( wt / wt ) . 5 wherein said growth medium comprises 3 . 76x10 - 5 M to 
95 . The method of any one of embodiments 88 to 92 , 1 . 10x10 - 4 M molybdenum , 2 . 28x10 - 5 M to 6 . 84x10 - 5 M 
wherein said growth medium comprises a carbon source and nickel , 3 . 60x10 ̂ - 3 M to 1 . 08x10 - 4M iron , or 4 . 70x10 - M to 
1 . 41x10 - 4M copper . a nitrogen source wherein said carbon source is at a con 
centration at least 320 - fold greater than the concentration of 108 . The method of any one of embodiments 88 to 95 , 10 wherein the growth medium comprises copper , iron , molyb the nitrogen source ( wt / wt ) . denum , and nickel . 96 . The method of any one of embodiments 88 to 95 , 109 . A method of isolating a genetically modified yeast cell wherein said growth medium comprises micronutrients ( e . g . from a plurality of yeast cells , comprising greater than 20 % cobalt , iron , magnesium , potassium , zinc , nickel , molybde wt /wt lipids , lipid precursors , and / or oleochemicals ( e . g . , 
num , manganese , copper , or boron ) . 15 lipid , lipids , lipid precursors , lipid precursor , oleochemicals , 
97 . The method of any one of embodiments 88 to 95 , or oleochemical ) in dry weight , comprising allowing a 
wherein said growth medium comprises cobalt in an amount genetically modified yeast cell to separate from a population 
equivalent to 7 . 5 to 22 . 5 mg / L CoCl2 , magnesium in an of yeast cells within said plurality of yeast cells by floating 
amount equivalent to 125 to 375 mg / L MgSO4 , potassium in above said population of yeast cells within an aqueous 
an amount equivalent to 7 . 5 to 22 . 5 mg / L KI , zinc in an 20 medium thereby isolating said genetically modified yeast 
amount equivalent to 10 to 30 mg / L ZnSO4 . 7H2O , manga cell , wherein said population of yeast cells comprises a 
nese in an amount equivalent to 6 to 18 mg / L MnSO4 . H20 , lower percentage wt / wt of lipids , lipid precursors , and / or 
boron in an amount equivalent to 6 to 18 mg / L Boric acid , oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre 
molybdenum in an amount equivalent to 7 . 5 to 22 . 5 mg / L cursor , oleochemicals , or oleochemical ) than said geneti 
( NH4 ) , Mo . 41 , 0 , nickel in an amount equivalent to 6 to 18 25 cally modified yeast cell . 
mg / L NISO . 6H , O , iron in an amount equivalent to 10 to 30 110 . The method of embodiment 109 , wherein said geneti 
mg / L FeSO . 7H , O , or copper in an amount equivalent to 7 . 5 cally modified yeast cell comprises greater than 30 % wt / wt 
to 22 . 5 mg /L CuSO4 lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , 
98 . The method of any one of embodiments 88 to 95 , lipids , lipid precursors , lipid precursor , oleochemicals , or 
wherein said growth medium comprises 5 . 77x10 - 5 M to 300 0 - 5 M T 30 Oleochemical ) in dry weight  
1 . 73x10 - 4 M cobalt , 0 . 001 M to 0 . 003 M magnesium , 111 . The method of embodiment 109 , wherein said geneti 
4 . 52x10 - 5 M to 1 . 35x10 - 4 M potassium , 4 . 05x10 - 5 M to cally modified yeast cell comprises greater than 40 % wt / wt 
1 . 22x10 - 4 M zinc , 3 . 55x10 - 5 M to 1 . 06x10 - 4 M manganese , lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid precursor , oleochemicals , or 9 . 07x10 - 5 M to 2 . 91x10 - 4 M boron , 3 . 76x10 - 5 M to 1 . 10x X 35 Oleochemical ) in dry weight . 10 - 4 M molybdenum , 2 . 28x10 - M to 6 . 84x10 - 5 M nickel , 112 . The method of embodiment 109 , wherein said geneti 3 . 60x10 - 5 M to 1 . 08x10 - 4 M iron , or 4 . 70x10 - 5 M to cally modified yeast cell comprises greater than 50 % wt /wt 1 . 41x10 - 4 M copper . lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , 
99 . The method of any one of embodiments 88 to 95 , lipids , lipid precursors , lipid precursor , oleochemicals , or 
wherein the growth medium comprises iron , copper , and 40 oleochemical ) in dry weight . 
molybdenum . 113 . The method of embodiment 109 , wherein said geneti 
100 . The method of any one of embodiments 88 to 95 , cally modified yeast cell comprises greater than 60 % wt / wt 
wherein said growth medium comprises molybdenum in an lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , 
amount equivalent to 7 . 5 to 22 . 5 mg / L ( NH4 ) 2M0 . 4H20 , lipids , lipid precursors , lipid precursor , oleochemicals , or 
iron in an amount equivalent to 10 to 30 mg / L FeSO4 . 7H , O , 45 oleochemical ) in dry weight . 
or copper in an amount equivalent to 7 . 5 to 22 . 5 mg / L 114 . The method of any one of embodiments 109 to 113 , 
Cuso . wherein said plurality of yeast cells are in a bioreactor with 
101 . The method of any one of embodiments 88 to 95 , agitation and aeration rates of about 0 . 5 vvm ( volume per 
wherein said growth medium comprises 3 . 76x10 - 3 M to volume per minute ) . 
1 . 10x10 - 4 M molybdenum , 3 . 60x10 - 5 M to 1 . 08x10 - 4 M 50 115 . The method of any one of embodiments 109 to 113 , 
iron , or 4 . 70x10 - 5 M to 1 . 41x10 - 4 M copper . wherein said plurality of yeast cells are in a bioreactor with 
102 . The method of any one of embodiments 88 to 95 , agitation and aeration rates of about 1 . 0 vvm ( volume per 
wherein the growth medium comprises copper and nickel . volume per minute ) . 
103 . The method of any one of embodiments 88 to 95 , 116 . The method of any one of embodiments 109 to 113 , 
wherein said growth medium comprises nickel in an amount 55 wherein said plurality of yeast cells are in a bioreactor with 
equivalent to 6 to 18 mg / L NISO2 . 6H , O or copper in an agitation and aeration rates of about 2 . 0 vvm ( volume per 
amount equivalent to 7 . 5 to 22 . 5 mg / L CuSO4 . volume per minute ) . 
104 . The method of any one of embodiments 88 to 95 , 117 . The method of any one of embodiments 109 to 113 , 
wherein said growth medium comprises 2 . 28x10 - 5 M to wherein said plurality of yeast cells are in a bioreactor with 
6 . 84x10 - SM nickel or 4 . 70x10 - 5M to 1 . 41x10 - 4 M copper . 60 agitation and aeration rates of about 3 . 0 vvm ( volume per 
105 . The method of any one of embodiments 88 to 95 , volume per minute ) . 
wherein the growth medium comprises copper , iron , and 118 . The method of any one of embodiments 109 to 113 , 
either molybdenum or nickel . wherein said plurality of yeast cells are in a bioreactor with 
106 . The method of any one of embodiments 88 to 95 , agitation and aeration rates of about 4 . 0 vvm ( volume per 
wherein said growth medium comprises molybdenum in an 65 volume per minute ) . 
amount equivalent to 7 . 5 to 22 . 5 mg / L ( NH4 ) 2Mo . 4H20 , 119 . The method of any one of embodiments 109 to 118 , 
nickel in an amount equivalent to 6 to 18 mg / L wherein said aqueous medium comprises a yeast growth 
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medium , minimal media , complete supplement media , or oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre 
greater than 50 g / L glucose and less than 5 g / L of a nitrogen cursor , oleochemicals , or oleochemical ) in dry weight . 
source . 130 . The method of embodiment 125 , wherein said yeast cell 
120 . The method of any one of embodiments 109 to 119 , comprising greater than 20 % wt / wt lipids , lipid precursors , 
wherein said allowing is performed by centrifugation or 5 and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 
simple sedimentation . lipid precursor , oleochemicals , or oleochemical ) comprises 
121 . The method of any one of embodiments 109 to 120 , greater than 70 % wt /wt lipids , lipid precursors , and / or 
wherein said genetically modified yeast cell was formed by oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre 
transforming a yeast cell with a recombinant nucleic acid . cursor , oleochemicals , or oleochemical ) in dry weight . 
122 . The method of any one of embodiments 109 to 120 . 10 131 . The method of embodiment 125 , wherein said yeast cell 
wherein said genetically modified yeast cell was formed by comprising greater than 20 % wt /wt lipids , lipid precursors , 
mutagenizing a yeast cell . and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 
123 . The method of any one of embodiments 109 to 120 , lipid precursor , oleochemicals , or oleochemical ) comprises greater than 80 % wt / wt lipids , lipid precursors , and / or wherein said genetically modified yeast cell is created by 15 oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre first exposing a yeast cell to a mutagen ( e . g . a chemical cursor , oleochemicals , or oleochemical ) in dry weight . mutagen , radiation , UV , or a biological mutagen ) . 132 . The method of embodiment 125 , wherein said yeast cell 124 . The method of any one of embodiments 109 to 120 , comprising greater than 20 % wt / wt lipids , lipid precursors , wherein said genetically modified yeast cell was formed by and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , mutagenizing a yeast cell . 20 lipid precursor , oleochemicals , or oleochemical ) comprises 
125 . A method of isolating a yeast cell comprising greater greater than 90 % wt / wt lipids , lipid precursors , and / or 
than 20 % wt / wt lipids , lipid precursors , and / or oleochemi - oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre 
cals ( e . g . , lipid , lipids , lipid precursors , lipid precursor , cursor , oleochemicals , or oleochemical ) in dry weight . 
oleochemicals , or oleochemical ) in dry weight from a plu - 133 . The method of one of embodiments 125 to 132 , 
rality of yeast cells , comprising allowing a yeast cell com - 25 wherein said yeast cell comprising greater than 20 % wt / wt 
prising greater than 20 % wt / wt lipids , lipid precursors , lipids , lipid precursors , and / or oleochemicals ( e . g . , lipid , 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipids , lipid precursors , lipid precursor , oleochemicals , or 
lipid precursor , oleochemicals , or oleochemical ) to separate oleochemical ) comprises a mutation created by natural 
from a population of yeast cells within said plurality of yeast genetic drift . 
cells by floating above said population of yeast cells within 30 134 . The method of any one of embodiments 88 to 95 , 
an aqueous medium thereby isolating said yeast cell com wherein said growth medium comprises cobalt . 
prising greater than 20 % wt / wt lipids , lipid precursors , 135 . The method of any one of embodiments 88 to 95 and 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 134 , wherein said growth medium comprises iron . 
lipid precursor , oleochemicals , or oleochemical ) , wherein 136 . The method of any one of embodiments 88 to 95 and 
said population of yeast cells comprises a lower percentage 35 134 to 135 , wherein said growth medium comprises mag 
wt / wt of lipids , lipid precursors , and / or oleochemicals ( e . g . , nesium 
lipid , lipids , lipid precursors , lipid precursor , oleochemicals , 137 . The method of any one of embodiments 88 to 95 and 
or oleochemical ) than said yeast cell comprising greater than 134 to 136 , wherein said growth medium comprises potas 
20 % wt / wt lipids , lipid precursors , and / or oleochemicals sium . 
( e . g . , lipid , lipids , lipid precursors , lipid precursor , oleo - 40 138 . The method of any one of embodiments 88 to 95 and 
chemicals , or oleochemical ) . 134 to 137 , wherein said growth medium comprises zinc . 
126 . The method of embodiment 125 , wherein said yeast cell 139 . The method of any one of embodiments 88 to 95 and 
comprising greater than 20 % wt / wt lipids , lipid precursors , 134 to 138 , wherein said growth medium comprises nickel . 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 140 . The method of any one of embodiments 88 to 95 and 
lipid precursor , oleochemicals , or oleochemical ) comprises 45 134 to 139 , wherein said growth medium comprises molyb 
greater than 30 % wt /wt lipids , lipid precursors , and / or denum . 
oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre - 141 . The method of any one of embodiments 88 to 95 and 
cursor , oleochemicals , or oleochemical ) in dry weight . 134 to 140 , wherein said growth medium comprises man 
127 . The method of embodiment 125 , wherein said yeast cell ganese . 
comprising greater than 20 % wt /wt lipids , lipid precursors , 50 142 . The method of any one of embodiments 88 to 95 and 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 134 to 141 , wherein said growth medium comprises copper . 
lipid precursor , oleochemicals , or oleochemical ) comprises 143 . The method of any one of embodiments 88 to 95 and 
greater than 40 % wt / wt lipids , lipid precursors , and / or 134 to 142 , wherein said growth medium comprises boron . 
oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre 
cursor , oleochemicals , or oleochemical ) in dry weight . 55 V . EXAMPLES 
128 . The method of embodiment 125 , wherein said yeast cell 
comprising greater than 20 % wt / wt lipids , lipid precursors , The following examples are meant to illustrate certain 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , embodiments of the invention and not to limit the scope of 
lipid precursor , oleochemicals , or oleochemical ) comprises the invention described herein . 
greater than 50 % wt / wt lipids , lipid precursors , and / or 60 
oleochemicals ( e . g . , lipid , lipids , lipid precursors , lipid pre A . MATERIALS AND METHODS 
cursor , oleochemicals , or oleochemical ) in dry weight . 
129 . The method of embodiment 125 , wherein said yeast cell B ase Strains and Media . 
comprising greater than 20 % wt / wt lipids , lipid precursors , E . coli strain DH10B was used for cloning and plasmid 
and / or oleochemicals ( e . g . , lipid , lipids , lipid precursors , 65 propagation . DH10B was grown at 37° C . with constant 
lipid precursor , oleochemicals , or oleochemical ) comprises shaking in Luria - Bertani Broth ( Teknova ) supplemented 
greater than 60 % wt / wt lipids , lipid precursors , and / or with 50 ug / ml of ampicillin for plasmid propagation . Yar 
79 
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rowia lipolytica strain PO1f ( ATCC # MYA - 2613 ) , a leucine induced in standard minimal ( YSC ) media . Thus , we con 
and uracil auxotroph devoid of any secreted protease activity firmed the beneficial effect of increasing C : N ratio towards 
( Madzak et al . , 2000 ) , was used as the base strain for all lipid ( e . g . triacylglyceride ) accumulation in non - engineered 
studies . Table 1 contains a list of Polf derivatives produced Y . lipolytica , so we sought to further improve oleo - content 
in this study . Y . lipolytica was cultivated at 30° C . with 5 with additional media supplementation . In particular , FeSO4 
constant agitation . 2 mL cultures of Y . lipolytica used in supplementation has been implicated in enabling increased 
large - scale screens were grown in a rotary drum ( CT - 7 , New citric acid accumulation in Y . lipolytica ( Kamzolova et al . 
Brunswick Scientific ) at speed seven , and larger culture 2003 ) , specifically under oxygen limiting conditions . Citric 
volumes were shaken in flasks at 225 rpm . acid and fatty acid accumulation are closely linked in Y . 
YSC media consisted of 20 g / L glucose ( Fisher Scien - 10 lipolytica , so we hypothesized that this iron - responsive citric 
tific ) , 0 . 79 g / L CSM supplement ( MP Biomedicals ) , and 6 . 7 acid accumulation could also increase downstream lipid 
g / L Yeast Nitrogen Base wlo amino acids ( Becton , Dickin - ( e . g . triacylglyceride ) accumulation . To fully analyze the 
son , and Company ) . YSC - URA , YSC - LEU , and YSC - LEU - potential benefits of micronutrient addition towards lipid 
URA media contained 0 . 77 g / L CSM - Uracil , 0 . 69 g / L ( e . g . triacylglyceride ) accumulation ( Song et al . 2012 ; Zhao 
CSM - Leucine , or 0 . 67 g / L CSM - Leucine - Uracil in place of 15 et al . 2008 ) , we cultivated Polf in minimal media supple 
CSM , respectively . YPD media contained 10 g / L yeast mented with cobalt , magnesium , potassium , zinc , manga 
extract ( Fisher Scientific ) , 20 g / L peptone ( Fisher Scientific ) nese , boric acid , molybdenum , nickel , iron , and copper 
and 20 g / L glucose , and was often supplemented with 300 ( FIG . 1 ) , and saw increased lipid ( e . g . triacylglyceride ) 
ug / ml Hygromycin B ( Invitrogen ) for knockout selection . accumulation with iron , nickel , copper , molybdenum , and 
Lipid accumulation response towards media formulation 20 zinc . We performed a combinatorial screening of iron , 
was investigated by cultivation in varying concentrations of nickel , copper , and molybdenum supplementation to detect 
glucose and nitrogen . These media formulations contained cumulative beneficial effects towards increasing cellular 
0 . 79 g / L CSM , 1 . 7 g / L Yeast Nitrogen Base w / o amino acid lipid content . Triple supplementation with copper , nickel , 
and wlo ( NH ) , SO . ( Becton , Dickinson , and Company ) , and iron increased lipid accumulation levels to the highest 
between 10 g / L and 320 g / L glucose , and between 0 . 04 g / L 25 observed at that time ( FIG . 2 ) . 
and 10 g / L ammonium sulfate ( NH4 ) 2SO4 ( Fisher Scien - Thus , manipulating media formulation effectively 
tific ) . These media are routinely referred to by their ratio of increased lipid formulation in a wildtype strain , however , the 
carbon content ( glucose ) to nitrogen content ( ammonium relationship between strain genotype and this effect has yet 
sulfate ) . For instance , media containing 80 g / L glucose and to be explored . We sought to determine if a strain rationally 
5 g / L ammonium sulfate is called Cso : N , media . When 30 engineered for increased lipid accumulation would benefit in 
utilizing alternative carbon sources , glucose was replaced by the same manner from increasing C : N ratio . In our initial 
80 g / L arabinose , 80 g / L fructose , 80 g / L galactose , 80 g / L attempts to engineer a Y . lipolytica strain for increased lipid 
glycerol ( Fisher Scientific ) , 80 g / L mannose , 80 g / L maltose accumulation , we overexpressed the AMPDp in a APEX10 
80 g / L ribose , 80 g / L sucrose ( Acros Organics ) , 80 g / L background to create a strain with a 17 - fold increase in nile 
Xylose , or 80 g / L of a saccharide mix resembling the 35 red fluorescence levels . To determine if genomic modifica 
composition of lignocellulosic biomass ( 57 % Glucose , 32 % tions could affect differential responses towards media 
Xylose , 5 % Arabinose , 3 % Mannose , and 3 % Galactose by induced lipid accumulation , we cultivated unmodified Polf 
weight ) . Solid media for E . coli and Yarrowia lipolytica was and our engineered high lipid producer in twenty media 
prepared by adding 20 g / L agar ( Teknova ) to liquid media formulations that varied in carbon and nitrogen levels ( Table 
formulations . 40 3 ) and analyzed for lipid content with nile red fluorescence 
When analyzing the effect of micronutrient supplemen - flow cytometry after two days , four days , and eight days . 
tation , CoCl , ( 15 mg / L ) , MgSO . ( 250 mg / L ) , KI ( 15 mg /L ) , Two days was insufficient time to induce lipid accumulation , 
ZnSO4 . 7H2O ( 20 mg / L ) , MnSO4 . H2O ( 12 . 5 mg / L ) , Boric while lipid accumulation is evident a majority of media 
acid ( 12 . 5 mg / L ) , ( NH ) , Mo . 4H , O ( 15 mg / L ) , NiSO4 . 6H2O formulation for the Polf APEX10 AMPDp overexpression 
( 12 . 5 mg / L ) , FeSO4 . 7H2O ( 20 mg /L ) , or CuSO4 ( 15 mg / L ) 45 strain after eight days . Heat graphs of relative fluorescent 
were added to the stated media formulation . Concentrations values illustrate that the PO1fAPEX10 AMPDp overexpres 
given are the final concentrations of the metal ion . sion strain accumulates lipids efficiently at an optimum 
Initial Optimization of Media Formulation for Wildtype value of 80 g / L glucose after 4 days , while Polf is only 
and Engineered Strains . slight induced in any condition , most noticeably after six to 
Nitrogen starvation is the accepted impetus for effecting 50 eight days in C160No . 2 media . In general , the 320 g / L glucose 
a state of lipid accumulation in oleaginous organisms ( Ra - condition is too high to induce lipid accumulation effec 
tledge 2002 ) . As a preliminary analysis of this induction tively , most likely because the high sugar content prevents 
potential , we selected seven media variations wildly variant cell growth . Likewise , formulations 0 . 04 and 0 . 2 g / L ammo 
in their ratios ' of carbon content ( glucose ) to nitrogen nium sulfate tend to poorly induce lipid accumulation , 
content ( ammonium sulfate ) to assay for their ability to 55 especially within four days or less . Finally , an optimum C : N 
induce lipid accumulation . These media formulations are ratio of ~ 10 to 40 can be observed when discounting these 
routinely referred to by this carbon to nitrogen ratio ( C : N highest glucose and lowest ammonium sulfate . 
ratio ) , i . e . , media containing 160 g / L glucose and 0 . 2 g / L 
ammonium sulfate is called C160 : No . 2 media . We cultivated B . CLONING AND TRANSFORMATION 
wildtype Y . lipolytica strain POlf in these seven media 60 PROCEDURES 
formulations and assayed for relative lipid ( e . g . triacylglyc 
eride ) accumulation using nile red fluorescence flow cytom - All restriction enzymes were purchased from New Eng 
etry after 2 , 4 , 6 , and 8 days . We observed a strong land Biolabs and all digestions were performed according to 
correlation between increasing carbon to nitrogen ratio and standard protocols . PCR reactions were set up with recom 
increased lipid ( e . g . triacylglyceride ) accumulation that 65 mended conditions using Phusion high fidelity DNA poly 
spanned a 10 - fold range , and we were able to increase nile merase ( Finnzymes ) , or Long Amp Taq DNA polymerase 
red fluorescence levels by three - fold compared to levels ( New England Biolabs ) . Ligation reactions were performed 
87 
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overnight at room temperature using T4 DNA Ligase ( Fer ( ACL2 ) , MEA1 , DGA1 , and DGA2 . This formed plasmids 
mentas ) . Gel extractions were performed using the Fermen - PUC - S1 - UAS1B16 - TEF - AMPD , PUC - S1 - UAS1B16 - TEF 
tas GeneJET extraction kit purchased from Fisher Thermo ACL1 , PUC - S1 - UAS1B16 - TEF - ACL2 , PUC - S1 - UAS1B16 
Scientific . E . coli minipreps were performed using the TEF - MEA1 , and PUC - S1 - UAS1B16 - TEF - DGA1 , and PUC 
Zyppy Plasmid Miniprep Kit ( Zymo Research Corporation ) . 5 S1 - UAS1B , 6 - TEF - DGA2 . The loxP - surrounded uracil 
E . coli maxipreps were performed using the Qiagen HiSpeed marker of these integrative plasmids was replaced with a 
Plasmid Maxi Kit . Transformation of E . coli strains was loxP - surrounded leucine marker to enable integrative selec 
performed using standard electroporator protocols ( Sam - tion with leucine auxotrophy and co - expression of two 
brook and Russell , 2001 ) . Large amounts of linearized DNA enzymes without marker retrieval . These leucine marker 
( > 20n ) , necessary for Y . lipolytica Polf transformation were 10 integrative plasmids were dubbed plasmids PUC - S2 
cleaned and precipitated using a standard phenol : chloroform UAS1B16 - TEF - AMPD , PUC - S2 - UAS1B16 - TEF - ACL1 , 
extraction followed by an ethanol precipitation ( Kirby , PUC - S2 - UAS1B16 - TEF - ACL2 , PUC - S2 - UAS1B16 - TEF 
1956 ) . MEA1 , and PUC - S2 - UAS1B16 - TEF - DGA1 , and PUC - S2 
Genomic DNA ( gDNA ) was extracted from Y . lipolytica UAS1B , 6 - TEF - DGA2 . 
using the Wizard Genomic DNA Purification kit ( Promega ) . 15 ACL1 and ACL2 were similarly inserted into PUC - S1 
Transformation of Y . lipolytica with replicative plasmids UAS1B16 - Leum with primers , respectively , to form plas 
was performed using the Zymogen Frozen EZ Yeast Trans - mids PUC - S1 - UAS1B16 - Leum - ACL1 and PUC - S1 
formation Kit II ( Zymo Research Corporation ) , with plating UAS1B16 - Leum - ACL2 . 
on YSC - LEU plates . Transformation of Y . lipolytica Polf Strain Construction . 
with linearized cassettes was performed as described previ - 20 All strains were confirmed through gDNA extraction and 
ously ( Blazeck et al . 2013a ) , with selection on appropriate PCR confirmation and are listed in Table 1 . We previously 
plates . All auxotrophic or antibiotic selection markers were constructed two markerless single - gene deletion strains in 
flanked with LoxP sites to allow for retrieval of integrated the Y . lipolytica PO1f background , PO1f - Amfel and PO1f 
markers the pMCS - UAS1B16 - TEF - Cre replicative vector Apex10 , deficient in their B - oxidation and peroxisomal bio 
( Blazeck et al . 2013a ) . 25 genesis capacity , respectively ( Blazeck et al . 2013a ) . Fol 
Plasmid Construction . lowing our previous protocol , the PEX10 gene was deleted 
Primer sequences can be found in the Table 2 . All Y . from strain PO1f - Amfel to form the markerless double 
lipolytica episomal plasmids were centromeric , replicative mutant Polf - Amfel - Apex 10 . These four strains , Polf , 
vectors derived from plasmid pS116 - Cen1 - 1 ( 227 ) ( Yamane PO1f - Amfel , PO1f - Apex10 , and PO1f - Amfel - Apex 10 were 
et al . 2008 ) after it had been modified to include a multi - 30 utilized as backgrounds for single and double overexpres 
cloning site , a hrGFP green fluorescent reporter gene sion of the AMPD , ACL1 , ACL2 , MEA , DGA1 , and DGA2 
( PIRES - hrGFP , Agilent ) driven by the strong UASIB , 6 - TEF genes , including variation in selective marker utilized , i . e . , 
promoter ( Blazeck et al . 2011 ) , and a cycl terminator ( Mum - leucine ( S2 integrative cassette or PMCS episomal cassette ) 
berg et al . 1995 ) to create plasmid PMCS - UAS1B16 - TEF vs . uracil ( Si integrative cassette ) . S2 and Si integrative 
hrGFP . Integrative plasmids were derived from plasmids 35 cassettes were linearized , transformed into our four back 
PUC - S1 - UAS1B16 - Leum or PUC - S1 - UAS1B16 - TEF ground strains , and selected for on appropriate dropout 
( Blazeck et al . 2013a ) that contained 5 ' and 3 ' rDNA plates . Table 1 contains a list of rationally engineered strains 
integrative sequences surrounding the following elements derived in this manner . ORF - less plasmids PUC - S1 
( from 5 ' to 3 ' ) a uracil section marker surrounded by LoxP U AS1B , 6 - TEF and PUC - S1 - UAS1B16 - TEF were utilized to 
sites for marker retrieval , the strong UAS1B16 - Leum or 40 create strains lacking leucine , uracil , or both leucine and 
UAS1B16 - TEF promoter , Asch and Pad restriction enzyme uracil auxotrophies , dubbed S1 - 0 , S2 - Ø , and S1 - S2 - 0 
sites for gene insertion , and a XPR2 minimal terminator . ( Table 1 ) . 
These integrative plasmids were also designed to contain Combinatorial Genome Engineering . 
two identical Noti restriction enzyme sites directly outside Prior engineering efforts have successfully increased lipid 
of the rDNA regions so that plasmid linearization would 45 accumulation in Y . lipolytica by manipulating fatty acid , 
simultaneously remove E . coli pUC19 - based DNA . All lipid , or central carbon metabolism , but no attempt has been 
plasmids containing expression cassettes were sequenced made to simultaneously alter these metabolic functionalities 
confirmed before transformation into Y . lipolytica . ( Beopoulos et al . 2008 ; Dulermo and Nicaud 2011 ; Tai and 
Construction of Episomal Expression Cassettes : Stephanopoulos 2013 ) . We sought to concurrently control 
The following genes were PCR amplified from Y . 50 these aspects of lipid synthesis by overexpressing three 
lipolytica Polf gDNA and inserted into vector pMCS - enzymes that control metabolic flux from central carbon 
UASIB - TEF - hrGFP in place of hrGFP with an Ascl / Pacl metabolism into fatty acid synthesis ( AMPDp , ACLp , and 
digest : AMPD , ACL subunit 1 ( ACL1 ) , ACL subunit 2 MEAlp ) or two isozymes that control lipid synthesis 
( ACL2 ) , MEA1 , DGA1 , DGA2 , the Tupl general transcrip - ( DGAlp and DGA2p ) in four genomic backgrounds with 
tional repressor ( Morin et al . 2011 ) , and the HAC1 basic 55 altered fatty acid catabolic ability . These four genomic 
leucine zipper transcription factor involved in unfolded backgrounds included the Polf ( WT ) strain , a PO1f MFE1 
protein response ( Morin et al . 2011 ) with primers , respec deletion strain ( AMFE1 ) , a Polf PEX10 deletion strain 
tively . This formed plasmids pMCS - UAS1B16 - TEF - AMPD , ( APEX10 ) , and a MFE1 PEX10 double knockout strain 
PMCS - UAS1B16 - TEF - ACL1 , PMCS - UAS1B16 - TEF ( APEX10AMFE1 ) . The majority of enzymatic overexpres 
ACL2 , PMCS - UAS1B16 - TEF - MEA , PMCS - UAS1B16 - 60 sions were driven by the high strength UAS1B16 - TEF 
TEF - DGA1 , PMCS - UAS1B16 - TEF - DGA2 , PMCS constitutive promoter ( Blazeck et al . 2011 ) , were integrated 
UAS1B16 - TEF - TUP1 , and pMCS - UAS1B16 - TEF - HAC1 . into Y . lipolytica ' s genomic rDNA repeats ( Blazeck et al . 
Construction of Integrative Expression Cassettes : 2013a ; Ledall et al . 1994 ) , and alleviated either PO1f s uracil 
The following genes were gel extracted from the previ - or leucine auxotrophy . In our previous work , we noticed that 
ously constructed episomal expression vectors and inserted 65 alleviation of the leucine auxotrophy tended to increase lipid 
into vector PUC - S1 - UAS1B16 - TEF with an AscI / PacI ( e . g . triacylglyceride ) accumulation far more than allevia 
digest : AMPD , ACL subunit 1 ( ACL1 ) , ACL subunit 2 tion of the uracil auxotrophy . Therefore , nearly identical 
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strains were routinely created differing only in the marker During bioreactor runs , these strains are able to produce 
utilized to integrate an enzymatic overexpression cassette , significant amounts of lipids and cells exhibit 88 % by dry 
enabling either uracil synthesis ( S1 ) or leucine synthesis cell weight lipids . Improved lipid production with one of the 
( S2 ) . Initial overexpressions of the DGAlp and DGA2p highest producing strains , APEX10AMFE1 - S1 - S2 - DGA1 in 
enzymes occurred episomally with an identical UAS1B16 - 5 a bioreactor . Lipid levels have reached 22 g / L in media 
TEF promoter on a leucine - marker containing plasmid , containing only 80 g / L glucose , 5 g / L ammonium sulfate , 
though final strain construction entailed integrating these and 1 . 7 g / L Yeast Nitrogen Base ( without amino acids or 
cassettes . Strain names included background ( WT , AMFEL , ammonium sulfate ) . Increasing dissolved oxygen content 
APEX10 , or APEX10AMFE1 ) , markers used ( S1 , S2 , S1 - S2 , and maintaining pH at or above 5 . 0 enabled this yield . This 
or pMCS ) , and enzymes overexpressed ( AMPD , MEA , " represents - 86 % of the theoretical yield . Furthermore , in 
ACL1 , ACL2 , DGA1 , DGA2 ) so a strain overexpressing the these strains , we identify the presence of unique C17 fatty 
AMPDp enzyme with a leucine marker in the 
????10??FE1 background is called ????10??FE1 Complex control of cellular processes , like lipid accumu 
S2 - AMPD . S1 - Ø , S2 - 0 , and S1 , 2 - Ø refer to strains without 15 lation , is coordinated by transcription factors that regulate 
protein overexpressions but with uracil , leucine , or uracil + gene networks . In particular , the Tupl general transcriptional 
leucine auxotrophies alleviated . ACL1p and ACL2p form a repressor and the Had leucine zipper transcription factor 
heterodimer in vivo so were tested as concurrent overex - involved in unfolded protein response have been shown to 
pressions . be upregulated in lipid ( e . g . triacylglyceride ) accumulation 
Our combinatorial approach generated over 46 distinct 20 cell states ( Morin et al . 2011 ) . However , overexpression of 
genotypes that were analyzed for lipid ( e . g . triacylglyceride ) these two proteins decreased lipid ( e . g . triacylglyceride ) 
accumulation with nile red fluorescence flow cytometry after accumulation in the Polf WT background . 
four days growth in CsoN , media and produced a large range Dissection of Genotype - Dependence Towards Media 
in lipid ( e . g . triacylglyceride ) accumulation ability , culmi - Induction . 
nating in a 60 - fold improvement over PO1f WT control 25 We more fully examined how C : N ratio and genotype 
( FIG . 3 ) . We saw that the deletion of the pex 10 peroxisomal interacted towards enabling lipid ( e . g . triacylglyceride ) 
biogenesis transcription factor combined with overexpres - accumulate on a larger scale by examining the response of 
sion of a acyl - CoA : diacylglycerol acyltransferase ( DGA1 or twelve strains grown in thirteen different C : N ratios ( Table 
DGA2 ) are essential for the highest lipid ( e . g . triacylglyc - 5 ) . We were pleased to observe a strong tendency towards 
eride ) production ( FIG . 3 ) . When comparing ammonia 30 high lipid ( e . g . triacylglyceride ) levels in most high produc 
depletion in Polf WT and our highest lipid producer e rs at a single media formulation CeN , ( FIG . 5 - 8 ) , allow 
APEX10AMFE1 PMCSDGA1 , we observed a pronounced ing us to pinpoint a formulation for later use . Two trends 
reduction in steady state nitrogen concentration in the stand out ( 1 ) The 0 . 2 g / L ammonium sulfate formulations 
APEX10AMFE1 PMCSDGA1 strain . We saw a very notice - rarely enable lipid ( e . g . triacylglyceride ) accumulation , so 
able correlation between the ability to synthesize leucine and 35 that ( 2 ) the difference in induction from media containing 1 
lipid ( e . g . triacylglyceride ) accumulation ability , with an g / L and 5 g / L is slight , making glucose concentration seem 
average increase of five fold in lipid content between more important towards increasing content than nitrogen 
comparable strains with and without a leucine marker pres content ( after a certain threshold is reached ) . 
ent ( FIG . 4 ) . Deletion of mfel drastically reduced this Lipid Accumulation on Multiple Carbon Sources . 
increase in lipid ( e . g . triacylglyceride ) content . AMFE1 and 40 Viability of lipid ( e . g . triacylglyceride ) production 
APEX10AMFE1 saw only a 1 . 42 fold and 2 . 58 fold depends on the capacity to fully convert all sugars from 
increases in lipid ( e . g . triacylglyceride ) content granted from lignocellulosic biomass to lipids or to use carbon from 
the capacity to synthesize leucine compared to 8 . 16 and 7 . 45 industrial waste streams for lipid production . We analyzed 
fold increases in WT and APEX10 backgrounds ( FIG . 4 ) . In the ability PO1f WT , APEX10 S1 - MEA , APEX10 
three of our four backgrounds , DGAlp outperformed 45 S2 - AMPD , APEX10AMFE1 S2 - DGA1 , and APEX10AMFE 
DGA2p ( FIG . 3 ) ; WT PMCSDGA2 was not included , but PMCSDGA1 to generate lipids ( e . g . triacylglyceride ) when 
subsequent testing showed WT PMCSDGA1 to give higher utilizing glucose , glycerol , Xylose , fructose , mannose , 
lipid ( e . g . triacylglyceride ) levels than WT PMCSDGA2 . ribose , sucrose , or a lignocellulosic sugar blend as their 
Overall , fluorescence levels were highest in the APEX10 and carbon source ( FIG . 9 ) . APEX10AMFE1 S2 - DGA1 and 
APEX10AMFE1 backgrounds ( ~ 3 - fold WT ) , and lowest in 50 APEX10AMFE1 PMCSDGA1 generated the highest lipid 
the AMFE1 background ( ~ 65 % of WT ) , although mfel ( e . g . triacylglyceride ) content across the board under con 
deletion has been shown to increase lipid ( e . g . triacylglyc ditions tested , and all engineered strains demonstrated the 
eride ) accumulation in media containing higher C : N ratio in capacity to utilize each carbon source for lipid ( e . g . triacyl 
eight day cultivation periods ( Blazeck et al . 2013a ) . Because glyceride ) production . Glucose , mannose , and the lignocel 
mfel deletion should further inhibit fatty acid degradation in 55 lulosic saccharide blend were utilized easiest while ribose 
the APEX10AMFE1 background in long - scale fermenta utilizations generated the least lipid ( e . g . triacylglyceride ) 
tions , the DGA1p was integrated into the APEX10AMFE1 content of the conditions tested . The Polf WT and 
background with S2 cassette and a S1 - Ø to form our final APEX10AMFE1 S2 - DGA1 strain were tested to determine if 
fully heterotrophic rationally engineered strain . This decreasing carbon content or increasing initial inoculum 
APEX10AMFE1 S1 - S2 - DGA1 strain displayed similar lipid 60 amount could increase xylose - generate lipid ( e . g . triacyl 
( e . g . triacylglyceride ) content to strains containing episo - glyceride ) accumulation . Increasing xylose concentration 
mally expressed DGAlp and could accumulate lipids ( e . g . and decreasing inoculum amount increased lipid ( e . g . tria 
triacylglyceride ) effectively without any amino acid supple cylglyceride ) content in the APEX10AMFE1 S2 - DGA1 
mentation ( Table 4 ) and yielded are highest % lipid ( e . g . strain , while little difference was noticeable in the PO1f WT 
triacylglyceride ) content of 32 % dry cell weight for a total 65 strain . However , PO1fWT demonstrated a surprising capac 
of 1 . 32 g / L . Furthermore , we saw no significant difference ity to utilize pure glycerol for lipid ( e . g . triacylglyceride ) 
in LEU3 or DGA1 mRNA levels between these two strains . generation . 
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Isolation of a Novel MGA2 Mutation with Whole Y . lipolytica strains were routinely inoculated from glycerol 
Genome Sequencing . stock in biological triplicate in appropriate media for 72 
During the screening of a gDNA overexpression library hours at 30° C . with shaking Cell concentrations were intended to increase Y . lipolytica ' s lipid ( e . g . triacylglycer normalized to a specific OD600 for reinoculation in fresh ide ) production , we isolated a strain , dubbed L36 , with 5 media and further incubation . In general , 2 mL cultures were incredible lipid ( e . g . triacylglyceride ) accumulation ability inoculated to an ODon = 2 . 5 , and larger volume cultures ( FIG . 10 ) . L36 ' s lipid ( e . g . triacylglyceride ) production 
could be enhanced with micronutrient supplementation were inoculated to an OD600 = 0 . 1 . Cultures were incubated 
( FIG . 10 ) . Complete sequencing of the L36 genome revealed for two to eight days at 30° C . with constant agitation . 2 mL 
a missense mutation in the MGA2 lipid synthesis regulator cultures were incubated in a rotary drum ( CT - 7 , New Bruns 
( MGA2G643R ) as the most likely potential cause for L36 ' s 6 ' s 10 wick Scientific ) at speed seven and flasks were shaken at 225 
lipid ( e . g . triacylglyceride ) production capacity . Overex rpm in a standing incubator . To harvest , one OD600 unit of 
pression of a truncated MGA2p in a PO1f WT background each cultures was spun down at 1000 g for three minutes and 
reconstituted 58 % of the observed L36 phenotype . resuspended in 500 uL Phosphate Buffered Saline solution 
Directed Evolution with EMS Mutagenesis to Increase ( PBS ) ( Sigma Aldrich ) . 6 uL of 1 mM Nile Red ( dissolved 
Lipid Accumulation 15 in DMSO ) was added , and then cells were incubated in the 
Direct evolution is commonly utilized to increase growth dark at room temperature for 15 minutes . Cells were spun 
rate or to decrease sensitivity to a toxic metabolite . How down at 1000 g for three minutes , resuspended in 800 uL ice 
ever , directed evolution has never been evaluated as a tool cold water , spun down again , and resuspended again in 800 
to increase lipid ( e . g . triacylglyceride ) production in oleagi uL ice cold water . 300 uL of stained cells were added to 1 
nous organisms . As evidenced by the isolation of strain L36 , 20 ml ice cold water and tested with a FACS Fortessa ( BD 
it is likely that Y . lipolytica is amenable to this approach . We Biosciences ) , a voltage of 350 , a 10 , 000 cell count , a 
subjected both L36 ( FIG . 11 ) and APEX10AMFE1 forward scatter of 125 , a side scatter of 125 , and the 535LP S2 - DGA1 to EMS mutagenesis followed by serial selection and 585 / 42BP filters for fluorescence detection using the via subculturing and then nile red staining . Both back GFP fluorochrome . Samples were kept on ice and in the dark grounds proved highly responsive towards the directed 25 25 during the test and the data was analyzed using Flow Jo evolution approach , and an increase in fluorescence with a software ( Tree Star Inc . , Ashland , Oreg . ) to compute mean large increase in final cell concentration ( Table 6 ) . 
Besides the minerals , during the experiments , we also fluorescence values . Day - to - day variability was mitigated by 
observed a critical phenotype for lipid ( e . g . triacylglyceride ) analyzing all comparable strains on the same day . An 
production in Yarrowia lipolytica : the lipid ( e . g . triacylglyc average fluorescence and standard deviation were calculated 
eride ) de novo lipid ( e . g . triacylglyceride ) accumulation is 30 
close related to leucine biosynthesis pathway . A 5 fold lipid were routinely examined with fluorescence microscopy 
( e . g . triacylglyceride ) level increase was achieved with under a 100x oil immersion objective using the FITC 
strain harboring complete LEU biosynthesis pathway com channel on an Axiovert 200M microscope ( Zeiss ) . 
paring to the one without complete pathway . Although this 
phenotype has been reported with engineered Saccharomy - 35 D . LIPID QUANTIFICATION AND FATTY ACID 
ces cerevisiae ( Kamisaka et al . 2007 ) , this is the first PROFILE ANALYSIS 
observation in oleaginous yeast to our best knowledge . 
Understanding of this phenotype could be essential to under Lipids from ~ 20 - 30 OD600 equivalents were extracted 
stand the basic differences between oleaginous microbes and following the procedure described by ( Folch et al . 1957 ) and 
normal ones . However , to the date , the fundamental reason 40 modified for yeast ( Schneiter and Daum 2006 ) . Dried lipids 
is still missing . Two possible routes may contribute to this , were transesterified with N - tert - Butyldimethylsilyl - N - meth 
one is through TOR pathway ( Kim and Guan 2011 ; Laplante yltrifluoroacetamide ( Sigma - Aldrich ) following the proce 
and Sabatini 2009 ) and the other one is through leucine dure of ( Paik et al . , 2009 ) , and 2 uL samples were injected 
degradation and ketone body generation ( Endemann et al . into a GC - FID ( Agilent Technologies 6890 Network GC 
1982 ) . Either pathway heavily interacts with the whole cell 45 System ) equipped with an Agilent HP - 5 column ( 5 % phe 
metabolism which requires deep analysis to reveal the true nyl - 95 % methylsiloxane product number 19091J - 413 ) to 
mechanism behind . analyze fatty acid fractions . Briefly , the following settings 
Engineering with Known : Biosynthesis pathways and were used : Detector Temp = 300° C . , He Flow = 1 . 0 mL / min , 
basic regulations . Rational systematic engineering Yarrowia Oven Temp = 80° C . for 2 min , increased at 30° C . / min to 
lipolytica for high lipid production . Engineering with 50 200° C . , increased at 2° C . / min to 229° C . , increased at 1° 
Unknown : Pathway interactions and complex regulation C . / min to 232° C . , increased at 50° C . / min to 325° C . Fatty 
networks . Engineering lipid production in Yarrowia acid standards for C16 : 0 palmitic acid , C16 : 1 ( n - 7 ) palmi 
lipolytica through Inverse combinatorial metabolic Engi - toleic acid , C18 : 0 stearic acid , C18 : 1 ( n - 9 ) oleic acid , and 
neering . Confirmed lipid enhancers include DGA1 ( Diacyl - C18 : 2 ( n - 6 ) linoleic acid were purchased from Sigma 
glycerol acyltransferase ) 300 % improvement , MRM2 ( Mi - 55 Aldrich , transesterified , and analyzed by GC to identify fatty 
tochondrial 2 O - ribose methyltransferase ) 25 % acid peaks . 
improvement , MGMT ( 0 - 6 - methylguanine - DNA methyl 
transferase ) 15 % improvement . E . CITRIC ACID QUANTIFICATION 
C . FATTY ACID CHARACTERIZATION BY 60 A 2 mL culture sample was pelleted down for 5 minutes 
NILE RED STAINING COUPLE WITH FLOW at 3000xg , and the supernatant was filtered using a 0 . 2 mm 
CYTOMETRY OR FLUORESCENCE syringe filter ( Corning Incorporated ) . Filtered supernatant 
MICROSCOPY was analyzed with a HPLC Ultimate 3000 ( Dionex ) and a 
Zorbax SB - Aq column ( Agilent Technologies ) . A 2 . 0 uL 
Nile Red is commonly utilized to stain oleaginous cellular 65 injection volume was used in a mobile phase composed of 
material , and can be coupled with fluorescence flow cytom - a 99 . 5 : 0 . 5 ratio of 25 mM potassium phosphate buffer 
etry to gauge relative lipid content ( Greenspan et al . 1985 ) . ( pH = 2 . 0 ) to acetonitrile with a flow rate of 1 . 25 mL / min . 
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The column temperature was maintained at 30° C . and SnpSift with QUAL > = 30 ( Pablo , Viral et al . 2012 ) The 
UV - Vis absorption was measured at 210 nm . A citric acid SNPs identified from Polf , EMS26 and EMS13 were com 
standard ( Sigma - Aldrich ) was used to detect and quantify pared to extract the authentic SNPs in EMS26 and EMS13 . 
citric acid production . The identified SNPs were then visualized in the IGV genome 
5 visualization software to validate as well as study the 
F . EMS MUTAGENESIS AND ISOLATION OF location of the SNPs in the genome due to the high false 
HIGH LIPID PRODUCING STRAINS error rate in SNP calling process ( Liu , Guo et al . 2012 ) . Information on identified targets in E26 and E13 strains 
following mutagenesis . Succinate semialdehyde dehydroge 
10 OD units from cultures grown overnight were spun nase ( SSADH ) , which coverts succinate semialdehyde to 
down in sterile microcentrifuge tubes at 5000 g for 10 " succinate after UGA1 , 4 - aminobutyrate aminotransferase , 
seconds . Cell pellets were resuspended in 1 mL H2O , deaminates GABA to succinate ( Ramos , El Guezzar et al . 
repelleted , and resuspended in 1 mL PBS . Two samples were 1985 ) . Higher levels of accumulation of a - ketoglutarate 
spun down from each culture , one for EMS mutagenesis ( 30 were found in uga2 mutants in Saccharomyces cerevisiae 
ul of EMS added ) and one as a control to determine the ( Cao , Barbosa et al . 2013 ) ( 3VZ1 ; 3VZ3 ) . In the same time , 
prevalence of spontaneous beneficial mutation ( no EMS 1 mutation ( no EMS 15 lower levels of succinic acid ( more than 5 fold decrease ) were also identified in the yeast ( Kamei , Tamura et al . 2011 ) . added ) . Cells were incubated for 1 hr at 30° C . , with The identified mutation in UGA2 in sequenced strains of agitation , pelleted and resuspended in 200 ul of 5 % sodium Proline 209 is a highly conserved residual and close to a thiosulfate , transferred to fresh microcentrifuge tubes , hydrogen bond forming Serine ( Yuan , Yin et al . 2013 ) . 
washed twice in 200 ul of 5 % sodium thiosulfate , and 20 GABA metabolism is closely related to nitrogen assimilation 
resuspended in 1 mL H , O . Cells were then grown to in yeast and nitrogen limitation has been studied as a key 
stationary phase in YSC media , and then reinoculated at an function for triggering lipogenesis in Yarrowia lipolytica 
OD600 = 2 . 5 in 1 mL C80N5 media and grown for four days . ( Beopoulos , Cescut et al . 2009 ) . Nitrogen sources have also 
Three to six serial transfers of the cell cultures followed in been proven as an important factor for lipid accumulation 
which the 1 mL cultures were spun down at 1000 g for two 25 inside cells ( Evans and Ratledge 1984 ) . A relationship 
minutes , and the top 200 uL of the supernatant was trans - between GABA metabolism and the TOR pathway , an 
ferred to 1 mL of fresh YSC media and allowed to grow to important signaling pathway for lipid accumulation 
stationary phase before again spinning down and transfer ( Blazeck , Hill et al . 2014 ) , has also been suggested ( Carde 
ring . Final cultures ( top 200 uL after spin down ) were plated nas , Cutler et al . 1999 ; Staschke , Dey et al . 2010 ) . 
on YSC plates containing 0 . 01 mM Nile Red . After four 30 YALIOE17215 g codes for a protein with similarity to 
days , high lipid producers were selected by viewing plates Saccharomyces cerevisiae RME1 , which is a zinc finger 
under a blue fluorescent light and picking colonies with protein involved in the control of meiosis ( Covitz , Herskow 
brighter pink fluorescent color . Lipid amount was deter - itz et al . 1991 ) . A similar protein has shown significant levels 
mined by coupling Nile Red staining with flow cytometry as of increase in mRNA levels in a lipid accumulation - im 
described above . 35 proved snfl mutant in Yarrowia lipolytica ( Xue , Sharpe et al . 
The EMS mutagenesis procedures were performed fol - 2013 ) . YALIOE20449p shows limited similarity to known 
lowing the protocol described by Winston ( Winston 2001 ) . protein sequences except the homeodomain , a DNA binding 
Briefly , an overnight culture was cultivated to OD about 10 . domain involved in the transcriptional regulation of key 
Cells were then harvested , washed and resuspended with 0 . 1 eukaryotic developmental processes , which shows similari 
M sodium phosphate buffer ( pH 7 ) . 30 ul of EMS were 40 ties . Mutation V289G in YALIOE20449p exists outside of 
added and incubated with unmutagenized control for 1 hr at the homeodomain . S . cerevisiae homeodomain protein yoxl 
30° C . , with agitation . The cells were then washed with 5 % is able to bind leucine - tRNA ( Kaufmann 1993 ) and leucine 
sodium thiosulfate and ready for serial transfer experiments tRNA synthase plays an important role ( Han , Jeong et al . 
to enrich the high lipid population . The EMS treated cells 2012 ) in the TOR pathway . Leucine has been suggested to 
and unmutagenized cells were first cultured YSC media for 45 be a critical lipid production enhancer ( Blazeck , Hill et al . 
72 hours and then cultured in high glucose media with 2014 ) . Recently , IRC20 containing a Snf2 / Swi2 family 
starting OD at 2 . 5 for 96 hours . The cells were centrifuged ATPase / helicase and a RING finger domain , has been shown 
down with 100 g , the unclear supernatant , which contains to be an E3 ubiquitin ligase ( Richardson , Gardner et al . 
high lipid accumulation strains , was used as seed for another 2013 ) as well as a putative helicase . OSH6 overexpression 
round of cultivation . After five rounds of transfer , the cells 50 has shown lifespan extension effect on yeast by increasing 
were plated on Nile Red YSC plate to facilitate the isolation vacuole fusion and may relate to TORC ( Gebre , Connor et 
of high lipid production strains . Individual colonies were al . 2012 ) . 
picked from the EMS treated cells as well as unmutagenized 
cells for characterization . G . REFERENCES 
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TABLE 1 
List of select strains used in this study 
Reference or 
Source Host Strain Name Genotype 
Escherichia coli strains 
DH10B Open Biosystems F - mcrA A ( mrr - hsdRMS - mcrBC ) 980d / acZAM15 
AlacX74 endAl recAl deoR A ( ara , leu ) 7697 
araD139 galu galK nupG rpsL À 
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TABLE 1 - continued 
List of select strains used in this study 
Reference or 
Source Host Strain Name Genotype 
Yarrowia lipolytica base strains 
WT ( PO1f ) Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 Madzak et al . 
2000 
Blazeck et al . 2013 AMFE1 ( PO1f - Amfel ) 
APEX10 ( PO1f - Apex10 ) Blazeck et al . 2013 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Aacol 
Selected Yarrowia lipolytica overexpression strains 
APEX10AMFE1 ( PO1f 
Apex 10 - Amfel ) 
AACO1 ( PO1f - Aacol ) 
This work 
This work 
WT -S1 - 0 This work 
WT -S2 - 0 This work 
WT -S1 - S2 - 0 This work 
WT -pMCS This work 
WT - PMCS - TUP1 This work 
WT - PMCS - HACI This work 
WT -S1 - AMPD This work 
WT -S2 - AMPD This work 
WT - S1 - MEA1 This work 
WT -S2 - MEA1 This work 
WT -S1 - S2 - AMPD - MEA1 This work 
WT -PMCS - DGA1 This work 
AMFE1 - S1 - 0 This work 
AMFE1 - S2 - 0 This work 
AMFE1 - S1 - S2 - 0 This work 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
URA3 ( S1 ) 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
LEU2 ( S2 ) 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
URA3 , LEU2 ( S1 , S2 ) 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
LEU2 ( PMCS ) 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
LEU2 ( PMCS ) , UAS1B16 - TEF - TUP1 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
LEU2 ( PMCS ) , UAS1B16 - TEF - HAC1 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
URA3 ( S1 ) , UAS1B16 - TEF - AMPD 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
LEU2 ( S2 ) , UAS1B16 - TEF - AMPD 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
URA3 ( S1 ) , UAS1B16 - TEF - MEA1 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
LEU2 ( S2 ) , UAS1B16 - TEF - MEAL 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
URA3 , LEU2 ( S1 , S2 ) , UAS1B16 - TEF - AMPD , 
UAS1B16 - TEF - MEA1 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
LEU2 ( PMCS ) , UAS1B16 - TEF - DGA1 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , URA3 ( S1 ) 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , LEU2 ( S2 ) 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , URA3 , LEU2 ( S1 , S2 ) 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , URA3 ( S1 ) , UAS1B16 - TEF - AMPD 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , LEU2 ( S2 ) , UAS1B16 - TEF - AMPD 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , URA3 ( S1 ) , UAS1B16 - TEFMEA1 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , LEU2 ( S2 ) , UAS1B16 - TEF - MEA1 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , URA3 , LEU2 ( S1 , S2 ) , UAS1B16 - TEF 
AMPD , UAS1B16 - TEF - MEAL 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , URA3 , LEU2 ( S1 , S2 ) , UAS1B16 - TEF 
ACL1 , UAS1B16 - TEF - ACL2 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , LEU2 ( PMCS ) , UAS1B16 - TEF - DGA1 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , LEU2 ( PMCS ) , UAS1B16 - TEF - DGA2 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , URA3 ( S1 ) 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , LEU2 ( S2 ) 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , URA3 , LEU2 ( S1 , S2 ) 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , URA3 ( S1 ) , UAS1B16 - TEF - AMPD 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , LEU2 ( S2 ) , UAS1B16 - TEF - AMPD 
MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , URA3 ( S1 ) , UAS1B16 - TEFMEA1 
AMFE1 - S1 - AMPD This work 
AMFE1 - S2 - AMPD This work 
AMFE1 - S1 - MEA1 This work 
AMFE1 - S2 - MEA1 This work 
AMFE1 - S1 - S2 - AMPD - MEAL This work 
AMFE1 - S1 - S2 - ACL1 - ACL2 This work 
AMFE1 - pMCS - DGA1 This work 
AMFE1 - PMCS - DGA2 This work 
APEX10 - S1 - 0 This work 
APEX10 - S2 - 0 This work 
APEX10 - S1 - S2 - 0 This work 
APEX10 - S1 - AMPD This work 
APEX10 - S2 - AMPD This work 
APEX10 - S1 - MEA1 This work 
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TABLE 1 - continued 
List of select strains used in this study 
Reference or 
















APEX10 - S2 - MEAL Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , LEU2 ( S2 ) , UAS1B16 - TEF - MEAL 
APEX10 - S1 - S2 - AMPD - MEA1 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , URA3 , LEU2 ( S1 , S2 ) , UAS1B16 - TEF 
AMPD , UAS1B16 - TEF - MEAL 
APEX10 - pMCS - DGA1 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , LEU2 ( PMCS ) , UAS1B 16 - TEF - DGA1 
APEX10 - pMCS - DGA2 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , LEU2 ( PMCS ) , UAS1B 16 - TEF - DGA2 
APEX10AMFE1 - S1 - MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , URA3 ( S1 ) 
APEX10AMFE1 - S2 - Ø MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , LEU2 ( S2 ) 
APEX10AMFE1 - S1 - S2 - Ø MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , URA3 , LEU2 ( S1 , S2 ) 
APEX10AMFE1 - S1 - AMPD MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , URA3 ( S1 ) , UAS1B16 - TEF 
AMPD 
APEX10AMFE1 - S2 - AMPD MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , LEU2 ( S2 ) , UAS1B16 - TEF 
AMPD 
APEX10AMFE1 - S1 - MEA1 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , URA3 ( S1 ) , UAS1B16 - TEFMEA1 
APEX10AMFE1 - S2 - MEAL MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , LEU2 ( S2 ) , UAS1B16 - TEF 
MEA1 
APEX10AMFE1 - S1 - S2 - AMPD - Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
MEA1 Apex10 , Amfel , URA3 , LEU2 ( S1 , S2 ) , UAS1B16 
TEF - AMPD , UAS1B16 - TEF - MEA1 
APEX10AMFE1 - S1 - S2 - ACL1 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
ACL2 Apex10 , Amfel , URA3 , LEU2 ( S1 , S2 ) , UAS1B16 
TEF - ACL1 , UAS1B16 - TEF - ACL2 
APEX10AMFE1 - pMCS - DGA1 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , LEU2 ( PMCS ) , UAS1B16 - TEF 
DGA1 
APEX10AMFE1 - PMCS - DGA2 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , LEU2 ( PMCS ) , UAS1B16 - TEF 
DGA2 
APEX10AMFE1 - S2 - DGA1 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , LEU2 ( S2 ) , UAS1B16 - TEF - DGA1 
APEX10AMFE1 - 51 - 0 - S2 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
DGAL Apex10 , Amfel , URA3 ( S1 ) , LEU2 ( S2 ) , 
UAS1B16 - TEF - DGA1 
APEX10AMFE1 - S1 - AMPD - S2 Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
DGA1 Apex10 , Amfel , URA3 ( S1 ) , LEU2 ( S2 ) , 
UAS1B16 - TEF - AMPD , UAS1B16 - TEF - DGA1 
APEX10AMFE1 - S1 - MEA1 - S2 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
DGA1 Apex10 , Amfel , URA3 ( S1 ) , LEU2 ( S2 ) , 
UAS1B16 - TEF - MEAI , UAS1B16 - TEF - DGA1 
APEX10AMFE1 - S1 - DGA1 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , URA3 ( S1 ) , UAS1B16 - TEF - DGA1 
WT -S2 - DGA1 Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Leu2 ( S2 ) , UAS1B16 - TEF - DGA1 
APEX10AMFE1 - S1 - DGA1 Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , URA3 ( S1 ) , UAS1B16 - TEF - DGA1 
APEX10 - S2 - DGA1 Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , LEU2 ( S2 ) , UAS1B16 - TEF - DGA1 
WT - PMCS - DGA2 Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
LEU2 ( PMCS ) , UAS1B16 - TEF - DGA1 
APEX10AMFE1 - S1 - DGA1 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , URA3 , UAS1B16 - TEF - DGA1 
AMFE1 - S2 - DGA1 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , LEU2 ( S2 ) , UAS1B16 - TEF - DGA1 
AMFE1 - S2 - DGA2 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Amfel , LEU2 ( S2 ) , UAS1B16 - TEF - DGA2 
APEX10AMFE1 - S1 - Ø - pMCS MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
DGA1 Apex10 , Amfel , URA3 ( S1 ) , LEU2 ( PMCS ) , 
UAS1B 16 - TEF - DGA1 
Polf PMCSMga2 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 
LEU2 ( PMCS ) , UAS1B16 - TEF - Mga2 
Polf PMCSMga2dTM MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 
LEU2 ( PMCS ) , UAS1B16 - TEF - Mga2dTM 
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TABLE 1 - continued 
List of select strains used in this study 
Reference or 
Source Host Strain Name Genotype 
Polf PMCSMga2L36 This work 
Polf PMCSMRM2 This work 
Polf PMCSO6M 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 
LEU2 ( PMCS ) , UAS1B16 - TEF - Mga2L36 ( has 
SNP found in L36 strain ) 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
LEU2 ( PMCS ) , UAS1B 16 - TEF - MRM2 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
LEU2 ( PMCS ) , UAS1B 16 - TEF - O6M 
Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Aaco1 , URA3 ( S1 ) , LEU2 ( S2 ) , UAS1B16 - TEF 
DGA1 
L36 and EMS derived strains 
This work 







L36 MatA , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
LEU2 ( PMCS ) - isolated and fully sequenced to 
determine source of high lipid accumulation - 
most likely from mutation in MGA2 ORF . 
L36 E1S6 - 4 L36 strain mutagenized further with EMS 
L36 E186 - 5 L36 strain mutagenized further with EMS 
L36 E1S6 - 6 L36 strain mutagenized further with EMS 
APEX10AMFE1 - S2 - DGA1 E1 APEX10AMFE1 - S2 - DGA1 strain mutagenized 
with EMS 
APEX10AMFE1 - S2 - DGA1 E6 APEX10AMFE1 - S2 - DGA1 strain mutagenized 
with EMS 
APEX10AMFE1 - S2 - DGA1 E12 APEX10AMFE1 - S2 - DGA1 strain mutagenized 
with EMS 
E13 Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , URA3 ( S1 ) , LEU2 ( S2 ) , 
UAS1B 16 - TEF - DGA1 strain mutagenized with 
EMS and selected 
E26 Mata , leu2 - 270 , ura3 - 302 , xpr2 - 322 , axp1 - 2 , 
Apex10 , Amfel , URA3 ( S1 ) , LEU2 ( S2 ) , 
UAS1B 16 - TEF - DGA1 strain mutagenized with 
EMS and selected 
This work 
This work 
This work . 
TABLE 2 
List of primers used in this study 
JB387 YL AMPD 5 ' 
ASCI 
TTGGCGCGCCatgccgcagcaagcaatgg 
( SEQ ID NO . : 1 ) 
JB388 YL AMPD 3 ! 
Paci 
CCTTAATTAAttaaccatgcagccgctcaaac 
( SEQ ID NO . : 2 ) 
JB402 YL ACL1 5 ' 
ASCI 
TTGGCGCGCCatgtctgccaacgagaacat 
( SEQ ID NO . : 3 ) 
JB403 YL ACL1 + 
4 5 ' AscI 
TTGGCGCGCCtctgccaacgagaacatctc 
( SEQ ID NO . : 4 ) 
JB404 YL ACL1 3 ! 
PacI 
CCTTAATTAActatgatcgagtcttggccttg 
( SEQ ID NO . : 5 ) 
JB405 YL ACL2 5 : 
Asci 
TTGGCGCGCCATGTCAGCGAAATCCATTCACG 
( SEQ ID NO . : 6 ) 
JB406 YL ACL2 + 
4 5 ' AscI 
TTGGCGCGCCTCAGCGAAATCCATTCACGAG 
( SEQ ID NO . : 7 ) 
JB407 YL ACL2 3 ! 
Paci 
CCTTAATTAATTAAACTCCGAGAGGAGTGGAA 
( SEQ ID NO . : 8 ) 
JB862 Loxleu 5 ! 
SacII 
CCAccgcggataacttcgtataatgtatgctatacgaagttatgagtctttattggtgatgggaaga 
( SEQ ID NO . : 9 ) 
JB863 Loxleu 3 ! 
Bstbi 
CGGTTCGAAataacttcgtatagcatacattatacgaagttatcagtcgccagcttaaagatatcta 
( SEQ ID NO . : 10 ) 
JB865 hygR 3 ! 
bglII 
GgaacggtAGATCE CGAGCGTCCCAAAACCTTCTC 
( SEO ID NO . : 11 ) 
US 9 , 896 , 691 B2 
99 100 
TABLE 2 - continued 
List of primers used in this study 
JB883 hygR 5 ! 
Nae 
GtggacGGgccggcgtttggcgcccgttttttcg 
( SEQ ID NO . : 12 ) 
JB911 DGA1 5 ! 
AscI 
CattcaaaGGCGCGCCatgactatcgactcacaatactaca 
( SEQ ID NO . : 13 ) 
JB912 DGA1 3 ! 
Pacl 
GCGGATCCTTAATTAAttactcaatcattcggaactctgg 
( SEQ ID NO . : 14 ) 
JB913 DGA2 50 
AscI 
CattcaaaGGCGCGCCATGGAAGTCCGACGACGAAA 
( SEO ID NO . : 15 ) 
JB914 DGA2 3 ' 
Pacl 
GcGGATCCTTAATTAACTACTGGTTCTGCTTGTAGTTGT 
( SEQ ID NO . : 16 ) 
AH011 Tupi 5 ' 
Asc 
GACTGGCGCGCATGAGCTTCCCCCAACAAGTA 
( SEQ ID NO . : 17 ) 
AH012 Tupl 3 ! 
Paci 
GTCCTTAATTAATTATCTGTTGACAGGAAAGTATCGC 
( SEQ ID NO . : 18 ) 
AHOO7 HacI 5 ! 
ASCI 
GACTGGCGCGCATGTCTATCAAGCGAGAAGAGT 
( SEQ ID NO . : 19 ) 
AH008 HacI 3 ! 
PacI 
GTccTTAATTAACTAGATCAGCAATAAAGTcGTGCT 
( SEQ ID NO . : 20 ) 
AH020 MAE 5 ' 
AscI 
GACTGGCGCGCCATGTTACGACTACGAACCATGC 
( SEQ ID NO . : 21 ) 
AHO21 MAE 3 
Paci 
GTccTTAATTAACTAGTCGTAATcccGCACATG 
( SEQ ID NO . : 22 ) 
LQ310 Mga2 5 ' 
AscI 
ACTGGGCGCGCC atggotaaagacaaggaaatcgactttgac 
( SEQ ID NO . : 23 ) 
LQ303 Mga2 TM 3 ' 
Paci 
ACTGTTAATTAA tcagtaaatgtaagccagaacatcgt 
( SEQ ID NO . : 24 ) 
LQ309 Mga2 3 ! 
Paci 
ACTGTTAATTAA tcatgcagcctgggcctgg 
( SEQ ID NO . : 25 ) 
LQ294 06M 5 ' 
ASCI 
ACTGGGCGCGCC atgttttacaccaagcccgacccg 
( SEQ ID NO . : 26 ) 
LQ295 06M 3 ' 
Paci 
ACTGTTAATTAA ttagagagtcccccacatgtcaccc 




( SEQ ID NO . : 28 ) 
LQ260 MRM2 3 ' 
Pac? 
ACTGTTAATTAA ttatggcttcccttctgccacatc 
( SEQ ID NO . : 29 ) 
LO261 DGA1 5 ! 
AscI 
ACTGGGCGCGCC Atgactatcgactcacaatactac 
( SEQ ID NO . : 30 ) 
LQ262 DGAI 3 ' 
PacI 
ACTGTTAATTAA ttactcaatcattcggaactctgg 
( SEQ ID NO . : 31 ) 
TABLE 3 55 TABLE 3 - continued 
Media formulations used for two strain test Media formulations used for two strain testi .
Carbon Source 
Glucose 
( g / L ) 
Nitrogen Source 
Ammonium Sulfate 
( g / L ) 
Carbon Source 
Glucose 
( g / L ) 
Nitrogen Source 
Ammonium Sulfate 
( g / L ) Media Name 60 Media Name 
Cions 5 0 . 2 
C20N0 .04 
C20 No . 2 
C20N 





0 . 04 
0 . 2 C2015 ( YSC ) 
C20N10 1 
US 9 , 896 , 691 B2 
102 101 
TABLE 3 - continued TABLE 5 - continued 
Media formulations used for two strain testing Media Formulations used for 12 strain testing 
5 
Carbon Source Carbon Source 
Glucose 
( g / L ) 
Nitrogen Source 
Ammonium Sulfate 
( g / L ) 
Media Glucose 
( g / L ) 
Nitrogen Source 
Ammonium Sulfate 
( g / L ) Media Name Name 
160 C160N 







C320No . 2 
160 
160 9 -men TABLE 6 
320 
C320N 320 RFU and OD for EMS data 
C320N5 320 
RFU OD 
APEX10AMFE1 S2 23750 8 . 81 
TABLE 4 DGA1 Control 
25 E1 31800 21 . 91 
E6 35400 18 . 86 
E12 37100 
AP?x10 , Mfe Siø , S2 - DGA1 CSM vs Minimal Media ( - CSM ) 
Comparison 
AP?x10 , Mfe S1 , S2 - DGA1 CSM vs Minimal Media ( - CSM ) 
Comparison 
Strain : AP?x10 , Mfe S1 - 0 , S2 - DGA1 
22 . 5 
11 . 83 23133 . 33 L36 Control 





20 . 58 
E1868 18 . 31 
Media Sample Day 4 OD Day 4 GFP Fluorescence 
35 
16 . 83 36696 
TABLE 7 
CSM - C80N5 
CSM - C80N5 
CSM - C80N5 
16 . 76 34397 
16 . 31 39166 List of genes and genetic changes 
Minimal Media - CSONS AO SAO 11 . 7 29365 40 
Minimal Media - C80N5 11 . 46 52520 Gene of Modification 
Minimal Media - C80N5 11 . 87 32427 
Over - expression 
45 TABLE 5 




( g / L ) 
Nitrogen Source 
Ammonium Sulfate 
( g / L ) Name 
| _n
Leucine Biosynthesis Gene ( LEU2 ) - Note 
may also be able to include rest of genes of 
leucine biosynthetic pathway , have yet to test 
these additional ones 
Uracil Biosynthesis gene ( URA3 ) 
multifunctional enzyme ( MFE1 ) in b - oxidation 
50 Deletion pathway 
Transcription Factor ( PEX10 ) 
AMP Deaminase ( AMPD ) 
ATP - Citrate Lyase ( ACL1 and / or ACL2 ) 
Malic Enzyme ( MAE / MEA ) 
Acetyl - CoA Carboxylase ( ACC ) 
acyl - CoArdiacylglycerol acyltransferases 
( DGA1 and / or DGA2 ) 
Mitochondrial 2 ' O - ribose 
methyltransferase ( MRM2 ) 
0 - 6 - methylguanine - DNA methyltransferase 
( MGMT ) 
Aconitase ( ACO1 ) 
65 Citrate Synthase ( CIT1 ) 
Deletion 
Over - expression 
Over - expression 
Over - expression 
Over - expression 
Over - expression 
8 55 C20No . 2 C20N 
C20N5 
( YSC ) 
C40 No .2 
C40N , 
C40N 




C160No . 2 
Over - expression 
8 
Over - expression 
- nga
Deletion 
8 Over - expression 
8 
US 9 , 896 , 691 B2 
103 104 
TABLE 8 
Strain L36 important SNP list 
Mutation 
Chromosome Position type 
Accession 
numbers sequence Gene 
1644655 SNP C > T mga 2 123429 
A 2401168 Insertion A > AG 189649 sorbitol utilization 
protein SOU2 
1837892 SNP C > A CENOE 154448 
1837894 SNP T > A CENOE 15444s 
4025540 SNP C > A 338919 DEHAOA1298g IPF 
95 . 1 
4025542 SNP G > C DEHAOA12989 IPF 
95 . 1 
338919 
F F 216379 2861334 Insertion A > AGAGGG RLF2 chromatin 
CTAGAGAG asembly complex 
AGGGAGA subunit p90 
A 
( SEQ ID 
NO . : 32 ) 
Gene Targets : The reference number given for each name 
corresponds to the Genolevures database : http : / / www . ge - 
nolevures . org / . YALIO stands for Yarrowia lipolytica . A , B , 
C , D , E , F specifies chromosome , and the following number 
specifies location . Note : Leu2 and Ura3 given as GenBank 
Accession numbers 
AMPD - YALIOE11495 























US 9 , 896 , 691 B2 
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( SEQ ID NO . : 34 ) 













LAFRDETL THELALVDKYTNLEEFERLHG * 
Leu2 - AF260230 











US 9 , 896 , 691 B2 
107 










( SEQ ID NO . : 36 ) 







Ura3 - YLU40564 















( SEQ ID NO . : 38 ) 






ACLsubuniti - YALIOE34793 
( SEQ ID NO . : 39 ) 
Nucleotide = atgtctgccaacgagaacatctcccgattcgacgcccctgtgggcaaggagcaccccgcctacgagctct 
tccataaccacacacgatctttcgtctatggtctccagcctcgagcctgccagggtatgctggacttcga 
110 





























( SEQ ID NO . : 40 ) 











ACLsubunit2 - YALIOD24431 




























( SEQ ID NO . : 42 ) 









MEA1 - YALIOE18634 
( note : 4 nucleotide difference compared to the reference sequence . 
In embodiments , MEA1 is the reference sequence associated with 
YALIOE18634 . In embodiments , MEA1 is the reference sequence with 
the four nucleotide differences from the reference sequence 
shown below . ) 
































( SEQ ID NO . : 44 ) 










DGA1 - YALIOE32769 




























( SEQ ID NO . : 46 ) 









DGA2 - YALIOD07986 




























( SEO ID NO . : 48 ) 









MGA2 - YALIOB12342 




























































( SEQ ID NO . : 50 ) 






















I HQAQAQAA * 
Mga2 - L36 - mutant version 





























































( SEQ ID NO . : 52 ) 























Mga2 - truncated version removing of transmembrane span . 
















































( SEQ ID NO . : 54 ) 




































( SEQ ID NO . : 56 ) 
Nucleotide = Cacaaatattcttgatttactttggttttgccctattcggaaattttattgatatctaatagaagtatta 
aagtaaaaatgtactaatacttaattgtaatgtcatcagaaataacatttgaggaa aatatttcaaacct 
aattgatatatatattagagatgtcccgcttctctgtcattaatatattcaagcaatcga 
DEHAOA12989 IPF 95 . 1 YALIOE338919 














RLF2 chromatin assembly complex subunit p90 YALIOF216379 




























TUP1 - YALIOA14542 






























( SEO ID NO . : 60 ) 














HACI - YALIOB12716 















( SEO ID NO . : 62 ) 






MRM2 - YALIOE31933 













( SEO ID NO . : 64 ) 





06M - YALIOC10010p 
136 
US 9 , 896 , 691 B2 
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( SEQ ID NO . : 66 ) 









CITI - YALIOE02684 






























( SEQ ID NO . : 68 ) 








ACC - YALIOC11407 



















































































































( SEQ ID NO . : 70 ) 






































PEX10 - YALIOC010239 



















( SEQ ID NO . : 72 ) 







MFE1 - YALIOE15378 








































( SEO ID NO . : 74 ) 













ACO1 - YALIOD09361 













































( SEQ ID NO . : 76 ) 
Amino Acid = 
MLASRVSIKAPRLARSLATTTNASLNLDSKVRMNNWEANNFLNFKKHTENVOIVKERLNRPLTYAEKILY 











































































